-DOCSTART- -X- -X- O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Discharge NN NN O
Summary NN NN O
- NN NN O
Mesothelioma NN NN O
- NN NN O
1 NN NN O
Description NN NN O
: NN NN O
Mesotheliom NN NN B-PROBLEM
a NN NN O
, NN NN O
pleural NN NN B-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
, NN NN O
atrial NN NN B-PROBLEM
fibrillatio NN NN I-PROBLEM
n NN NN O
, NN NN O
anemi NN NN B-PROBLEM
a NN NN O
, NN NN O
ascite NN NN B-PROBLEM
s NN NN O
, NN NN O
esophageal NN NN B-PROBLEM
reflu NN NN I-PROBLEM
x NN NN O
, NN NN O
and NN NN O
history NN NN O
of NN NN O
deep NN NN B-PROBLEM
venous NN NN I-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PRINCIPAL NN NN O
DIAGNOSIS NN NN O
: NN NN O
Mesotheliom NN NN B-PROBLEM
a NN NN O
. NN NN O

SECONDARY NN NN O
DIAGNOSES NN NN O
: NN NN O
Pleural NN NN B-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
, NN NN O
atrial NN NN B-PROBLEM
fibrillatio NN NN I-PROBLEM
n NN NN O
, NN NN O
anemi NN NN B-PROBLEM
a NN NN O
, NN NN O
ascite NN NN B-PROBLEM
s NN NN O
, NN NN O
esophageal NN NN B-PROBLEM
reflu NN NN I-PROBLEM
x NN NN O
, NN NN O
and NN NN O
history NN NN O
of NN NN O
deep NN NN B-PROBLEM
venous NN NN I-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
. NN NN O

PROCEDURES NN NN O

1 NN NN O
. NN NN O
On NN NN O
August NN NN B-DATE
24 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
decortication NN NN B-TREATMENT
of NN NN I-TREATMENT
the NN NN I-TREATMENT
lun NN NN I-TREATMENT
g NN NN O
with NN NN O
pleural NN NN B-TEST
biops NN NN I-TEST
y NN NN O
and NN NN O
transpleural NN NN B-TEST
fluoroscop NN NN I-TEST
y NN NN O
. NN NN O

2 NN NN O
. NN NN O
On NN NN O
August NN NN B-DATE
20 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
thoracentesi NN NN B-TREATMENT
s NN NN O
. NN NN O

3 NN NN O
. NN NN O
On NN NN O
August NN NN B-DATE
31 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
Port-A-Cath NN NN B-TREATMENT
placemen NN NN I-TREATMENT
t NN NN O
. NN NN O

HISTORY NN NN O
AND NN NN O
PHYSICAL NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
41-year-ol NN NN B-AGE
d NN NN O
Vietnames NN NN B-LOCATION
e NN NN O
female NN NN O
with NN NN O
a NN NN B-PROBLEM
nonproductive NN NN I-PROBLEM
coug NN NN I-PROBLEM
h NN NN O
that NN NN O
started NN NN O
last NN NN O
week NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
right-sided NN NN B-PROBLEM
chest NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
radiating NN NN O
to NN NN O
her NN NN O
back NN NN O
with NN NN O
feve NN NN B-PROBLEM
r NN NN O
starting NN NN O
yesterday NN NN O
. NN NN O

She NN NN O
has NN NN O
a NN NN O
history NN NN O
of NN NN O
pericarditi NN NN B-PROBLEM
s NN NN O
and NN NN O
pericardectom NN NN B-TREATMENT
y NN NN O
in NN NN O
May NN NN B-DATE
200 NN NN I-DATE
6 NN NN O
and NN NN O
developed NN NN O
coug NN NN B-PROBLEM
h NN NN O
with NN NN O
right-sided NN NN B-PROBLEM
chest NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
and NN NN O
went NN NN O
to NN NN O
an NN NN O
urgent NN NN O
care NN NN O
center NN NN O
. NN NN O

Chest NN NN B-TEST
x-ra NN NN I-TEST
y NN NN O
revealed NN NN O
right-sided NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Pericardectom NN NN B-TREATMENT
y NN NN O
. NN NN O

2 NN NN O
. NN NN O
Pericarditi NN NN B-PROBLEM
s NN NN O
. NN NN O

2 NN NN O
. NN NN O
Atrial NN NN B-PROBLEM
fibrillatio NN NN I-PROBLEM
n NN NN O
. NN NN O

4 NN NN O
. NN NN O
RNCA NN NN O
with NN NN O
intracranial NN NN B-TREATMENT
thrombolytic NN NN I-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
. NN NN O

5 NN NN O
PTA NN NN O
of NN NN O
MCA NN NN O
. NN NN O

6 NN NN O
. NN NN O
Mesenteric NN NN B-PROBLEM
venous NN NN I-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
. NN NN O

7 NN NN O
. NN NN O
Pericardial NN NN B-TREATMENT
windo NN NN I-TREATMENT
w NN NN O
. NN NN O

8 NN NN O
. NN NN O
Cholecystectom NN NN B-TREATMENT
y NN NN O
. NN NN O

9 NN NN O
. NN NN O
Left NN NN B-TEST
thoracentesi NN NN I-TEST
s NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
No NN NN O
family NN NN O
history NN NN O
of NN NN O
coronary NN NN B-PROBLEM
artery NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
CV NN NN B-PROBLEM
A NN NN O
, NN NN O
diabete NN NN B-PROBLEM
s NN NN O
, NN NN O
CH NN NN B-PROBLEM
F NN NN O
or NN NN O
M NN NN B-PROBLEM
I NN NN O
. NN NN O
The NN NN O
patient NN NN O
has NN NN O
one NN NN O
family NN NN O
member NN NN O
, NN NN O
a NN NN O
sister NN NN O
, NN NN O
with NN NN O
history NN NN O
of NN NN O
cance NN NN B-PROBLEM
r NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
is NN NN O
married NN NN O
. NN NN O

Employed NN NN O
with NN NN O
the NN NN O
US NN NN B-LOCATION
Post NN NN I-LOCATION
Offic NN NN I-LOCATION
e NN NN O
. NN NN O

She NN NN O
is NN NN O
a NN NN O
mother NN NN O
of NN NN O
three NN NN O
. NN NN O

Denies NN NN O
tobacco NN NN O
, NN NN O
alcohol NN NN O
or NN NN O
illicit NN NN O
drug NN NN O
use NN NN O
. NN NN O

MEDICATIONS NN NN O

1 NN NN O
. NN NN O
Coumadi NN NN B-TREATMENT
n NN NN O
1 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

Last NN NN O
IN NN NN B-TEST
R NN NN O
was NN NN O
on NN NN O
Tuesda NN NN B-DATE
y NN NN O
, NN NN O
August NN NN B-DATE
14 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
and NN NN O
her NN NN B-TEST
IN NN NN I-TEST
R NN NN O
was NN NN O
2.3 NN NN O
. NN NN O

2 NN NN O
. NN NN O
Amiodaron NN NN B-TREATMENT
e NN NN O
100 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
p NN NN B-ROUTE
. NN NN I-ROUTE

o NN NN O
. NN NN O

dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
Complete NN NN O
review NN NN O
of NN NN O
system NN NN B-TEST
s NN NN O
negative NN NN O
except NN NN O
as NN NN O
in NN NN O
pulmonary NN NN O
as NN NN O
noted NN NN O
above NN NN O
. NN NN O

The NN NN O
patient NN NN O
also NN NN O
reports NN NN O
occasional NN NN B-PROBLEM
numbnes NN NN I-PROBLEM
s NN NN O
and NN NN O
tingling NN NN B-PROBLEM
of NN NN I-PROBLEM
her NN NN I-PROBLEM
left NN NN I-PROBLEM
ar NN NN I-PROBLEM
m NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Blood NN NN B-TEST
pressur NN NN I-TEST
e NN NN O
123/95 NN NN O
, NN NN O
heart NN NN B-TEST
rat NN NN I-TEST
e NN NN O
83 NN NN O
, NN NN O
respiration NN NN B-TEST
s NN NN O
20 NN NN O
, NN NN O
temperatur NN NN B-TEST
e NN NN O
97 NN NN O
, NN NN O
and NN NN O
oxygen NN NN B-TEST
saturatio NN NN I-TEST
n NN NN O
97% NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
Positive NN NN O
nonproductive NN NN B-PROBLEM
coug NN NN I-PROBLEM
h NN NN O
and NN NN O
pai NN NN B-PROBLEM
n NN NN O
with NN NN O
coughin NN NN B-PROBLEM
g NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
Pupils NN NN O
are NN NN O
equal NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
and NN NN O
accommodation NN NN O
. NN NN O

Tympanic NN NN O
membranes NN NN O
are NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

No NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
masse NN NN B-PROBLEM
s NN NN O
. NN NN O

RESPIRATORY NN NN O
: NN NN O
Pleural NN NN B-PROBLEM
friction NN NN I-PROBLEM
ru NN NN I-PROBLEM
b NN NN O
is NN NN O
noted NN NN O
. NN NN O

GI NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nondistende NN NN B-PROBLEM
d NN NN O
, NN NN O
and NN NN O
nontende NN NN B-PROBLEM
r NN NN O
. NN NN O

Positive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
organomegal NN NN B-PROBLEM
y NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
edem NN NN B-PROBLEM
a NN NN O
, NN NN O
no NN NN O
clubbin NN NN B-PROBLEM
g NN NN O
, NN NN O
no NN NN O
cyanosi NN NN B-PROBLEM
s NN NN O
, NN NN O
no NN NN O
tendernes NN NN B-PROBLEM
s NN NN O
. NN NN O

Full NN NN O
range NN NN O
of NN NN O
motion NN NN O
. NN NN O

Normal NN NN O
pulses NN NN O
in NN NN O
all NN NN O
extremities NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
breakdow NN NN B-PROBLEM
n NN NN O
or NN NN O
lesion NN NN B-PROBLEM
s NN NN O
. NN NN O

No NN NN O
ulcer NN NN B-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Grossly NN NN O
intact NN NN O
. NN NN O

No NN NN O
focal NN NN B-PROBLEM
deficit NN NN I-PROBLEM
s NN NN O
. NN NN O

Awake NN NN O
, NN NN O
alert NN NN O
, NN NN O
and NN NN O
oriented NN NN O
to NN NN O
person NN NN O
, NN NN O
place NN NN O
, NN NN O
and NN NN O
time NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
Lab NN NN B-TEST
s NN NN O
are NN NN O
pending NN NN O
. NN NN O

HOSPITAL NN NN O
COURSE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
admitted NN NN O
for NN NN O
a NN NN B-PROBLEM
right-sided NN NN I-PROBLEM
pleural NN NN I-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
for NN NN O
thoracentesi NN NN B-TREATMENT
s NN NN O
on NN NN O
Monda NN NN B-DATE
y NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
. NN NN O
Her NN NN O
Coumadi NN NN B-DRUG
n NN NN O
was NN NN O
placed NN NN O
on NN NN O
hold NN NN O
. NN NN O

A NN NN B-TEST
repeat NN NN I-TEST
echocardiogra NN NN I-TEST
m NN NN O
was NN NN O
checked NN NN O
. NN NN O

She NN NN O
was NN NN O
started NN NN O
on NN NN O
prophylaxi NN NN B-TREATMENT
s NN NN O
for NN NN O
DV NN NN B-PROBLEM
T NN NN O
with NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
40 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
subcutaneousl NN NN B-ROUTE
y NN NN O
. NN NN O

Her NN NN O
history NN NN O
dated NN NN O
back NN NN O
to NN NN O
March NN NN B-DATE
200 NN NN I-DATE
5 NN NN O
when NN NN O
she NN NN O
first NN NN O
sought NN NN O
medical NN NN O
attention NN NN O
for NN NN O
evidence NN NN O
of NN NN O
pericarditi NN NN B-PROBLEM
s NN NN O
, NN NN O
which NN NN O
was NN NN O
treated NN NN O
with NN NN O
pericardial NN NN B-TREATMENT
windo NN NN I-TREATMENT
w NN NN O
in NN NN O
an NN NN O
outside NN NN O
hospital NN NN O
, NN NN O
at NN NN O
that NN NN O
time NN NN O
she NN NN O
was NN NN O
also NN NN O
found NN NN O
to NN NN O
have NN NN O
mesenteric NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
and NN NN O
thrombosi NN NN B-PROBLEM
s NN NN O
, NN NN O
is NN NN O
now NN NN O
anticoagulate NN NN B-TREATMENT
d NN NN O
. NN NN O

Her NN NN O
pericardial NN NN O
fluid NN NN O
was NN NN O
accumulated NN NN O
and NN NN O
she NN NN O
was NN NN O
seen NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Y NN NN O
. NN NN O
At NN NN O
that NN NN O
time NN NN O
, NN NN O
she NN NN O
was NN NN O
recommended NN NN O
for NN NN O
pericardectom NN NN B-TREATMENT
y NN NN O
, NN NN O
which NN NN O
was NN NN O
performed NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Z NN NN O
. NN NN O
Review NN NN O
of NN NN O
her NN NN B-TEST
CT NN NN I-TEST
sca NN NN I-TEST
n NN NN O
from NN NN O
March NN NN B-DATE
200 NN NN I-DATE
6 NN NN O
prior NN NN O
to NN NN O
her NN NN B-TREATMENT
pericardectom NN NN I-TREATMENT
y NN NN O
, NN NN O
already NN NN O
shows NN NN O
bilateral NN NN B-PROBLEM
plural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
. NN NN O

The NN NN O
patient NN NN O
improved NN NN O
clinically NN NN O
after NN NN O
the NN NN B-TREATMENT
pericardectom NN NN I-TREATMENT
y NN NN O
with NN NN O
resolution NN NN O
of NN NN O
her NN NN B-PROBLEM
symptom NN NN I-PROBLEM
s NN NN O
. NN NN O

Recently NN NN O
, NN NN O
she NN NN O
was NN NN O
readmitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
with NN NN O
chest NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
and NN NN O
found NN NN O
to NN NN O
have NN NN O
bilateral NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
, NN NN O
the NN NN O
right NN NN O
greater NN NN O
than NN NN O
the NN NN O
left NN NN O
. NN NN O

CT NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
ches NN NN I-TEST
t NN NN O
also NN NN O
revealed NN NN O
a NN NN B-PROBLEM
large NN NN I-PROBLEM
mediastinal NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
. NN NN O

We NN NN O
reviewed NN NN O
the NN NN B-TEST
patholog NN NN I-TEST
y NN NN O
obtained NN NN O
from NN NN O
the NN NN B-TREATMENT
pericardectom NN NN I-TREATMENT
y NN NN O
in NN NN O
March NN NN B-DATE
200 NN NN I-DATE
6 NN NN O
, NN NN O
which NN NN O
was NN NN O
diagnostic NN NN O
of NN NN O
mesotheliom NN NN B-PROBLEM
a NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
chest NN NN B-TREATMENT
tube NN NN I-TREATMENT
placemen NN NN I-TREATMENT
t NN NN O
for NN NN O
drainage NN NN B-PROBLEM
of NN NN I-PROBLEM
the NN NN I-PROBLEM
flui NN NN I-PROBLEM
d NN NN O
occurred NN NN O
and NN NN O
thoracoscop NN NN B-TREATMENT
y NN NN O
with NN NN O
fluid NN NN B-TEST
biopsie NN NN I-TEST
s NN NN O
, NN NN O
which NN NN O
were NN NN O
performed NN NN O
, NN NN O
which NN NN O
revealed NN NN O
epithelioid NN NN B-PROBLEM
malignant NN NN I-PROBLEM
mesotheliom NN NN I-PROBLEM
a NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
then NN NN O
stained NN NN O
with NN NN O
a NN NN B-TEST
PET NN NN I-TEST
C NN NN I-TEST
T NN NN O
, NN NN O
which NN NN O
showed NN NN O
extensive NN NN B-PROBLEM
uptake NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
ches NN NN I-PROBLEM
t NN NN O
, NN NN O
bilateral NN NN B-PROBLEM
pleural NN NN I-PROBLEM
pericardial NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
, NN NN O
and NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
. NN NN O

She NN NN O
also NN NN O
had NN NN O
acidic NN NN B-PROBLEM
flui NN NN I-PROBLEM
d NN NN O
, NN NN O
pectoral NN NN B-PROBLEM
and NN NN I-PROBLEM
intramammary NN NN I-PROBLEM
lymph NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
and NN NN O
uptake NN NN B-PROBLEM
in NN NN I-PROBLEM
L NN NN I-PROBLEM
4 NN NN O
with NN NN O
SU NN NN B-TEST
V NN NN O
of NN NN O

4 NN NN O
. NN NN O
This NN NN O
was NN NN O
consistent NN NN O
with NN NN O
stage NN NN B-PROBLEM
III NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
. NN NN O

Her NN NN B-TEST
repeat NN NN I-TEST
echocardiogra NN NN I-TEST
m NN NN O
showed NN NN O
an NN NN B-TEST
ejection NN NN I-TEST
fractio NN NN I-TEST
n NN NN O
of NN NN O
45% NN NN O
to NN NN O
49% NN NN O
. NN NN O

She NN NN O
was NN NN O
transferred NN NN O
to NN NN O
Oncology NN NN O
service NN NN O
and NN NN O
started NN NN O
on NN NN O
chemotherap NN NN B-TREATMENT
y NN NN O
on NN NN O
September NN NN B-DATE
1 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
with NN NN O
cisplati NN NN B-TREATMENT
n NN NN O
75 NN NN B-STRENGTH
mg/centimete NN NN I-STRENGTH
r NN NN O
squared NN NN O
equaling NN NN O
109 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
I NN NN B-ROUTE
V NN NN O
piggybac NN NN B-DRUG
k NN NN O
over NN NN B-DURATION
2 NN NN I-DURATION
hour NN NN I-DURATION
s NN NN O
on NN NN O
September NN NN B-DATE
1 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
Alimt NN NN B-TREATMENT
a NN NN O
500 NN NN B-STRENGTH
mg NN NN I-STRENGTH
/ NN NN O
centimeter NN NN B-FORM
square NN NN I-FORM
d NN NN O
equaling NN NN O
730 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
I NN NN B-ROUTE
V NN NN O
piggybac NN NN B-DRUG
k NN NN O
over NN NN B-DURATION
10 NN NN I-DURATION
minute NN NN I-DURATION
s NN NN O
. NN NN O

This NN NN O
was NN NN O
all NN NN O
initiated NN NN O
after NN NN O
a NN NN B-TREATMENT
Port-A-Cat NN NN I-TREATMENT
h NN NN O
was NN NN O
placed NN NN O
. NN NN O

The NN NN O
chemotherap NN NN B-DRUG
y NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
discharged NN NN O
the NN NN O
following NN NN O
day NN NN O
after NN NN O
discontinuing NN NN O
I NN NN B-ROUTE
V NN NN O
flui NN NN B-DRUG
d NN NN O
and NN NN O
I NN NN B-ROUTE
V NN NN O
. NN NN O
Her NN NN B-TREATMENT
Port-A-Cat NN NN I-TREATMENT
h NN NN O
was NN NN O
packed NN NN O
with NN NN O
hepari NN NN B-TREATMENT
n NN NN O
according NN NN O
to NN NN O
protocol NN NN O
. NN NN O

DISCHARGE NN NN B-TREATMENT
MEDICATION NN NN I-TREATMENT
S NN NN O
: NN NN O
Zofra NN NN B-TREATMENT
n NN NN O
, NN NN O
Phenerga NN NN B-TREATMENT
n NN NN O
, NN NN O
Coumadi NN NN B-TREATMENT
n NN NN O
, NN NN O
and NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
, NN NN O
and NN NN O
Vicodi NN NN B-TREATMENT
n NN NN O
DISCHARGE NN NN O
INSTRUCTIONS NN NN O
: NN NN O
She NN NN O
was NN NN O
instructed NN NN O
to NN NN O
followup NN NN O
with NN NN O
Dr NN NN O
. NN NN O
XY NN NN B-NAME
Z NN NN O
in NN NN O
the NN NN O
office NN NN O
to NN NN O
check NN NN O
her NN NN B-TEST
IN NN NN I-TEST
R NN NN O
on NN NN O
Tuesda NN NN B-DATE
y NN NN O
. NN NN O

She NN NN O
was NN NN O
instructed NN NN O
to NN NN O
call NN NN O
if NN NN O
she NN NN O
had NN NN O
any NN NN O
other NN NN O
questions NN NN O
or NN NN O
concerns NN NN O
in NN NN O
the NN NN O
interim NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
mesotheliom NN NN B-PROBLEM
a NN NN O
, NN NN O
pleural NN NN B-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
, NN NN O
atrial NN NN B-PROBLEM
fibrillatio NN NN I-PROBLEM
n NN NN O
, NN NN O
anemi NN NN B-PROBLEM
a NN NN O
, NN NN O
ascite NN NN B-PROBLEM
s NN NN O
, NN NN O
esophageal NN NN B-PROBLEM
reflu NN NN I-PROBLEM
x NN NN O
, NN NN O
deep NN NN B-PROBLEM
venous NN NN I-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
, NN NN O
port-a-cath NN NN B-TREATMENT
placemen NN NN I-TREATMENT
t NN NN O
, NN NN O
port NN NN B-TREATMENT
a NN NN I-TREATMENT
cat NN NN I-TREATMENT
h NN NN O
, NN NN O
iv NN NN B-TREATMENT
piggybac NN NN I-TREATMENT
k NN NN O
, NN NN O
venous NN NN B-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
, NN NN O
atria NN NN B-PROBLEM
l NN NN O
, NN NN O
thrombosi NN NN B-PROBLEM
s NN NN O
, NN NN O
pericardia NN NN B-TREATMENT
l NN NN O
, NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
, NN NN O
flui NN NN B-PROBLEM
d NN NN O
, NN NN O
pericardectom NN NN B-TREATMENT
y NN NN O
, NN NN O
chest NN NN B-PROBLEM
, NN NN I-PROBLEM
pleura NN NN I-PROBLEM
l NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
BCCa NN NN B-TREATMENT
Excision NN NN I-TREATMENT
- NN NN I-TREATMENT
Lower NN NN I-TREATMENT
Li NN NN I-TREATMENT
d NN NN O
Description NN NN O
: NN NN O
Excisio NN NN B-TREATMENT
n NN NN O
of NN NN O
large NN NN B-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN O
lower NN NN O
lid NN NN O
, NN NN O
and NN NN O
repaired NN NN O
with NN NN O
used NN NN O
dorsal NN NN B-TREATMENT
conjunctival NN NN I-TREATMENT
flap NN NN I-TREATMENT
in NN NN I-TREATMENT
the NN NN I-TREATMENT
upper NN NN I-TREATMENT
li NN NN I-TREATMENT
d NN NN O
and NN NN O
a NN NN B-TREATMENT
large NN NN I-TREATMENT
preauricular NN NN I-TREATMENT
skin NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Extremely NN NN B-PROBLEM
large NN NN I-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN B-PROBLEM
lower NN NN I-PROBLEM
li NN NN I-PROBLEM
d NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Extremely NN NN B-PROBLEM
large NN NN I-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN B-PROBLEM
lower NN NN I-PROBLEM
li NN NN I-PROBLEM
d NN NN O
. NN NN O

TITLE NN NN O
OF NN NN O
OPERATION NN NN O
: NN NN O
Excisio NN NN B-TREATMENT
n NN NN O
of NN NN O
large NN NN B-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN O
lower NN NN O
lid NN NN O
, NN NN O
and NN NN O
repaired NN NN O
with NN NN O
used NN NN O
dorsal NN NN B-TREATMENT
conjunctival NN NN I-TREATMENT
flap NN NN I-TREATMENT
in NN NN I-TREATMENT
the NN NN I-TREATMENT
upper NN NN I-TREATMENT
li NN NN I-TREATMENT
d NN NN O
and NN NN O
a NN NN B-TREATMENT
large NN NN I-TREATMENT
preauricular NN NN I-TREATMENT
skin NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
brought NN NN O
into NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
prepped NN NN O
and NN NN O
draped NN NN O
in NN NN O
usual NN NN O
fashion NN NN O
. NN NN O

Xylocain NN NN B-TREATMENT
e NN NN O
2 NN NN B-STRENGTH
% NN NN O
with NN NN O
epinephrin NN NN B-TREATMENT
e NN NN O
was NN NN O
injected NN NN O
beneath NN NN O
the NN NN O
conjunctiva NN NN O
and NN NN O
skin NN NN O
of NN NN O
the NN NN O
lower NN NN O
lid NN NN O
and NN NN O
also NN NN O
beneath NN NN O
the NN NN O
conjunctiva NN NN O
and NN NN O
skin NN NN O
of NN NN O
the NN NN O
upper NN NN O
lid NN NN O
. NN NN O

A NN NN B-PROBLEM
frontal NN NN I-PROBLEM
nerve NN NN I-PROBLEM
bloc NN NN I-PROBLEM
k NN NN O
was NN NN O
also NN NN O
given NN NN O
on NN NN O
the NN NN O
right NN NN O
upper NN NN O
lid NN NN O
. NN NN O

The NN NN B-TREATMENT
anesthetic NN NN I-TREATMENT
agen NN NN I-TREATMENT
t NN NN O
was NN NN O
also NN NN O
injected NN NN O
in NN NN O
the NN NN O
right NN NN O
preauricular NN NN O
region NN NN O
which NN NN O
would NN NN O
provide NN NN O
a NN NN B-TREATMENT
donor NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
for NN NN O
the NN NN B-PROBLEM
right NN NN I-PROBLEM
lower NN NN I-PROBLEM
lid NN NN I-PROBLEM
defec NN NN I-PROBLEM
t NN NN O
. NN NN O

The NN NN O
area NN NN O
was NN NN O
marked NN NN O
with NN NN O
a NN NN O
marking NN NN O
pen NN NN O
with NN NN O
margins NN NN O
of NN NN O
3 NN NN O
to NN NN O
4 NN NN O
mm NN NN O
, NN NN O
and NN NN O
a NN NN B-TREATMENT
#15 NN NN I-TREATMENT
Bard-Parker NN NN I-TREATMENT
blad NN NN I-TREATMENT
e NN NN O
was NN NN O
used NN NN O
to NN NN O
make NN NN O
an NN NN B-PROBLEM
incision NN NN I-PROBLEM
at NN NN I-PROBLEM
the NN NN I-PROBLEM
nasal NN NN I-PROBLEM
and NN NN I-PROBLEM
temporal NN NN I-PROBLEM
margin NN NN I-PROBLEM
s NN NN O
of NN NN O
the NN NN B-PROBLEM
lesio NN NN I-PROBLEM
n NN NN O
. NN NN O

The NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
carried NN NN O
inferiorly NN NN O
, NN NN O
and NN NN O
using NN NN O
a NN NN B-TREATMENT
Steven NN NN I-TREATMENT
scissor NN NN I-TREATMENT
s NN NN O
the NN NN O
normal NN NN O
skin NN NN O
, NN NN O
muscle NN NN O
, NN NN O
and NN NN O
conjunctiva NN NN O
was NN NN O
excised NN NN B-TREATMENT
inferiorl NN NN I-TREATMENT
y NN NN O
. NN NN O

The NN NN B-TEST
specime NN NN I-TEST
n NN NN O
was NN NN O
then NN NN O
marked NN NN O
and NN NN O
sent NN NN O
to NN NN O
pathology NN NN O
for NN NN O
frozen NN NN B-TEST
sectio NN NN I-TEST
n NN NN O
. NN NN O

Bleedin NN NN B-PROBLEM
g NN NN O
was NN NN O
controlled NN NN O
with NN NN O
a NN NN B-TREATMENT
wet-field NN NN I-TREATMENT
cauter NN NN I-TREATMENT
y NN NN O
, NN NN O
and NN NN O
the NN NN O
right NN NN O
upper NN NN O
lid NN NN O
was NN NN O
everted NN NN O
, NN NN O
and NN NN O
an NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
made NN NN O
3 NN NN O
mm NN NN O
above NN NN O
the NN NN O
lid NN NN O
margin NN NN O
with NN NN O
the NN NN B-TREATMENT
Bard-Parker NN NN I-TREATMENT
blad NN NN I-TREATMENT
e NN NN O
in NN NN O
the NN NN O
entire NN NN O
length NN NN O
of NN NN O
the NN NN O
upper NN NN O
lid NN NN O
. NN NN O

The NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
reached NN NN O
the NN NN O
orbicularis NN NN O
, NN NN O
and NN NN O
Steven NN NN B-TREATMENT
scissor NN NN I-TREATMENT
s NN NN O
were NN NN O
used NN NN O
to NN NN O
separate NN NN O
the NN NN O
tarsus NN NN O
from NN NN O
the NN NN O
underlying NN NN O
orbicularis NN NN O
. NN NN O

Vertical NN NN O
cuts NN NN O
were NN NN O
made NN NN O
nasally NN NN O
and NN NN O
temporally NN NN O
, NN NN O
and NN NN O
a NN NN B-TREATMENT
large NN NN I-TREATMENT
dorsal NN NN I-TREATMENT
conjunctival NN NN I-TREATMENT
fla NN NN I-TREATMENT
p NN NN O
was NN NN O
fashioned NN NN O
with NN NN O
the NN NN O
conjunctiva NN NN O
attached NN NN O
superiorly NN NN O
. NN NN O

It NN NN O
was NN NN O
placed NN NN O
into NN NN O
the NN NN B-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
lower NN NN I-PROBLEM
lid NN NN I-PROBLEM
and NN NN I-PROBLEM
suture NN NN I-PROBLEM
d NN NN O
with NN NN O
multiple NN NN B-TREATMENT
interrupted NN NN I-TREATMENT
6-0 NN NN I-TREATMENT
Vicryl NN NN I-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
nasally NN NN O
, NN NN O
temporally NN NN O
, NN NN O
and NN NN O
inferiorly NN NN O
. NN NN O

The NN NN B-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
ski NN NN I-PROBLEM
n NN NN O
was NN NN O
measured NN NN O
and NN NN O
an NN NN B-TREATMENT
appropriate NN NN I-TREATMENT
large NN NN I-TREATMENT
preauricular NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
excised NN NN O
from NN NN O
the NN NN O
right NN NN O
preauricular NN NN O
region NN NN O
. NN NN O

The NN NN B-PROBLEM
defec NN NN I-PROBLEM
t NN NN O
was NN NN O
closed NN NN O
with NN NN O
interrupted NN NN B-TREATMENT
5-0 NN NN I-TREATMENT
Prolene NN NN I-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
, NN NN O
and NN NN O
the NN NN B-TREATMENT
preauricular NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
sutured NN NN O
in NN NN O
place NN NN O
with NN NN O
multiple NN NN B-TREATMENT
interrupted NN NN I-TREATMENT
6-0 NN NN I-TREATMENT
silk NN NN I-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
. NN NN O

The NN NN O
upper NN NN O
border NN NN O
of NN NN O
the NN NN B-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
attached NN NN O
to NN NN O
the NN NN O
upper NN NN O
lid NN NN O
after NN NN O
incisio NN NN B-PROBLEM
n NN NN O
was NN NN O
made NN NN O
in NN NN O
the NN NN B-TREATMENT
gray NN NN I-TREATMENT
lin NN NN I-TREATMENT
e NN NN O
with NN NN O
a NN NN B-TREATMENT
Superblad NN NN I-TREATMENT
e NN NN O
, NN NN O
and NN NN O
the NN NN O
superior NN NN O
portion NN NN O
of NN NN O
the NN NN B-TREATMENT
skin NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
sutured NN NN O
to NN NN O
the NN NN O
upper NN NN O
lid NN NN O
through NN NN O
the NN NN O
anterior NN NN O
lamella NN NN O
created NN NN O
by NN NN O
the NN NN B-PROBLEM
razor NN NN I-PROBLEM
blade NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
. NN NN O

Cryotherap NN NN B-TREATMENT
y NN NN O
was NN NN O
then NN NN O
used NN NN O
to NN NN O
treat NN NN O
the NN NN O
nasal NN NN O
and NN NN O
temporal NN NN O
margins NN NN O
of NN NN O
the NN NN O
area NN NN O
of NN NN O
excisio NN NN B-TREATMENT
n NN NN O
because NN NN O
of NN NN O
positive NN NN B-PROBLEM
margin NN NN I-PROBLEM
s NN NN O
, NN NN O
and NN NN O
following NN NN O
this NN NN O
an NN NN O
antibiotic NN NN B-DRUG
steroi NN NN I-DRUG
d NN NN O
ointmen NN NN B-FORM
t NN NN O
was NN NN O
instilled NN NN O
and NN NN O
a NN NN B-TREATMENT
light NN NN I-TREATMENT
pressure NN NN I-TREATMENT
dressin NN NN I-TREATMENT
g NN NN O
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
well NN NN O
and NN NN O
was NN NN O
sent NN NN O
to NN NN O
recovery NN NN O
room NN NN O
in NN NN O
good NN NN O
condition NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
basal NN NN B-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
cryotherap NN NN B-TREATMENT
y NN NN O
, NN NN O
steven NN NN B-TREATMENT
scissor NN NN I-TREATMENT
s NN NN O
, NN NN O
conjunctiva NN NN B-TREATMENT
, NN NN I-TREATMENT
conjunctival NN NN I-TREATMENT
fla NN NN I-TREATMENT
p NN NN O
, NN NN O
frontal NN NN B-PROBLEM
nerve NN NN I-PROBLEM
bloc NN NN I-PROBLEM
k NN NN O
, NN NN O
frozen NN NN O
section NN NN O
, NN NN O
lower NN NN B-TREATMENT
lid NN NN I-TREATMENT
, NN NN I-TREATMENT
orbicularis NN NN I-TREATMENT
, NN NN I-TREATMENT
skin NN NN I-TREATMENT
graft NN NN I-TREATMENT
, NN NN I-TREATMENT
nasal NN NN I-TREATMENT
and NN NN I-TREATMENT
temporal NN NN I-TREATMENT
margins NN NN I-TREATMENT
, NN NN I-TREATMENT
dorsal NN NN I-TREATMENT
conjunctival NN NN I-TREATMENT
flap NN NN I-TREATMENT
, NN NN I-TREATMENT
upper NN NN I-TREATMENT
lid NN NN I-TREATMENT
, NN NN I-TREATMENT
basa NN NN I-TREATMENT
l NN NN O
, NN NN O
carcinom NN NN B-PROBLEM
a NN NN O
, NN NN O
preauricular NN NN O
, NN NN O
incisio NN NN B-PROBLEM
n NN NN O
, NN NN O
conjunctival NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Anemi NN NN B-PROBLEM
a NN NN O
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
that NN NN O
is NN NN O
transfusion NN NN B-PROBLEM
dependen NN NN I-PROBLEM
t NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
anemi NN NN B-PROBLEM
a NN NN O
with NN NN O
hemoglobi NN NN B-TEST
n NN NN O
of NN NN O
7.1 NN NN O
and NN NN O
requiring NN NN O
transfusio NN NN B-TREATMENT
n NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
DIAGNOSIS NN NN O
: NN NN O
Refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
that NN NN O
is NN NN O
transfusion NN NN B-PROBLEM
dependen NN NN I-PROBLEM
t NN NN O
. NN NN O

CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
I NN NN O
needed NN NN O
a NN NN O
blood NN NN O
transfusio NN NN B-ROUTE
n NN NN O
. NN NN O

HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
78-year-ol NN NN B-AGE
d NN NN O
gentleman NN NN O
with NN NN O
no NN NN O
substantial NN NN O
past NN NN O
medical NN NN O
history NN NN O
except NN NN O
for NN NN O
diabete NN NN B-PROBLEM
s NN NN O
. NN NN O

He NN NN O
denies NN NN O
any NN NN B-PROBLEM
comorbid NN NN I-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
of NN NN O
the NN NN B-PROBLEM
diabete NN NN I-PROBLEM
s NN NN O
including NN NN O
kidney NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
heart NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
strok NN NN B-PROBLEM
e NN NN O
, NN NN O
vision NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
, NN NN O
or NN NN O
neuropath NN NN B-PROBLEM
y NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
anemi NN NN B-PROBLEM
a NN NN O
with NN NN O
hemoglobi NN NN B-TEST
n NN NN O
of NN NN O
7.1 NN NN O
and NN NN O
requiring NN NN O
transfusio NN NN B-TREATMENT
n NN NN O
. NN NN O

He NN NN O
reports NN NN O
that NN NN O
he NN NN O
has NN NN O
no NN NN O
signs NN NN O
or NN NN O
symptom NN NN O
of NN NN O
bleedin NN NN B-PROBLEM
g NN NN O
and NN NN O
had NN NN O
a NN NN B-TREATMENT
blood NN NN I-TREATMENT
transfusio NN NN I-TREATMENT
n NN NN O
approximately NN NN O
two NN NN O
months NN NN O
ago NN NN O
and NN NN O
actually NN NN O
several NN NN O
weeks NN NN O
before NN NN O
that NN NN B-TREATMENT
blood NN NN I-TREATMENT
transfusio NN NN I-TREATMENT
n NN NN O
, NN NN O
he NN NN O
had NN NN O
a NN NN B-TREATMENT
transfusio NN NN I-TREATMENT
n NN NN O
for NN NN O
anemi NN NN B-PROBLEM
a NN NN O
. NN NN O

He NN NN O
has NN NN O
been NN NN O
placed NN NN O
on NN NN O
B1 NN NN B-TREATMENT
2 NN NN O
, NN NN O
oral NN NN B-TREATMENT
iro NN NN I-TREATMENT
n NN NN O
, NN NN O
and NN NN O
Procri NN NN B-TREATMENT
t NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
we NN NN O
are NN NN O
asked NN NN O
to NN NN O
evaluate NN NN O
him NN NN O
for NN NN O
further NN NN O
causes NN NN O
and NN NN O
treatmen NN NN B-TREATMENT
t NN NN O
for NN NN O
his NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
. NN NN O

He NN NN O
denies NN NN O
any NN NN B-PROBLEM
constitutional NN NN I-PROBLEM
complaint NN NN I-PROBLEM
s NN NN O
except NN NN O
for NN NN O
fatigu NN NN B-PROBLEM
e NN NN O
, NN NN O
malais NN NN B-PROBLEM
e NN NN O
, NN NN O
and NN NN O
some NN NN B-PROBLEM
dyspne NN NN I-PROBLEM
a NN NN O
. NN NN O

He NN NN O
has NN NN O
no NN NN O
adenopath NN NN B-PROBLEM
y NN NN O
that NN NN O
he NN NN O
reports NN NN O
. NN NN O

No NN NN O
fever NN NN B-PROBLEM
s NN NN O
, NN NN O
night NN NN B-PROBLEM
sweat NN NN I-PROBLEM
s NN NN O
, NN NN O
bone NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
ras NN NN B-PROBLEM
h NN NN O
, NN NN O
arthralgia NN NN B-PROBLEM
s NN NN O
, NN NN O
or NN NN O
myalgia NN NN B-PROBLEM
s NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Diabete NN NN B-PROBLEM
s NN NN O
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O
: NN NN O
Hernia NN NN B-TREATMENT
repai NN NN I-TREATMENT
r NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
He NN NN O
has NN NN O
no NN NN O
allergie NN NN B-PROBLEM
s NN NN O
. NN NN O

MEDICATIONS NN NN O
: NN NN O
Listed NN NN O
in NN NN O
the NN NN O
chart NN NN O
and NN NN O
include NN NN O
Coumadi NN NN B-TREATMENT
n NN NN O
, NN NN O
Lasi NN NN B-TREATMENT
x NN NN O
, NN NN O
metformi NN NN B-TREATMENT
n NN NN O
, NN NN O
folic NN NN B-TREATMENT
aci NN NN I-TREATMENT
d NN NN O
, NN NN O
diltiaze NN NN B-TREATMENT
m NN NN O
, NN NN O
B1 NN NN B-TREATMENT
2 NN NN O
, NN NN O
Prevaci NN NN B-TREATMENT
d NN NN O
, NN NN O
and NN NN O
Feoso NN NN B-TREATMENT
l NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
is NN NN O
a NN NN O
tobacco NN NN O
user NN NN O
. NN NN O

He NN NN O
does NN NN O
not NN NN O
drink NN NN O
. NN NN O

He NN NN O
lives NN NN O
alone NN NN O
, NN NN O
but NN NN O
has NN NN O
family NN NN O
and NN NN O
social NN NN O
support NN NN O
to NN NN O
look NN NN O
on NN NN O
him NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Negative NN NN O
for NN NN O
blood NN NN B-PROBLEM
or NN NN I-PROBLEM
cancer NN NN I-PROBLEM
disorder NN NN I-PROBLEM
s NN NN O
according NN NN O
to NN NN O
the NN NN O
patient NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
He NN NN O
is NN NN O
an NN NN O
elderly NN NN O
gentleman NN NN O
in NN NN O
no NN NN O
acute NN NN B-PROBLEM
distres NN NN I-PROBLEM
s NN NN O
. NN NN O

He NN NN O
is NN NN O
sitting NN NN O
up NN NN O
in NN NN O
bed NN NN O
eating NN NN O
his NN NN O
breakfast NN NN O
. NN NN O

He NN NN O
is NN NN O
alert NN NN O
and NN NN O
oriented NN NN O
and NN NN O
answering NN NN O
questions NN NN O
appropriately NN NN O
. NN NN O

VITAL NN NN O
SIGNS NN NN O
: NN NN O
Blood NN NN B-TEST
pressur NN NN I-TEST
e NN NN O
of NN NN O
110/60 NN NN O
, NN NN O
puls NN NN B-TEST
e NN NN O
of NN NN O
99 NN NN O
, NN NN O
respiratory NN NN B-TEST
rat NN NN I-TEST
e NN NN O
of NN NN O
14 NN NN O
, NN NN O
and NN NN O
temperatur NN NN B-TEST
e NN NN O
of NN NN O
97.4 NN NN O
. NN NN O

He NN NN O
is NN NN O
69 NN NN O
inches NN NN O
tall NN NN O
and NN NN O
weighs NN NN O
174 NN NN O
pounds NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
Sclerae NN NN O
show NN NN O
mild NN NN B-PROBLEM
arcus NN NN I-PROBLEM
senilis NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
righ NN NN I-PROBLEM
t NN NN O
. NN NN O

Left NN NN O
is NN NN O
clear NN NN O
. NN NN O

Pupils NN NN O
are NN NN O
equally NN NN O
round NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Extraocular NN NN O
movements NN NN O
are NN NN O
intact NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

Trachea NN NN O
is NN NN O
midline NN NN O
. NN NN O

No NN NN O
jugular NN NN B-PROBLEM
venous NN NN I-PROBLEM
pressure NN NN I-PROBLEM
distentio NN NN I-PROBLEM
n NN NN O
is NN NN O
noted NN NN O
. NN NN O

No NN NN O
adenopathy NN NN B-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
cervical NN NN I-PROBLEM
, NN NN I-PROBLEM
supraclavicular NN NN I-PROBLEM
, NN NN I-PROBLEM
or NN NN I-PROBLEM
axillary NN NN I-PROBLEM
area NN NN I-PROBLEM
s NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
and NN NN O
nontende NN NN B-PROBLEM
r NN NN O
. NN NN O

There NN NN O
may NN NN O
be NN NN O
some NN NN B-PROBLEM
fullness NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
left NN NN I-PROBLEM
upper NN NN I-PROBLEM
quadran NN NN I-PROBLEM
t NN NN O
, NN NN O
although NN NN O
I NN NN O
do NN NN O
not NN NN O
appreciate NN NN O
a NN NN O
true NN NN O
spleen NN NN O
with NN NN O
inspiration NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
clubbin NN NN B-PROBLEM
g NN NN O
, NN NN O
but NN NN O
there NN NN O
is NN NN O
some NN NN B-PROBLEM
edem NN NN I-PROBLEM
a NN NN O
, NN NN O
but NN NN O
no NN NN O
cyanosi NN NN B-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

DERMATOLOGIC NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

IMPRESSION NN NN O
: NN NN O
At NN NN O
this NN NN O
time NN NN O
is NN NN O
refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
, NN NN O
which NN NN O
is NN NN O
transfusion NN NN B-PROBLEM
dependen NN NN I-PROBLEM
t NN NN O
. NN NN O

He NN NN O
is NN NN O
on NN NN O
B1 NN NN B-TREATMENT
2 NN NN O
, NN NN O
iro NN NN B-TREATMENT
n NN NN O
, NN NN O
folic NN NN B-TREATMENT
aci NN NN I-TREATMENT
d NN NN O
, NN NN O
and NN NN O
Procri NN NN B-TREATMENT
t NN NN O
. NN NN O

There NN NN O
are NN NN O
no NN NN O
sign NN NN O
or NN NN O
symptom NN NN O
of NN NN O
blood NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
and NN NN O
a NN NN B-TEST
recent NN NN I-TEST
esophagogastroduodenoscop NN NN I-TEST
y NN NN O
, NN NN O
which NN NN O
was NN NN O
negative NN NN O
. NN NN O

His NN NN B-TEST
creatinin NN NN I-TEST
e NN NN O
was NN NN O

1 NN NN O
. NN NN O
My NN NN O
impression NN NN O
at NN NN O
this NN NN O
time NN NN O
is NN NN O
that NN NN O
he NN NN O
probably NN NN O
has NN NN O
an NN NN B-PROBLEM
underlying NN NN I-PROBLEM
myelodysplastic NN NN I-PROBLEM
syndrom NN NN I-PROBLEM
e NN NN O
or NN NN O
bone NN NN B-PROBLEM
marrow NN NN I-PROBLEM
failur NN NN I-PROBLEM
e NN NN O
. NN NN O

His NN NN B-TEST
creatinin NN NN I-TEST
e NN NN O
on NN NN O
this NN NN O
hospitalization NN NN O
was NN NN O
up NN NN O
slightly NN NN O
to NN NN O
1.6 NN NN O
and NN NN O
this NN NN O
may NN NN O
contribute NN NN O
to NN NN O
his NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
. NN NN O

RECOMMENDATIONS NN NN O
: NN NN O
At NN NN O
this NN NN O
time NN NN O
, NN NN O
my NN NN O
recommendation NN NN O
for NN NN O
the NN NN O
patient NN NN O
is NN NN O
that NN NN O
he NN NN O
undergoes NN NN O
further NN NN B-TEST
serologic NN NN I-TEST
evaluatio NN NN I-TEST
n NN NN O
with NN NN O
reticulocyte NN NN B-TEST
coun NN NN I-TEST
t NN NN O
, NN NN O
serum NN NN B-TEST
protei NN NN I-TEST
n NN NN O
, NN NN O
and NN NN O
electrophoresi NN NN B-TEST
s NN NN O
, NN NN O
LD NN NN B-TEST
H NN NN O
, NN NN O
B1 NN NN B-TEST
2 NN NN O
, NN NN O
folat NN NN B-TEST
e NN NN O
, NN NN O
erythropoietin NN NN B-TEST
leve NN NN I-TEST
l NN NN O
, NN NN O
and NN NN O
he NN NN O
should NN NN O
undergo NN NN O
a NN NN B-TREATMENT
bone NN NN I-TREATMENT
marrow NN NN I-TREATMENT
aspiratio NN NN I-TREATMENT
n NN NN O
and NN NN O
biops NN NN B-TEST
y NN NN O
. NN NN O

I NN NN O
have NN NN O
discussed NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
in NN NN O
detail NN NN O
which NN NN O
the NN NN O
patient NN NN O
. NN NN O

I NN NN O
have NN NN O
discussed NN NN O
the NN NN O
risks NN NN O
, NN NN O
benefits NN NN O
, NN NN O
and NN NN O
successes NN NN O
of NN NN O
that NN NN O
treatment NN NN O
and NN NN O
usefulness NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
bone NN NN I-TEST
marro NN NN I-TEST
w NN NN O
and NN NN O
predicting NN NN O
his NN NN O
cause NN NN O
of NN NN O
refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
and NN NN O
further NN NN O
therapeutic NN NN B-TREATMENT
intervention NN NN I-TREATMENT
s NN NN O
, NN NN O
which NN NN O
might NN NN O
be NN NN O
beneficial NN NN O
to NN NN O
him NN NN O
. NN NN O

He NN NN O
is NN NN O
willing NN NN O
to NN NN O
proceed NN NN O
with NN NN O
the NN NN B-TEST
studie NN NN I-TEST
s NN NN O
I NN NN O
have NN NN O
described NN NN O
to NN NN O
him NN NN O
. NN NN O

We NN NN O
will NN NN O
order NN NN O
an NN NN B-TEST
ultrasound NN NN I-TEST
of NN NN I-TEST
his NN NN I-TEST
abdome NN NN I-TEST
n NN NN O
because NN NN O
of NN NN O
the NN NN O
possible NN NN O
fullness NN NN B-PROBLEM
of NN NN I-PROBLEM
the NN NN I-PROBLEM
splee NN NN I-PROBLEM
n NN NN O
, NN NN O
and NN NN O
I NN NN O
will NN NN O
probably NN NN O
see NN NN O
him NN NN O
in NN NN O
follow NN NN O
up NN NN O
after NN NN O
this NN NN B-TREATMENT
hospitalizatio NN NN I-TREATMENT
n NN NN O
. NN NN O

As NN NN O
always NN NN O
, NN NN O
we NN NN O
greatly NN NN O
appreciate NN NN O
being NN NN O
able NN NN O
to NN NN O
participate NN NN O
in NN NN O
the NN NN O
care NN NN O
of NN NN O
your NN NN O
patient NN NN O
. NN NN O

We NN NN O
appreciate NN NN O
the NN NN O
consultation NN NN O
of NN NN O
the NN NN O
patient NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
electrophoresi NN NN B-TEST
s NN NN O
, NN NN O
ld NN NN B-TEST
h NN NN O
, NN NN O
b1 NN NN B-TEST
2 NN NN O
, NN NN O
folat NN NN B-TEST
e NN NN O
, NN NN O
erythropoieti NN NN B-DRUG
n NN NN O
level NN NN O
, NN NN O
reticulocyte NN NN B-TEST
coun NN NN I-TEST
t NN NN O
, NN NN O
serum NN NN B-TEST
protei NN NN I-TEST
n NN NN O
, NN NN O
blood NN NN B-TEST
transfusio NN NN I-TEST
n NN NN O
, NN NN O
bone NN NN B-PROBLEM
marro NN NN I-PROBLEM
w NN NN O
, NN NN O
refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
, NN NN O
anemi NN NN B-PROBLEM
a NN NN O
, NN NN O
myalgia NN NN B-PROBLEM
s NN NN O
, NN NN O
marro NN NN B-PROBLEM
w NN NN O
, NN NN O
bon NN NN B-PROBLEM
e NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Intensity-Modulated NN NN O
Radiation NN NN O
Therapy NN NN O
Description NN NN O
: NN NN O
Intensity-modulated NN NN B-TREATMENT
radiation NN NN I-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
is NN NN O
a NN NN O
complex NN NN O
set NN NN O
of NN NN O
procedure NN NN B-TREATMENT
s NN NN O
which NN NN O
requires NN NN O
appropriate NN NN O
positioning NN NN O
and NN NN O
immobilizatio NN NN B-TREATMENT
n NN NN O
typically NN NN O
with NN NN O
customized NN NN B-TREATMENT
immobilization NN NN I-TREATMENT
device NN NN I-TREATMENT
s NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
INTENSITY-MODULATED NN NN O
RADIATION NN NN O
THERAPY NN NN O
Intensity-modulated NN NN B-TREATMENT
radiation NN NN I-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
is NN NN O
a NN NN O
complex NN NN O
set NN NN O
of NN NN O
procedure NN NN B-TREATMENT
s NN NN O
which NN NN O
requires NN NN O
appropriate NN NN O
positioning NN NN O
and NN NN O
immobilizatio NN NN B-TREATMENT
n NN NN O
typically NN NN O
with NN NN O
customized NN NN B-TREATMENT
immobilization NN NN I-TREATMENT
device NN NN I-TREATMENT
s NN NN O
. NN NN O

The NN NN B-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
planning NN NN O
process NN NN O
requires NN NN O
at NN NN O
least NN NN O
4 NN NN O
hours NN NN O
of NN NN O
physician NN NN O
time NN NN O
. NN NN O

The NN NN O
technology NN NN O
is NN NN O
appropriate NN NN O
in NN NN O
this NN NN O
patient's NN NN O
case NN NN O
due NN NN O
to NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
target NN NN O
volume NN NN O
is NN NN O
adjacent NN NN O
to NN NN O
significant NN NN O
radiosensitive NN NN O
structures NN NN O
. NN NN O

Sequential NN NN B-TEST
CT NN NN I-TEST
scan NN NN I-TEST
s NN NN O
are NN NN O
obtained NN NN O
and NN NN O
transferred NN NN O
to NN NN O
the NN NN O
treatment NN NN O
planning NN NN O
software NN NN O
. NN NN O

Extensive NN NN B-TEST
analysi NN NN I-TEST
s NN NN O
occurs NN NN O
. NN NN O

The NN NN O
target NN NN O
volumes NN NN O
, NN NN O
including NN NN O
margins NN NN O
for NN NN O
uncertainty NN NN O
, NN NN O
patient NN NN O
movement NN NN O
and NN NN O
occult NN NN B-PROBLEM
tumor NN NN I-PROBLEM
extensio NN NN I-PROBLEM
n NN NN O
are NN NN O
selected NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
organs NN NN O
at NN NN O
risk NN NN O
are NN NN O
outlined NN NN O
. NN NN O

Doses NN NN O
are NN NN O
selected NN NN O
both NN NN O
for NN NN O
targets NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
for NN NN O
organs NN NN O
at NN NN O
risk NN NN O
. NN NN O

Associated NN NN B-TREATMENT
dose NN NN I-TREATMENT
constraint NN NN I-TREATMENT
s NN NN O
are NN NN O
placed NN NN O
. NN NN O

Inverse NN NN B-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
planning NN NN O
is NN NN O
then NN NN O
performed NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
the NN NN O
physics NN NN O
staff NN NN O
. NN NN O

These NN NN O
are NN NN O
reviewed NN NN O
by NN NN O
the NN NN O
physician NN NN O
and NN NN O
ultimately NN NN O
performed NN NN O
only NN NN O
following NN NN O
approval NN NN O
by NN NN O
the NN NN O
physician NN NN O
. NN NN O

Multiple NN NN B-TREATMENT
beam NN NN I-TREATMENT
arrangement NN NN I-TREATMENT
s NN NN O
may NN NN O
be NN NN O
tested NN NN O
for NN NN O
appropriateness NN NN O
and NN NN O
optimal NN NN B-TREATMENT
dose NN NN I-TREATMENT
deliver NN NN I-TREATMENT
y NN NN O
in NN NN O
order NN NN O
to NN NN O
maximize NN NN O
the NN NN O
chance NN NN O
of NN NN O
controlling NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
while NN NN O
minimizing NN NN O
exposure NN NN O
to NN NN O
organs NN NN O
at NN NN O
risk NN NN O
. NN NN O

This NN NN O
is NN NN O
performed NN NN O
in NN NN O
hopes NN NN O
of NN NN O
minimizing NN NN O
associated NN NN B-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
. NN NN O

The NN NN O
physician NN NN O
delineates NN NN O
the NN NN O
treatment NN NN O
type NN NN O
, NN NN O
number NN NN O
of NN NN O
fractions NN NN O
and NN NN O
total NN NN O
volume NN NN O
. NN NN O

During NN NN O
the NN NN O
time NN NN O
of NN NN O
treatmen NN NN B-TREATMENT
t NN NN O
, NN NN O
there NN NN O
is NN NN O
extensive NN NN B-TREATMENT
physician NN NN I-TREATMENT
interventio NN NN I-TREATMENT
n NN NN O
, NN NN O
monitorin NN NN B-TEST
g NN NN O
the NN NN O
patient NN NN O
set NN NN O
up NN NN O
and NN NN O
tolerance NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
specific NN NN O
QA NN NN O
is NN NN O
performed NN NN O
by NN NN O
the NN NN O
physics NN NN O
staff NN NN O
under NN NN O
the NN NN O
physician's NN NN O
direction NN NN O
. NN NN O

In NN NN O
view NN NN O
of NN NN O
the NN NN O
above NN NN O
, NN NN O
the NN NN B-TREATMENT
special NN NN I-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
code NN NN O
7747 NN NN B-ID
0 NN NN O
is NN NN O
deemed NN NN O
appropriate NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
multiple NN NN B-TREATMENT
beam NN NN I-TREATMENT
arrangement NN NN I-TREATMENT
s NN NN O
, NN NN O
intensity NN NN B-TREATMENT
modulated NN NN I-TREATMENT
radiation NN NN I-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Neck NN NN O
Dissection NN NN O
Description NN NN O
: NN NN O
Left NN NN B-PROBLEM
neck NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
. NN NN O

Metastatic NN NN B-PROBLEM
papillary NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
left NN NN B-PROBLEM
nec NN NN I-PROBLEM
k NN NN O
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
thyroid NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
papillary NN NN B-PROBLEM
cell NN NN I-PROBLEM
typ NN NN I-PROBLEM
e NN NN O
, NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
total NN NN I-TREATMENT
thyroidectom NN NN I-TREATMENT
y NN NN O
and NN NN O
then NN NN O
subsequently NN NN B-PROBLEM
recurrent NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
was NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
paratracheal NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
papillary NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
left NN NN O
neck NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
papillary NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
left NN NN O
neck NN NN O
. NN NN O

OPERATION NN NN O
PERFORMED NN NN O
: NN NN O
Left NN NN B-TREATMENT
neck NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN O
endotracheal NN NN O
. NN NN O

INDICATIONS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
gentleman NN NN O
, NN NN O
who NN NN O
has NN NN O
had NN NN O
thyroid NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
papillary NN NN B-PROBLEM
cell NN NN I-PROBLEM
typ NN NN I-PROBLEM
e NN NN O
, NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
total NN NN I-TREATMENT
thyroidectom NN NN I-TREATMENT
y NN NN O
and NN NN O
then NN NN O
subsequently NN NN B-PROBLEM
recurrent NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
was NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
paratracheal NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
. NN NN O

He NN NN O
now NN NN O
has NN NN O
evidence NN NN O
of NN NN O
lesion NN NN B-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
left NN NN I-PROBLEM
mid NN NN I-PROBLEM
nec NN NN I-PROBLEM
k NN NN O
and NN NN O
the NN NN O
left NN NN O
superior NN NN O
neck NN NN O
on NN NN O
ultrasoun NN NN B-TEST
d NN NN O
, NN NN O
which NN NN O
are NN NN O
suspicious NN NN O
for NN NN O
recurrent NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
. NN NN O

Left NN NN B-TREATMENT
neck NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
is NN NN O
indicated NN NN O
. NN NN O

DESCRIPTION NN NN O
OF NN NN O
OPERATION NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
placed NN NN O
on NN NN O
the NN NN O
operating NN NN O
room NN NN O
table NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
. NN NN O

After NN NN O
adequate NN NN O
general NN NN O
endotracheal NN NN O
anesthesi NN NN B-DRUG
a NN NN O
was NN NN O
administered NN NN O
, NN NN O
the NN NN O
table NN NN O
was NN NN O
then NN NN O
turned NN NN O
. NN NN O

A NN NN B-TREATMENT
shoulder NN NN I-TREATMENT
rol NN NN I-TREATMENT
l NN NN O
placed NN NN O
under NN NN O
the NN NN O
shoulders NN NN O
and NN NN O
the NN NN O
face NN NN O
was NN NN O
placed NN NN O
in NN NN O
an NN NN O
extended NN NN O
fashion NN NN O
. NN NN O

The NN NN O
left NN NN O
neck NN NN O
, NN NN O
chest NN NN O
, NN NN O
and NN NN O
face NN NN O
were NN NN O
prepped NN NN O
with NN NN O
Betadin NN NN B-TREATMENT
e NN NN O
and NN NN O
drape NN NN B-TREATMENT
d NN NN O
in NN NN O
a NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

A NN NN B-PROBLEM
hockey NN NN I-PROBLEM
stick NN NN I-PROBLEM
skin NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
performed NN NN O
, NN NN O
extending NN NN O
a NN NN B-TREATMENT
previous NN NN I-TREATMENT
incision NN NN I-TREATMENT
lin NN NN I-TREATMENT
e NN NN O
superiorly NN NN O
towards NN NN O
the NN NN O
mastoid NN NN O
cortex NN NN O
through NN NN O
skin NN NN O
, NN NN O
subcutaneous NN NN O
tissue NN NN O
and NN NN O
platysma NN NN O
with NN NN O
Bovie NN NN B-TREATMENT
electrocauter NN NN I-TREATMENT
y NN NN O
on NN NN O
cut NN NN O
mode NN NN O
. NN NN O

Subplatysmal NN NN B-TREATMENT
superior NN NN I-TREATMENT
and NN NN I-TREATMENT
inferior NN NN I-TREATMENT
flap NN NN I-TREATMENT
s NN NN O
were NN NN O
raised NN NN O
. NN NN O

The NN NN B-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
was NN NN O
left NN NN B-PROBLEM
lateral NN NN I-PROBLEM
neck NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
encompassing NN NN O
zones NN NN O
1 NN NN O
, NN NN O
2A NN NN O
, NN NN O
2 NN NN B-TEST
B NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
the NN NN O
superior NN NN O
portion NN NN O
of NN NN O

4 NN NN O
. NN NN O
The NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
was NN NN O
unwrapped NN NN O
at NN NN O
its NN NN O
fascial NN NN O
attachment NN NN O
and NN NN O
this NN NN O
was NN NN O
taken NN NN O
back NN NN O
posterior NN NN O
to NN NN O
the NN NN O
XI NN NN O
cranial NN NN O
nerve NN NN O
into NN NN O
the NN NN O
superior NN NN O
posterior NN NN O
most NN NN O
triangle NN NN O
of NN NN O
the NN NN O
neck NN NN O
. NN NN O

This NN NN O
was NN NN O
carried NN NN O
forward NN NN O
off NN NN O
of NN NN O
the NN NN O
deep NN NN O
rooted NN NN O
muscles NN NN O
including NN NN O
the NN NN B-PROBLEM
splenius NN NN I-PROBLEM
capiti NN NN I-PROBLEM
s NN NN O
and NN NN O
anterior NN NN B-PROBLEM
and NN NN I-PROBLEM
middle NN NN I-PROBLEM
scalene NN NN I-PROBLEM
s NN NN O
taken NN NN O
medially NN NN O
off NN NN O
of NN NN O
these NN NN O
muscles NN NN O
including NN NN O
the NN NN O
fascia NN NN O
of NN NN O
the NN NN O
muscles NN NN O
, NN NN O
stripped NN NN O
from NN NN O
the NN NN O
carotid NN NN O
artery NN NN O
, NN NN O
the NN NN O
X NN NN O
cranial NN NN O
nerve NN NN O
, NN NN O
the NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
and NN NN O
then NN NN O
carried NN NN O
anteriorly NN NN O
to NN NN O
the NN NN O
lateral NN NN O
most NN NN O
extent NN NN O
of NN NN O
the NN NN B-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
previously NN NN O
done NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
in NN NN O
the NN NN O
paratracheal NN NN O
region NN NN O
. NN NN O

The NN NN O
submandibular NN NN O
gland NN NN O
was NN NN O
removed NN NN O
as NN NN O
well NN NN O
. NN NN O

The NN NN O
X NN NN O
, NN NN O
XI NN NN O
, NN NN O
and NN NN O
XII NN NN O
cranial NN NN O
nerves NN NN O
were NN NN O
preserved NN NN O
. NN NN O

The NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
and NN NN O
carotid NN NN O
artery NN NN O
were NN NN O
preserved NN NN O
as NN NN O
well NN NN O
. NN NN O

Copious NN NN B-TREATMENT
irrigatio NN NN I-TREATMENT
n NN NN O
of NN NN O
the NN NN B-PROBLEM
wound NN NN I-PROBLEM
be NN NN I-PROBLEM
d NN NN O
showed NN NN O
no NN NN O
identifiable NN NN B-PROBLEM
bleedin NN NN I-PROBLEM
g NN NN O
at NN NN O
the NN NN O
termination NN NN O
of NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
. NN NN O

There NN NN O
were NN NN O
two NN NN B-PROBLEM
obviously NN NN I-PROBLEM
positive NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
in NN NN O
this NN NN B-PROBLEM
neck NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
. NN NN O

One NN NN O
was NN NN O
left NN NN O
medial NN NN O
neck NN NN O
just NN NN O
lateral NN NN O
to NN NN O
the NN NN B-PROBLEM
previous NN NN I-PROBLEM
tracheal NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
and NN NN O
one NN NN O
was NN NN O
in NN NN O
the NN NN O
mid NN NN O
region NN NN O
of NN NN O
zone NN NN O

2 NN NN O
. NN NN O
A NN NN B-TREATMENT
#10 NN NN I-TREATMENT
flat NN NN I-TREATMENT
fluted NN NN I-TREATMENT
Blake NN NN I-TREATMENT
drai NN NN I-TREATMENT
n NN NN O
was NN NN O
placed NN NN O
through NN NN O
a NN NN B-PROBLEM
separate NN NN I-PROBLEM
stab NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
and NN NN O
it NN NN O
was NN NN O
secured NN NN O
to NN NN O
the NN NN O
skin NN NN O
with NN NN O
a NN NN B-TREATMENT
2-0 NN NN I-TREATMENT
silk NN NN I-TREATMENT
ligatur NN NN I-TREATMENT
e NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
closed NN NN O
in NN NN O
layers NN NN O
using NN NN O
a NN NN B-TREATMENT
3-0 NN NN I-TREATMENT
Vicry NN NN I-TREATMENT
l NN NN O
in NN NN O
a NN NN B-TREATMENT
buried NN NN I-TREATMENT
kno NN NN I-TREATMENT
t NN NN O
interrupted NN NN O
fashion NN NN O
for NN NN O
the NN NN O
subcutaneous NN NN O
tissue NN NN O
and NN NN O
the NN NN O
skin NN NN O
was NN NN O
closed NN NN O
with NN NN O
staple NN NN B-TREATMENT
s NN NN O
. NN NN O

A NN NN B-TREATMENT
fluff NN NN I-TREATMENT
and NN NN I-TREATMENT
Kling NN NN I-TREATMENT
pressure NN NN I-TREATMENT
dressin NN NN I-TREATMENT
g NN NN O
was NN NN O
then NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
extubated NN NN O
in NN NN O
the NN NN O
operating NN NN O
room NN NN O
, NN NN O
brought NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
satisfactory NN NN O
condition NN NN O
. NN NN O

There NN NN O
were NN NN O
no NN NN O
intraoperative NN NN B-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
metastatic NN NN B-PROBLEM
papillary NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
thyroidectom NN NN B-TREATMENT
y NN NN O
, NN NN O
thyroid NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
papillary NN NN B-PROBLEM
cell NN NN I-PROBLEM
typ NN NN I-PROBLEM
e NN NN O
, NN NN O
dissection NN NN B-PROBLEM
, NN NN I-PROBLEM
neck NN NN I-PROBLEM
, NN NN I-PROBLEM
metastati NN NN I-PROBLEM
c NN NN O
, NN NN O
paratracheal NN NN B-PROBLEM
, NN NN I-PROBLEM
papillar NN NN I-PROBLEM
y NN NN O
, NN NN O
cance NN NN B-PROBLEM
r NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
HDR NN NN B-TREATMENT
Brachytherap NN NN I-TREATMENT
y NN NN O
Description NN NN O
: NN NN O
HDR NN NN B-TREATMENT
Brachytherap NN NN I-TREATMENT
y NN NN O
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
HDR NN NN B-TREATMENT
BRACHYTHERAP NN NN I-TREATMENT
Y NN NN O
The NN NN B-TREATMENT
intracavitary NN NN I-TREATMENT
brachytherapy NN NN I-TREATMENT
applicato NN NN I-TREATMENT
r NN NN O
was NN NN O
placed NN NN O
appropriately NN NN O
and NN NN O
secured NN NN O
after NN NN O
the NN NN O
patient NN NN O
was NN NN O
identified NN NN O
. NN NN O

Simulation NN NN B-TEST
film NN NN I-TEST
s NN NN O
were NN NN O
obtained NN NN O
, NN NN O
documenting NN NN O
its NN NN O
positioning NN NN O
. NN NN O

The NN NN O
3-dimensional NN NN O
treatment NN NN O
planning NN NN O
process NN NN O
was NN NN O
accomplished NN NN O
utilizing NN NN O
the NN NN B-TEST
C NN NN I-TEST
T NN NN O
derived NN NN O
data NN NN O
. NN NN O

A NN NN O
treatment NN NN O
plan NN NN O
was NN NN O
selected NN NN O
utilizing NN NN O
sequential NN NN O
dwell NN NN O
positions NN NN O
within NN NN O
a NN NN B-TREATMENT
single NN NN I-TREATMENT
cathete NN NN I-TREATMENT
r NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
treatment NN NN O
area NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
appropriately NN NN O
positioned NN NN O
and NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN B-TREATMENT
intracavitary NN NN I-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
was NN NN O
checked NN NN O
. NN NN O

Catheter NN NN B-TEST
length NN NN I-TEST
measurement NN NN I-TEST
s NN NN O
were NN NN O
taken NN NN O
. NN NN O

Appropriate NN NN O
measurements NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
probe NN NN I-TEST
dimension NN NN I-TEST
s NN NN O
and NN NN O
assembly NN NN O
were NN NN O
also NN NN O
performed NN NN O
. NN NN O

The NN NN B-TREATMENT
applicato NN NN I-TREATMENT
r NN NN O
was NN NN O
attached NN NN O
to NN NN O
the NN NN B-TREATMENT
HDR NN NN I-TREATMENT
after-loader NN NN I-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
. NN NN O

The NN NN B-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
ran NN NN O
through NN NN O
its NN NN O
checking NN NN O
sequences NN NN O
appropriately NN NN O
and NN NN O
the NN NN B-TREATMENT
brachytherap NN NN I-TREATMENT
y NN NN O
was NN NN O
then NN NN O
delivered NN NN O
without NN NN O
difficult NN NN B-PROBLEM
y NN NN O
or NN NN O
complicatio NN NN B-PROBLEM
n NN NN O
. NN NN O

The NN NN B-TREATMENT
brachytherap NN NN I-TREATMENT
y NN NN O
source NN NN O
was NN NN O
appropriately NN NN O
removed NN NN O
back NN NN O
to NN NN O
the NN NN B-TREATMENT
brachytherap NN NN I-TREATMENT
y NN NN O
safe NN NN O
within NN NN O
the NN NN B-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
. NN NN O

Radiation NN NN B-TEST
screenin NN NN I-TEST
g NN NN O
was NN NN O
performed NN NN O
with NN NN O
the NN NN B-TREATMENT
Geiger-Muller NN NN I-TREATMENT
counte NN NN I-TREATMENT
r NN NN O
both NN NN O
prior NN NN O
to NN NN O
and NN NN O
after NN NN O
the NN NN B-TREATMENT
brachytherapy NN NN I-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
was NN NN O
completed NN NN O
and NN NN O
the NN NN O
results NN NN O
were NN NN O
deemed NN NN O
appropriate NN NN O
. NN NN O

Following NN NN O
completion NN NN O
of NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
, NN NN O
the NN NN B-TREATMENT
intracavitary NN NN I-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
was NN NN O
removed NN NN O
without NN NN O
difficult NN NN B-PROBLEM
y NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
in NN NN O
no NN NN O
apparent NN NN B-PROBLEM
distres NN NN I-PROBLEM
s NN NN O
and NN NN O
was NN NN O
discharged NN NN O
home NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
geiger-mulle NN NN B-TREATMENT
r NN NN O
, NN NN O
treatmen NN NN B-TREATMENT
t NN NN O
planning NN NN O
, NN NN O
hdr NN NN B-TREATMENT
brachytherap NN NN I-TREATMENT
y NN NN O
, NN NN O
intracavitar NN NN B-TREATMENT
y NN NN O
, NN NN O
applicato NN NN B-TREATMENT
r NN NN O
, NN NN O
brachytherap NN NN B-TREATMENT
y NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Biops NN NN B-TEST
y NN NN O
- NN NN O
Cervical NN NN O
Lymph NN NN O
Node NN NN O
Description NN NN O
: NN NN O
Excisional NN NN B-TEST
biopsy NN NN I-TEST
of NN NN I-TEST
right NN NN I-TEST
cervical NN NN I-TEST
lymph NN NN I-TEST
nod NN NN I-TEST
e NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Cervical NN NN B-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Cervical NN NN B-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
Excisional NN NN B-TEST
biopsy NN NN I-TEST
of NN NN I-TEST
right NN NN I-TEST
cervical NN NN I-TEST
lymph NN NN I-TEST
nod NN NN I-TEST
e NN NN O
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN B-TREATMENT
endotracheal NN NN I-TREATMENT
anesthesi NN NN I-TREATMENT
a NN NN O
. NN NN O

SPECIMEN NN NN O
: NN NN O
Right NN NN B-PROBLEM
cervical NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
. NN NN O

EB NN NN B-TEST
L NN NN O
: NN NN O
10 NN NN O
cc NN NN O
. NN NN O

COMPLICATIONS NN NN O
: NN NN O
None NN NN O
. NN NN O

FINDINGS NN NN O
: NN NN O
Enlarged NN NN B-PROBLEM
level NN NN I-PROBLEM
2 NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
was NN NN O
identified NN NN O
and NN NN O
removed NN NN O
and NN NN O
sent NN NN O
for NN NN O
pathologic NN NN B-TEST
examinatio NN NN I-TEST
n NN NN O
. NN NN O

FLUIDS NN NN O
: NN NN O
Please NN NN O
see NN NN O
anesthesia NN NN O
report NN NN O
. NN NN O

URINE NN NN O
OUTPUT NN NN O
: NN NN O
None NN NN O
recorded NN NN O
during NN NN O
the NN NN O
case NN NN O
. NN NN O

INDICATIONS NN NN O
FOR NN NN O
PROCEDURE NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
43-year-ol NN NN B-AGE
d NN NN O
female NN NN O
with NN NN O
a NN NN O
several-year NN NN O
history NN NN O
of NN NN O
persistent NN NN B-PROBLEM
cervical NN NN I-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

She NN NN O
reports NN NN O
that NN NN O
it NN NN O
is NN NN O
painfu NN NN B-PROBLEM
l NN NN O
to NN NN O
palpation NN NN B-TEST
on NN NN I-TEST
the NN NN I-TEST
righ NN NN I-TEST
t NN NN O
and NN NN O
has NN NN O
had NN NN O
multiple NN NN B-TEST
CT NN NN I-TEST
scan NN NN I-TEST
s NN NN O
as NN NN O
well NN NN O
as NN NN O
an NN NN B-TEST
FN NN NN I-TEST
A NN NN O
which NN NN O
were NN NN O
all NN NN O
nondiagnostic NN NN O
. NN NN O

After NN NN O
risks NN NN O
and NN NN O
benefits NN NN O
of NN NN O
surger NN NN B-TREATMENT
y NN NN O
were NN NN O
discussed NN NN O
with NN NN O
the NN NN O
patient NN NN O
, NN NN O
an NN NN O
informed NN NN O
consent NN NN O
was NN NN O
obtained NN NN O
. NN NN O

She NN NN O
was NN NN O
scheduled NN NN O
for NN NN O
an NN NN B-TEST
excisional NN NN I-TEST
biopsy NN NN I-TEST
of NN NN I-TEST
the NN NN I-TEST
right NN NN I-TEST
cervical NN NN I-TEST
lymph NN NN I-TEST
nod NN NN I-TEST
e NN NN O
. NN NN O

PROCEDURE NN NN O
IN NN NN O
DETAIL NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
placed NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
. NN NN O

She NN NN O
was NN NN O
anesthetized NN NN O
with NN NN O
general NN NN B-TREATMENT
endotracheal NN NN I-TREATMENT
anesthesi NN NN I-TREATMENT
a NN NN O
. NN NN O

The NN NN O
neck NN NN O
was NN NN O
then NN NN O
prepped NN NN B-TREATMENT
and NN NN I-TREATMENT
drape NN NN I-TREATMENT
d NN NN O
in NN NN O
the NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

Again NN NN O
, NN NN O
noted NN NN O
on NN NN O
palpatio NN NN B-TEST
n NN NN O
there NN NN O
was NN NN O
an NN NN B-PROBLEM
enlarged NN NN I-PROBLEM
level NN NN I-PROBLEM
2 NN NN I-PROBLEM
cervical NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
. NN NN O

A NN NN B-PROBLEM
3-cm NN NN I-PROBLEM
horizontal NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
made NN NN O
over NN NN O
this NN NN O
lymph NN NN O
node NN NN O
. NN NN O

Dissectio NN NN B-TREATMENT
n NN NN O
was NN NN O
carried NN NN O
down NN NN O
until NN NN O
the NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
was NN NN O
identified NN NN O
. NN NN O

The NN NN B-PROBLEM
enlarged NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
that NN NN O
measured NN NN O
approximately NN NN O
2 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
was NN NN O
identified NN NN O
and NN NN O
was NN NN O
removed NN NN O
and NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
for NN NN O
touch NN NN B-TEST
prep NN NN I-TEST
evaluatio NN NN I-TEST
n NN NN O
. NN NN O

The NN NN O
area NN NN O
was NN NN O
then NN NN O
explored NN NN O
for NN NN O
any NN NN B-PROBLEM
other NN NN I-PROBLEM
enlarged NN NN I-PROBLEM
lymph NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
. NN NN O

None NN NN O
were NN NN O
identified NN NN O
, NN NN O
and NN NN O
hemostasi NN NN B-TREATMENT
s NN NN O
was NN NN O
achieved NN NN O
with NN NN O
electrocauter NN NN B-TREATMENT
y NN NN O
. NN NN O

A NN NN B-TREATMENT
quarter-inch NN NN I-TREATMENT
Penrose NN NN I-TREATMENT
drai NN NN I-TREATMENT
n NN NN O
was NN NN O
placed NN NN O
in NN NN O
the NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
then NN NN O
irrigated NN NN O
and NN NN O
closed NN NN O
with NN NN O
3-0 NN NN O
interrupted NN NN O
Vicryl NN NN B-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
for NN NN O
a NN NN B-TREATMENT
deep NN NN I-TREATMENT
closur NN NN I-TREATMENT
e NN NN O
followed NN NN O
by NN NN O
a NN NN B-TREATMENT
running NN NN I-TREATMENT
4-0 NN NN I-TREATMENT
Prolene NN NN I-TREATMENT
subcuticular NN NN I-TREATMENT
sutur NN NN I-TREATMENT
e NN NN O
. NN NN O

Mastiso NN NN B-TREATMENT
l NN NN O
and NN NN O
Steri-Stri NN NN B-TREATMENT
p NN NN O
were NN NN O
placed NN NN O
over NN NN O
the NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
, NN NN O
and NN NN O
sterile NN NN B-TREATMENT
bandag NN NN I-TREATMENT
e NN NN O
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
this NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
well NN NN O
and NN NN O
was NN NN O
extubated NN NN O
without NN NN O
complication NN NN B-PROBLEM
s NN NN O
and NN NN O
transported NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

She NN NN O
will NN NN O
return NN NN O
to NN NN O
the NN NN O
office NN NN O
tomorrow NN NN O
in NN NN O
followup NN NN O
to NN NN O
have NN NN O
the NN NN B-TREATMENT
Penrose NN NN I-TREATMENT
drai NN NN I-TREATMENT
n NN NN O
removed NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
, NN NN O
excisional NN NN B-TEST
biops NN NN I-TEST
y NN NN O
, NN NN O
fn NN NN B-TEST
a NN NN O
, NN NN O
mastiso NN NN B-TREATMENT
l NN NN O
, NN NN O
penrose NN NN B-TREATMENT
drai NN NN I-TREATMENT
n NN NN O
, NN NN O
cervical NN NN B-TREATMENT
, NN NN I-TREATMENT
cervical NN NN I-TREATMENT
lymph NN NN I-TREATMENT
nod NN NN I-TREATMENT
e NN NN O
, NN NN O
endotracheal NN NN B-TREATMENT
anesthesi NN NN I-TREATMENT
a NN NN O
, NN NN O
lymph NN NN B-TREATMENT
nod NN NN I-TREATMENT
e NN NN O
, NN NN O
sternocleidomastoid NN NN B-TREATMENT
, NN NN I-TREATMENT
cervical NN NN I-TREATMENT
lymp NN NN I-TREATMENT
h NN NN O
, NN NN O
lymp NN NN B-TREATMENT
h NN NN O
, NN NN O
anesthesi NN NN B-TREATMENT
a NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
Ovarian NN NN I-PROBLEM
Cance NN NN I-PROBLEM
r NN NN O
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
A NN NN O
very NN NN O
pleasant NN NN O
66-year-ol NN NN B-AGE
d NN NN O
woman NN NN O
with NN NN O
recurrent NN NN B-PROBLEM
metastatic NN NN I-PROBLEM
ovarian NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
ovarian NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
Mrs NN NN O
. NN NN O

ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
66-year-ol NN NN B-AGE
d NN NN O
woman NN NN O
who NN NN O
is NN NN O
followed NN NN O
in NN NN O
clinic NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
for NN NN O
history NN NN O
of NN NN O
renal NN NN B-PROBLEM
cell NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
breast NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
ovarian NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
which NN NN O
was NN NN O
initially NN NN O
diagnosed NN NN O
10 NN NN O
years NN NN O
ago NN NN O
, NN NN O
but NN NN O
over NN NN O
the NN NN O
last NN NN O
several NN NN O
months NN NN O
has NN NN O
recurred NN NN O
and NN NN O
is NN NN O
now NN NN O
metastati NN NN B-PROBLEM
c NN NN O
. NN NN O

She NN NN O
last NN NN O
saw NN NN O
Dr NN NN O
. NN NN O
X NN NN O
in NN NN O
clinic NN NN O
towards NN NN O
the NN NN O
beginning NN NN O
of NN NN O
this NN NN O
month NN NN O
. NN NN O

She NN NN O
has NN NN O
been NN NN O
receiving NN NN O
gemcitabin NN NN B-DRUG
e NN NN O
and NN NN O
carboplati NN NN B-DRUG
n NN NN O
, NN NN O
and NN NN O
she NN NN O
receives NN NN O
three NN NN O
cycles NN NN O
of NN NN O
this NN NN O
with NN NN O
the NN NN O
last NN NN O
one NN NN O
being NN NN O
given NN NN O
on NN NN O
12/15/0 NN NN B-DATE

8 NN NN O
. NN NN O
She NN NN O
was NN NN O
last NN NN O
seen NN NN O
in NN NN O
clinic NN NN O
on NN NN O
12/22/0 NN NN B-DATE
8 NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Y NN NN O
. NN NN O
At NN NN O
that NN NN O
point NN NN O
, NN NN O
her NN NN B-TEST
white NN NN I-TEST
coun NN NN I-TEST
t NN NN O
was NN NN O
0.9 NN NN O
with NN NN O
the NN NN B-TEST
hemoglobi NN NN I-TEST
n NN NN O
of NN NN O
10.3 NN NN O
, NN NN O
hematocri NN NN B-TEST
t NN NN O
of NN NN O
30% NN NN O
, NN NN O
and NN NN O
platelet NN NN B-TEST
s NN NN O
of NN NN O
81,000 NN NN O
. NN NN O

Her NN NN B-TEST
AN NN NN I-TEST
C NN NN O
was NN NN O
0.5 NN NN O
. NN NN O

She NN NN O
was NN NN O
started NN NN O
on NN NN O
prophylactic NN NN O
Augmenti NN NN B-DRUG
n NN NN O
as NN NN O
well NN NN O
as NN NN O
Neupogen NN NN B-TREATMENT
shot NN NN I-TREATMENT
s NN NN O
. NN NN O

She NN NN O
has NN NN O
also NN NN O
had NN NN O
history NN NN O
of NN NN O
recurrent NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusions NN NN I-PROBLEM
with NN NN I-PROBLEM
the NN NN I-PROBLEM
kne NN NN I-PROBLEM
e NN NN O
for NN NN O
thoracentesi NN NN B-TREATMENT
s NN NN O
. NN NN O

She NN NN O
had NN NN O
two NN NN O
of NN NN O
these NN NN O
performed NN NN O
in NN NN O
Novembe NN NN B-DATE
r NN NN O
and NN NN O
the NN NN O
last NN NN O
one NN NN O
was NN NN O
done NN NN O
about NN NN O
a NN NN O
week NN NN O
ago NN NN O
. NN NN O

Over NN NN O
the NN NN O
last NN NN O
2 NN NN O
or NN NN O
3 NN NN O
days NN NN O
, NN NN O
she NN NN O
states NN NN O
she NN NN O
has NN NN O
been NN NN O
getting NN NN O
more NN NN B-PROBLEM
short NN NN I-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
. NN NN O

Her NN NN O
history NN NN O
is NN NN O
somewhat NN NN O
limited NN NN O
today NN NN O
as NN NN O
she NN NN O
is NN NN O
very NN NN B-PROBLEM
tire NN NN I-PROBLEM
d NN NN O
and NN NN O
falls NN NN O
asleep NN NN O
readily NN NN O
. NN NN O

Her NN NN O
history NN NN O
comes NN NN O
from NN NN O
herself NN NN O
but NN NN O
also NN NN O
from NN NN O
the NN NN O
review NN NN O
of NN NN O
the NN NN O
records NN NN O
. NN NN O

Overall NN NN O
, NN NN O
her NN NN B-PROBLEM
shortness NN NN I-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
has NN NN O
been NN NN O
going NN NN O
on NN NN O
for NN NN O
the NN NN O
past NN NN O
few NN NN O
weeks NN NN O
related NN NN O
to NN NN O
her NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
. NN NN O

She NN NN O
was NN NN O
seen NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
this NN NN O
time NN NN O
and NN NN O
on NN NN O
chest NN NN B-TEST
x-ra NN NN I-TEST
y NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN B-PROBLEM
new NN NN I-PROBLEM
right-sided NN NN I-PROBLEM
pulmonic NN NN I-PROBLEM
consolidative NN NN I-PROBLEM
infiltrat NN NN I-PROBLEM
e NN NN O
, NN NN O
which NN NN O
was NN NN O
felt NN NN O
to NN NN O
be NN NN O
possibly NN NN O
related NN NN O
to NN NN O
pneumoni NN NN B-PROBLEM
a NN NN O
. NN NN O

She NN NN O
specifically NN NN O
denied NN NN O
any NN NN O
fever NN NN B-PROBLEM
s NN NN O
or NN NN O
chill NN NN B-PROBLEM
s NN NN O
. NN NN O

However NN NN O
, NN NN O
she NN NN O
was NN NN O
complaining NN NN O
of NN NN O
chest NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
. NN NN O

She NN NN O
states NN NN O
that NN NN O
the NN NN B-PROBLEM
chest NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
was NN NN O
located NN NN O
in NN NN O
the NN NN O
substernal NN NN O
area NN NN O
, NN NN O
described NN NN O
as NN NN O
achin NN NN B-PROBLEM
g NN NN O
, NN NN O
coming NN NN O
and NN NN O
going NN NN O
and NN NN O
associated NN NN O
with NN NN O
shortness NN NN B-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
and NN NN O
coug NN NN B-PROBLEM
h NN NN O
. NN NN O

When NN NN O
she NN NN O
did NN NN O
coug NN NN B-PROBLEM
h NN NN O
, NN NN O
it NN NN O
was NN NN O
nonproductive NN NN O
. NN NN O

While NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
on NN NN O
examinatio NN NN B-TEST
n NN NN O
, NN NN O
her NN NN B-TEST
vital NN NN I-TEST
sign NN NN I-TEST
s NN NN O
were NN NN O
stable NN NN O
except NN NN O
that NN NN O
she NN NN O
required NN NN O
5 NN NN B-DOSAGE
liter NN NN I-DOSAGE
s NN NN O
nasal NN NN B-ROUTE
cannul NN NN I-ROUTE
a NN NN O
to NN NN O
maintain NN NN O
oxygen NN NN B-TEST
saturation NN NN I-TEST
s NN NN O
. NN NN O

An NN NN B-TEST
EK NN NN I-TEST
G NN NN O
was NN NN O
performed NN NN O
, NN NN O
which NN NN O
showed NN NN O
sinus NN NN B-PROBLEM
rhyth NN NN I-PROBLEM
m NN NN O
without NN NN O
any NN NN O
evidence NN NN O
of NN NN O
Q NN NN B-PROBLEM
wave NN NN I-PROBLEM
s NN NN O
or NN NN O
other NN NN B-PROBLEM
ischemic NN NN I-PROBLEM
change NN NN I-PROBLEM
s NN NN O
. NN NN O

The NN NN B-TEST
chest NN NN I-TEST
x-ra NN NN I-TEST
y NN NN O
described NN NN O
above NN NN O
showed NN NN O
a NN NN B-PROBLEM
right NN NN I-PROBLEM
lower NN NN I-PROBLEM
lobe NN NN I-PROBLEM
infiltrat NN NN I-PROBLEM
e NN NN O
. NN NN O

A NN NN B-TEST
V/Q NN NN I-TEST
sca NN NN I-TEST
n NN NN O
was NN NN O
done NN NN O
, NN NN O
which NN NN O
showed NN NN O
a NN NN B-PROBLEM
small NN NN I-PROBLEM
mismatched NN NN I-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
left NN NN I-PROBLEM
upper NN NN I-PROBLEM
lob NN NN I-PROBLEM
e NN NN O
and NN NN O
a NN NN B-PROBLEM
mass NN NN I-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
right NN NN I-PROBLEM
upper NN NN I-PROBLEM
lob NN NN I-PROBLEM
e NN NN O
. NN NN O

The NN NN O
findings NN NN O
were NN NN O
compatible NN NN O
with NN NN O
an NN NN O
indeterminate NN NN O
study NN NN O
for NN NN O
a NN NN B-PROBLEM
pulmonary NN NN I-PROBLEM
embolis NN NN I-PROBLEM
m NN NN O
. NN NN O

Apparently NN NN O
, NN NN O
an NN NN B-TEST
ultrasound NN NN I-TEST
of NN NN I-TEST
the NN NN I-TEST
lower NN NN I-TEST
extremitie NN NN I-TEST
s NN NN O
was NN NN O
done NN NN O
and NN NN O
was NN NN O
negative NN NN O
for NN NN O
DV NN NN B-PROBLEM
T NN NN O
. NN NN O
There NN NN O
was NN NN O
apparently NN NN O
still NN NN O
some NN NN O
concern NN NN O
that NN NN O
this NN NN O
might NN NN O
be NN NN O
pulmonary NN NN B-PROBLEM
embolis NN NN I-PROBLEM
m NN NN O
and NN NN O
she NN NN O
was NN NN O
started NN NN O
on NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
. NN NN O

There NN NN O
was NN NN O
also NN NN O
concern NN NN O
for NN NN O
pneumoni NN NN B-PROBLEM
a NN NN O
and NN NN O
she NN NN O
was NN NN O
started NN NN O
on NN NN O
Zosy NN NN B-TREATMENT
n NN NN O
as NN NN O
well NN NN O
as NN NN O
vancomyci NN NN B-TREATMENT
n NN NN O
and NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
we NN NN O
have NN NN O
been NN NN O
consulted NN NN O
to NN NN O
help NN NN O
follow NN NN O
along NN NN O
with NN NN O
this NN NN O
patient NN NN O
who NN NN O
is NN NN O
well NN NN O
known NN NN O
to NN NN O
our NN NN O
clinic NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Ovarian NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
- NN NN O
This NN NN O
was NN NN O
initially NN NN O
diagnosed NN NN O
about NN NN O
10 NN NN O
years NN NN O
ago NN NN O
and NN NN O
treated NN NN O
with NN NN O
surgical NN NN B-TREATMENT
resectio NN NN I-TREATMENT
n NN NN O
including NN NN O
TA NN NN B-TREATMENT
H NN NN O
and NN NN O
BS NN NN B-TREATMENT
O NN NN O
. NN NN O
This NN NN O
has NN NN O
recurred NN NN O
over NN NN O
the NN NN O
last NN NN O
couple NN NN O
of NN NN O
months NN NN O
with NN NN O
metastatic NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
. NN NN O

2 NN NN O
. NN NN O
History NN NN O
of NN NN O
breast NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
- NN NN O
She NN NN O
has NN NN O
been NN NN O
treated NN NN O
with NN NN O
bilateral NN NN B-TREATMENT
mastectom NN NN I-TREATMENT
y NN NN O
with NN NN O
the NN NN O
first NN NN O
one NN NN O
about NN NN O
14 NN NN O
years NN NN O
and NN NN O
the NN NN O
second NN NN O
one NN NN O
about NN NN O
5 NN NN O
years NN NN O
ago NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
no NN NN O
recurrent NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
. NN NN O

3 NN NN O
. NN NN O
Renal NN NN B-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
- NN NN O
She NN NN O
is NN NN O
status NN NN O
post NN NN O
nephrectom NN NN B-TREATMENT
y NN NN O
. NN NN O

4 NN NN O
. NN NN O
Hypertensio NN NN B-PROBLEM
n NN NN O
. NN NN O

5 NN NN O
. NN NN O
Anxiety NN NN B-PROBLEM
disorde NN NN I-PROBLEM
r NN NN O
. NN NN O

6 NN NN O
. NN NN O
Chronic NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
from NN NN O
neuropath NN NN B-PROBLEM
y NN NN O
secondary NN NN O
to NN NN O
chemotherap NN NN B-DRUG
y NN NN O
from NN NN O
breast NN NN B-TREATMENT
cancer NN NN I-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
. NN NN O

7 NN NN O
. NN NN O
Ongoing NN NN O
tobacco NN NN O
use NN NN O
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Recent NN NN O
and NN NN O
multiple NN NN B-TREATMENT
thoracentesi NN NN I-TREATMENT
s NN NN O
as NN NN O
described NN NN O
above NN NN O
. NN NN O

2 NN NN O
. NN NN O
Bilateral NN NN B-TREATMENT
mastectomie NN NN I-TREATMENT
s NN NN O
. NN NN O

3 NN NN O
. NN NN O
Multiple NN NN B-TREATMENT
abdominal NN NN I-TREATMENT
surgerie NN NN I-TREATMENT
s NN NN O
. NN NN O

4 NN NN O
. NN NN O
Cholecystectom NN NN B-TREATMENT
y NN NN O
. NN NN O

5 NN NN O
. NN NN O
Remote NN NN B-PROBLEM
right NN NN I-PROBLEM
ankle NN NN I-PROBLEM
fractur NN NN I-PROBLEM
e NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NN NN B-PROBLEM
drug NN NN I-PROBLEM
allergie NN NN I-PROBLEM
s NN NN O
. NN NN O

MEDICATIONS NN NN O
: NN NN O
At NN NN O
home NN NN O
, NN NN O

1 NN NN O
. NN NN O
Atenolo NN NN B-TREATMENT
l NN NN O
50 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
dail NN NN B-FREQUENCY
y NN NN O

2 NN NN O
. NN NN O
Ativa NN NN B-TREATMENT
n NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

3 NN NN O
. NN NN O
Clonidin NN NN B-TREATMENT
e NN NN O
0.1 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
nightl NN NN B-FREQUENCY
y NN NN O
. NN NN O

4 NN NN O
. NN NN O
Compazin NN NN B-DRUG
e NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

5 NN NN O
. NN NN O
Dilaudi NN NN B-TREATMENT
d NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

6 NN NN O
. NN NN O
Gabapenti NN NN B-TREATMENT
n NN NN O
300 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
p NN NN B-ROUTE
. NN NN I-ROUTE

o NN NN O
. NN NN O

t.i NN NN B-FREQUENCY
. NN NN I-FREQUENCY
d NN NN O
. NN NN O

7 NN NN O
. NN NN O
K-Du NN NN B-TREATMENT
r NN NN O
20 NN NN B-STRENGTH
mE NN NN I-STRENGTH
q NN NN O
p NN NN B-ROUTE
. NN NN I-ROUTE

o NN NN O
. NN NN O

dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

8 NN NN O
. NN NN O
Lasi NN NN B-TREATMENT
x NN NN O
unknown NN NN O
dose NN NN O
dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

9 NN NN O
. NN NN O
Norvas NN NN B-TREATMENT
c NN NN O
5 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

10 NN NN O
. NN NN O
Zofra NN NN B-TREATMENT
n NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
smokes NN NN O
about NN NN O
6-7 NN NN O
cigarettes NN NN O
per NN NN O
day NN NN O
and NN NN O
has NN NN O
done NN NN O
so NN NN O
for NN NN O
more NN NN O
than NN NN O
50 NN NN O
years NN NN O
. NN NN O

She NN NN O
quit NN NN O
smoking NN NN O
about NN NN O
6 NN NN O
weeks NN NN O
ago NN NN O
. NN NN O

She NN NN O
occasionally NN NN O
has NN NN O
alcohol NN NN O
. NN NN O

She NN NN O
is NN NN O
married NN NN O
and NN NN O
has NN NN O
3 NN NN O
children NN NN O
. NN NN O

She NN NN O
lives NN NN O
at NN NN O
home NN NN O
with NN NN O
her NN NN O
husband NN NN O
. NN NN O

She NN NN O
used NN NN O
to NN NN O
work NN NN O
as NN NN O
a NN NN O
unit NN NN B-PROFESSION
cler NN NN I-PROFESSION
k NN NN O
at NN NN O
XYZ NN NN B-LOCATION
Medical NN NN I-LOCATION
Cente NN NN I-LOCATION
r NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Both NN NN O
her NN NN O
mother NN NN O
and NN NN O
father NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
lung NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
and NN NN O
both NN NN O
were NN NN O
smokers NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
GENERAL/CONSTITUTIONAL NN NN O
: NN NN O
She NN NN O
has NN NN O
not NN NN O
had NN NN O
any NN NN B-PROBLEM
feve NN NN I-PROBLEM
r NN NN O
, NN NN O
chill NN NN B-PROBLEM
s NN NN O
, NN NN O
night NN NN B-PROBLEM
sweat NN NN I-PROBLEM
s NN NN O
, NN NN O
but NN NN O
has NN NN O
had NN NN O
fatigu NN NN B-PROBLEM
e NN NN O
and NN NN O
weight NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
of NN NN O
unspecified NN NN O
amount NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
She NN NN O
has NN NN O
not NN NN O
had NN NN O
trouble NN NN O
with NN NN O
headache NN NN B-PROBLEM
s NN NN O
; NN NN O

mouth NN NN O
, NN NN O
jaw NN NN B-PROBLEM
, NN NN I-PROBLEM
or NN NN I-PROBLEM
teeth NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
; NN NN O

change NN NN B-PROBLEM
in NN NN I-PROBLEM
visio NN NN I-PROBLEM
n NN NN O
; NN NN O

double NN NN B-PROBLEM
visio NN NN I-PROBLEM
n NN NN O
; NN NN O

or NN NN O
loss NN NN B-PROBLEM
of NN NN I-PROBLEM
hearin NN NN I-PROBLEM
g NN NN O
or NN NN O
ringing NN NN B-PROBLEM
in NN NN I-PROBLEM
her NN NN I-PROBLEM
ear NN NN I-PROBLEM
s NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
she NN NN O
has NN NN O
had NN NN O
some NN NN B-PROBLEM
increasing NN NN I-PROBLEM
dyspne NN NN I-PROBLEM
a NN NN O
, NN NN O
shortness NN NN B-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
with NN NN O
exertion NN NN O
, NN NN O
coug NN NN B-PROBLEM
h NN NN O
, NN NN O
but NN NN O
no NN NN O
sputum NN NN B-PROBLEM
productio NN NN I-PROBLEM
n NN NN O
or NN NN O
hemoptysi NN NN B-PROBLEM
s NN NN O
. NN NN O

CV NN NN B-TEST
S NN NN O
: NN NN O
She NN NN O
has NN NN O
had NN NN O
the NN NN O
episodes NN NN O
of NN NN O
chest NN NN B-PROBLEM
pain NN NN I-PROBLEM
s NN NN O
as NN NN O
described NN NN O
above NN NN O
but NN NN O
has NN NN O
not NN NN O
had NN NN O
, NN NN O
PND NN NN B-PROBLEM
, NN NN I-PROBLEM
orthopnea NN NN I-PROBLEM
lower NN NN I-PROBLEM
extremity NN NN I-PROBLEM
swellin NN NN I-PROBLEM
g NN NN O
or NN NN O
palpitation NN NN B-PROBLEM
s NN NN O
. NN NN O

GI NN NN O
: NN NN O
No NN NN O
heartbur NN NN B-PROBLEM
n NN NN O
, NN NN O
odynophagi NN NN B-PROBLEM
a NN NN O
, NN NN O
dysphagi NN NN B-PROBLEM
a NN NN O
, NN NN O
nause NN NN B-PROBLEM
a NN NN O
, NN NN O
vomitin NN NN B-PROBLEM
g NN NN O
, NN NN O
diarrhe NN NN B-PROBLEM
a NN NN O
, NN NN O
constipatio NN NN B-PROBLEM
n NN NN O
, NN NN O
blood NN NN B-PROBLEM
in NN NN I-PROBLEM
her NN NN I-PROBLEM
stoo NN NN I-PROBLEM
l NN NN O
, NN NN O
and NN NN O
black NN NN B-PROBLEM
tarry NN NN I-PROBLEM
stool NN NN I-PROBLEM
s NN NN O
. NN NN O

GU NN NN O
: NN NN O
No NN NN O
dysuri NN NN B-PROBLEM
a NN NN O
, NN NN O
burning NN NN B-PROBLEM
with NN NN I-PROBLEM
urinatio NN NN I-PROBLEM
n NN NN O
, NN NN O
kidney NN NN B-PROBLEM
stone NN NN I-PROBLEM
s NN NN O
, NN NN O
and NN NN O
difficulty NN NN B-PROBLEM
voidin NN NN I-PROBLEM
g NN NN O
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
No NN NN O
new NN NN B-PROBLEM
back NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
hip NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
rib NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
swollen NN NN B-PROBLEM
joint NN NN I-PROBLEM
s NN NN O
, NN NN O
history NN NN O
of NN NN O
gou NN NN B-PROBLEM
t NN NN O
, NN NN O
or NN NN O
muscle NN NN B-PROBLEM
weaknes NN NN I-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
She NN NN O
has NN NN O
been NN NN O
diffusely NN NN B-PROBLEM
wea NN NN I-PROBLEM
k NN NN O
but NN NN O
no NN NN O
lateralizing NN NN B-PROBLEM
loss NN NN I-PROBLEM
of NN NN I-PROBLEM
strength NN NN I-PROBLEM
or NN NN I-PROBLEM
feelin NN NN I-PROBLEM
g NN NN O
. NN NN O

She NN NN O
has NN NN O
some NN NN B-PROBLEM
chronic NN NN I-PROBLEM
neuropathic NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
and NN NN O
numbnes NN NN B-PROBLEM
s NN NN O
as NN NN O
described NN NN O
above NN NN O
in NN NN O
the NN NN O
past NN NN O
medical NN NN O
history NN NN O
. NN NN O

She NN NN O
is NN NN O
fatigue NN NN B-PROBLEM
d NN NN O
and NN NN O
tire NN NN B-PROBLEM
d NN NN O
today NN NN O
and NN NN O
falls NN NN O
asleep NN NN O
while NN NN O
talking NN NN O
but NN NN O
is NN NN O
easily NN NN O
arousable NN NN O
. NN NN O

Some NN NN O
of NN NN O
this NN NN O
is NN NN O
related NN NN O
to NN NN O
her NN NN O
lack NN NN O
of NN NN O
sleep NN NN O
over NN NN O
the NN NN O
admission NN NN O
thus NN NN O
far NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Her NN NN B-TEST
T-ma NN NN I-TEST
x NN NN O
is NN NN O
99.3 NN NN O
. NN NN O

Her NN NN B-TEST
puls NN NN I-TEST
e NN NN O
is NN NN O
54 NN NN O
, NN NN O
her NN NN B-TEST
respiration NN NN I-TEST
s NN NN O
is NN NN O
12 NN NN O
, NN NN O
and NN NN O
blood NN NN B-TEST
pressur NN NN I-TEST
e NN NN O
118/61 NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
Somewhat NN NN B-PROBLEM
fatigue NN NN I-PROBLEM
d NN NN O
appearing NN NN O
but NN NN O
in NN NN O
no NN NN O
acute NN NN B-PROBLEM
distres NN NN I-PROBLEM
s NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
NC/A NN NN B-PROBLEM
T NN NN O
. NN NN O
Sclerae NN NN B-PROBLEM
anicteri NN NN I-PROBLEM
c NN NN O
. NN NN O

Conjunctiva NN NN O
clear NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
without NN NN O
any NN NN B-PROBLEM
erythem NN NN I-PROBLEM
a NN NN O
, NN NN O
exudat NN NN B-PROBLEM
e NN NN O
, NN NN O
or NN NN O
discharg NN NN B-PROBLEM
e NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

Nontende NN NN B-PROBLEM
r NN NN O
. NN NN O

No NN NN O
elevated NN NN B-PROBLEM
JV NN NN I-PROBLEM
P NN NN O
. NN NN O
No NN NN O
thyromegal NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
thyroid NN NN B-PROBLEM
nodule NN NN I-PROBLEM
s NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultatio NN NN B-TEST
n NN NN O
and NN NN O
percussio NN NN B-TEST
n NN NN O
bilaterally NN NN O
with NN NN O
decreased NN NN B-PROBLEM
breath NN NN I-PROBLEM
sounds NN NN I-PROBLEM
on NN NN I-PROBLEM
the NN NN I-PROBLEM
righ NN NN I-PROBLEM
t NN NN O
. NN NN O

CVS NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

No NN NN O
murmur NN NN B-PROBLEM
s NN NN O
, NN NN O
gallop NN NN B-PROBLEM
s NN NN O
or NN NN O
rub NN NN B-PROBLEM
s NN NN O
. NN NN O

Normal NN NN O
S1 NN NN O
and NN NN O
S2 NN NN O
. NN NN O

No NN NN O
S NN NN B-PROBLEM
3 NN NN O
or NN NN O
S NN NN B-PROBLEM

4 NN NN O
. NN NN O
ABDOMEN NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nontende NN NN B-PROBLEM
r NN NN O
, NN NN O
nondistende NN NN B-PROBLEM
d NN NN O
. NN NN O

Normoactive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
guardin NN NN B-PROBLEM
g NN NN O
or NN NN O
reboun NN NN B-PROBLEM
d NN NN O
. NN NN O

No NN NN O
hepatosplenomegal NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
masse NN NN B-PROBLEM
s NN NN O
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
Generalized NN NN B-PROBLEM
muscle NN NN I-PROBLEM
weaknes NN NN I-PROBLEM
s NN NN O
but NN NN O
no NN NN O
joint NN NN B-PROBLEM
swellin NN NN I-PROBLEM
g NN NN O
or NN NN O
other NN NN B-PROBLEM
abnormalitie NN NN I-PROBLEM
s NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
rashe NN NN B-PROBLEM
s NN NN O
, NN NN O
bruisin NN NN B-PROBLEM
g NN NN O
, NN NN O
or NN NN O
petechi NN NN B-PROBLEM
a NN NN O
. NN NN O

No NN NN O
non-healing NN NN B-PROBLEM
wound NN NN I-PROBLEM
s NN NN O
or NN NN O
ulceration NN NN B-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
She NN NN O
is NN NN O
oriented NN NN O
x3 NN NN O
but NN NN O
she NN NN O
falls NN NN O
asleep NN NN O
readily NN NN O
. NN NN O

On NN NN O
exa NN NN B-TEST
m NN NN O
and NN NN O
conversation NN NN O
, NN NN O
her NN NN O
cranial NN NN O
nerves NN NN O
are NN NN O
intact NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
sensory NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
. NN NN O

Her NN NN O
strength NN NN O
is NN NN O
symmetric NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
Her NN NN B-TEST
white NN NN I-TEST
blood NN NN I-TEST
cell NN NN I-TEST
coun NN NN I-TEST
t NN NN O
is NN NN O
8.0 NN NN O
, NN NN O
hemoglobi NN NN B-TEST
n NN NN O
11.1 NN NN O
, NN NN O
hematocri NN NN B-TEST
t NN NN O
33.2% NN NN O
, NN NN O
and NN NN O
platelet NN NN B-TEST
s NN NN O
29,000 NN NN O
. NN NN O

Her NN NN B-TEST
differentia NN NN I-TEST
l NN NN O
shows NN NN O
2% NN NN B-PROBLEM
metamyelocyte NN NN I-PROBLEM
s NN NN O
, NN NN O
57% NN NN O
neutrophil NN NN B-TEST
s NN NN O
, NN NN O
29% NN NN O
band NN NN B-TEST
s NN NN O
, NN NN O
6% NN NN O
lymphocyte NN NN B-TEST
s NN NN O
, NN NN O
5% NN NN B-TEST
monocyte NN NN I-TEST
s NN NN O
, NN NN O
and NN NN O
1% NN NN B-TEST
eosinophil NN NN I-TEST
s NN NN O
. NN NN O

Her NN NN B-TEST
sodiu NN NN I-TEST
m NN NN O
is NN NN O
138 NN NN O
, NN NN O
potassiu NN NN B-TEST
m NN NN O
4.0 NN NN O
, NN NN O
chlorid NN NN B-TEST
e NN NN O
101 NN NN O
, NN NN O
CO NN NN B-TEST
2 NN NN O
of NN NN O
23 NN NN O
, NN NN O
BU NN NN B-TEST
N NN NN O
21 NN NN O
, NN NN O
creatinin NN NN B-TEST
e NN NN O
1.4 NN NN O
, NN NN O
glucos NN NN B-TEST
e NN NN O
107 NN NN O
, NN NN O
and NN NN O
calciu NN NN B-TEST
m NN NN O
8.7 NN NN O
. NN NN O

Her NN NN B-TEST
IN NN NN I-TEST
R NN NN O
is NN NN O
1.0 NN NN O
, NN NN O
P NN NN B-TEST
T NN NN O
of NN NN O
12 NN NN O
, NN NN O
and NN NN O
PT NN NN B-TEST
T NN NN O

24 NN NN O
. NN NN O
Urinalysi NN NN B-TEST
s NN NN O
negative NN NN O
for NN NN O
nitrit NN NN B-PROBLEM
e NN NN O
and NN NN O
leukocyte NN NN B-TEST
esteras NN NN I-TEST
e NN NN O
with NN NN O
moderate NN NN B-PROBLEM
epithelial NN NN I-PROBLEM
cell NN NN I-PROBLEM
s NN NN O
, NN NN O
bacteri NN NN B-PROBLEM
a NN NN O
, NN NN O
white NN NN B-TEST
blood NN NN I-TEST
cell NN NN I-TEST
s NN NN O
, NN NN O
and NN NN O
yeas NN NN B-PROBLEM
t NN NN O
suggesting NN NN O
of NN NN O
contaminatio NN NN B-PROBLEM
n NN NN O
. NN NN O

Her NN NN B-TEST
troponin NN NN I-TEST
s NN NN O
have NN NN O
been NN NN O
negative NN NN O
x3 NN NN O
. NN NN O

IMAGINING NN NN O
DATA NN NN O
: NN NN O
CT NN NN B-TEST
scan NN NN I-TEST
of NN NN I-TEST
her NN NN I-TEST
ches NN NN I-TEST
t NN NN O
on NN NN O
12/25/0 NN NN B-DATE
8 NN NN O
shows NN NN O
bilateral NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
, NN NN O
larger NN NN O
on NN NN O
the NN NN O
right NN NN O
than NN NN O
the NN NN O
left NN NN O
but NN NN O
these NN NN O
are NN NN O
somewhat NN NN O
decreased NN NN O
in NN NN O
size NN NN O
compared NN NN O
to NN NN O
the NN NN B-TEST
prior NN NN I-TEST
CT NN NN I-TEST
sca NN NN I-TEST
n NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
Novembe NN NN B-DATE
r NN NN O
. NN NN O

There NN NN O
is NN NN O
some NN NN B-PROBLEM
consolidative NN NN I-PROBLEM
atelectasi NN NN I-PROBLEM
s NN NN O
at NN NN O
the NN NN O
bilateral NN NN O
basis NN NN O
. NN NN O

There NN NN O
is NN NN O
some NN NN B-PROBLEM
peripheral NN NN I-PROBLEM
interstitial NN NN I-PROBLEM
opacification NN NN I-PROBLEM
s NN NN O
noted NN NN O
in NN NN O
the NN NN O
right NN NN O
lung NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
in NN NN O
the NN NN O
left NN NN O
lung NN NN O
possibly NN NN O
consistent NN NN O
with NN NN O
pneumoniti NN NN B-PROBLEM
s NN NN O
. NN NN O

There NN NN O
are NN NN O
small NN NN B-PROBLEM
peripheral NN NN I-PROBLEM
nodular NN NN I-PROBLEM
densities NN NN I-PROBLEM
in NN NN I-PROBLEM
both NN NN I-PROBLEM
lung NN NN I-PROBLEM
s NN NN O
unchanged NN NN O
compared NN NN O
to NN NN O
prior NN NN B-TEST
sca NN NN I-TEST
n NN NN O
. NN NN O

There NN NN O
is NN NN O
an NN NN B-PROBLEM
enlarged NN NN I-PROBLEM
right NN NN I-PROBLEM
adrenal NN NN I-PROBLEM
glan NN NN I-PROBLEM
d NN NN O
again NN NN O
noted NN NN O
without NN NN O
change NN NN O
. NN NN O

ASSESSMENT NN NN O
: NN NN O
ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
66-year-ol NN NN B-AGE
d NN NN O
woman NN NN O
with NN NN O
recurrent NN NN B-PROBLEM
metastatic NN NN I-PROBLEM
ovarian NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
known NN NN O
to NN NN O
our NN NN O
clinic NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
she NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
shortness NN NN B-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
with NN NN O
possible NN NN O
presumed NN NN O
pneumoni NN NN B-PROBLEM
a NN NN O
. NN NN O

The NN NN O
possibility NN NN O
of NN NN O
a NN NN B-PROBLEM
P NN NN I-PROBLEM
E NN NN O
also NN NN O
remains NN NN O
and NN NN O
the NN NN O
plan NN NN O
has NN NN O
been NN NN O
to NN NN O
do NN NN O
a NN NN B-TEST
CT NN NN I-TEST
A NN NN O
once NN NN O
her NN NN B-TEST
kidney NN NN I-TEST
functio NN NN I-TEST
n NN NN O
improves NN NN O
. NN NN O

Currently NN NN O
, NN NN O
she NN NN O
is NN NN O
being NN NN O
treated NN NN O
with NN NN O
broad-spectrum NN NN B-TREATMENT
antibiotic NN NN I-TREATMENT
s NN NN O
and NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
prophylactically NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
it NN NN O
does NN NN O
not NN NN O
appear NN NN O
that NN NN O
her NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
have NN NN O
increased NN NN O
and NN NN O
this NN NN O
would NN NN O
not NN NN O
be NN NN O
the NN NN O
etiology NN NN O
behind NN NN O
her NN NN B-PROBLEM
worsening NN NN I-PROBLEM
symptom NN NN I-PROBLEM
s NN NN O
. NN NN O

Her NN NN B-TEST
blood NN NN I-TEST
count NN NN I-TEST
s NN NN O
appear NN NN O
to NN NN O
be NN NN O
recovering NN NN O
from NN NN O
chemotherap NN NN B-TREATMENT
y NN NN O
except NN NN O
for NN NN O
the NN NN O
fact NN NN O
that NN NN O
her NN NN B-TEST
platelet NN NN I-TEST
s NN NN O
have NN NN O
gone NN NN O
lower NN NN O
. NN NN O

It NN NN O
is NN NN O
unclear NN NN O
as NN NN O
to NN NN O
the NN NN O
etiology NN NN O
behind NN NN O
this NN NN O
but NN NN O
may NN NN O
still NN NN O
be NN NN O
related NN NN O
to NN NN O
chemotherap NN NN B-DRUG
y NN NN O
effect NN NN O
. NN NN O

This NN NN O
also NN NN O
could NN NN O
be NN NN O
related NN NN O
to NN NN O
consumptive NN NN B-PROBLEM
proces NN NN I-PROBLEM
s NN NN O
such NN NN O
as NN NN O
DI NN NN B-PROBLEM
C NN NN O
in NN NN O
the NN NN O
face NN NN O
of NN NN O
infection NN NN B-PROBLEM
s NN NN O
or NN NN O
medication NN NN B-PROBLEM
effec NN NN I-PROBLEM
t NN NN O
. NN NN O

We NN NN O
will NN NN O
keep NN NN O
track NN NN O
of NN NN O
her NN NN B-TEST
blood NN NN I-TEST
count NN NN I-TEST
s NN NN O
over NN NN O
this NN NN O
admission NN NN O
. NN NN O

We NN NN O
will NN NN O
continue NN NN O
to NN NN O
follow NN NN O
along NN NN O
through NN NN O
the NN NN O
course NN NN O
of NN NN O
her NN NN O
admission NN NN O
. NN NN O

She NN NN O
has NN NN O
requested NN NN O
being NN NN O
full NN NN B-TREATMENT
cod NN NN I-TREATMENT
e NN NN O
. NN NN O

I NN NN O
went NN NN O
back NN NN O
and NN NN O
looked NN NN O
at NN NN O
Dr NN NN O
. NN NN O
X's NN NN O
chart NN NN O
after NN NN O
our NN NN O
clinic NN NN O
chart NN NN O
and NN NN O
at NN NN O
the NN NN O
last NN NN O
visit NN NN O
with NN NN O
Dr NN NN O
. NN NN O
X NN NN O
and NN NN O
Dr NN NN O
. NN NN O
Y NN NN O
, NN NN O
she NN NN O
confirmed NN NN O
that NN NN O
she NN NN O
wanted NN NN O
to NN NN O
be NN NN O
DNR/DNI NN NN O
. NN NN O

I NN NN O
am NN NN O
not NN NN O
sure NN NN O
why NN NN O
this NN NN O
is NN NN O
changed NN NN O
and NN NN O
I NN NN O
will NN NN O
address NN NN O
this NN NN O
issue NN NN O
with NN NN O
her NN NN O
once NN NN O
she NN NN O
is NN NN O
more NN NN O
alert NN NN O
. NN NN O

Thank NN NN O
you NN NN O
very NN NN O
much NN NN O
for NN NN O
this NN NN O
consult NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
renal NN NN B-PROBLEM
cell NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
breast NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
metastatic NN NN B-PROBLEM
ovarian NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
shortness NN NN B-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
, NN NN O
pleural NN NN B-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
, NN NN O
cance NN NN B-PROBLEM
r NN NN O
, NN NN O
ovarian NN NN B-PROBLEM
, NN NN I-PROBLEM
recurren NN NN I-PROBLEM
t NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Breast NN NN O
Radiation NN NN O
Therapy NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
Breast NN NN O
radiation NN NN O
therapy NN NN O
followup NN NN O
note NN NN O
. NN NN O

Left NN NN B-PROBLEM
breast NN NN I-PROBLEM
adenocarcinoma NN NN I-PROBLEM
stage NN NN I-PROBLEM
T NN NN I-PROBLEM
3 NN NN O
N1b NN NN O
M0 NN NN O
, NN NN O
stage NN NN B-PROBLEM
III NN NN I-PROBLEM
A NN NN O
. NN NN O
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NN NN B-PROBLEM
breast NN NN I-PROBLEM
adenocarcinoma NN NN I-PROBLEM
stage NN NN I-PROBLEM
T NN NN I-PROBLEM
3 NN NN O
N1b NN NN O
M0 NN NN O
, NN NN O
stage NN NN B-PROBLEM
III NN NN I-PROBLEM
A NN NN O
. NN NN O
She NN NN O
has NN NN O
been NN NN O
found NN NN O
more NN NN O
recently NN NN O
to NN NN O
have NN NN O
stage NN NN B-PROBLEM
IV NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
with NN NN O
metastatic NN NN B-PROBLEM
deposit NN NN I-PROBLEM
s NN NN O
and NN NN O
recurrence NN NN B-PROBLEM
involving NN NN I-PROBLEM
the NN NN I-PROBLEM
chest NN NN I-PROBLEM
wal NN NN I-PROBLEM
l NN NN O
and NN NN O
lower NN NN B-PROBLEM
left NN NN I-PROBLEM
neck NN NN I-PROBLEM
lymph NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O

1 NN NN O
. NN NN O
Glucosamin NN NN B-DRUG
e NN NN O
complex NN NN O
. NN NN O

2 NN NN O
. NN NN O
Toprol NN NN B-TREATMENT
X NN NN I-TREATMENT
L NN NN O
. NN NN O

3 NN NN O
. NN NN O
Alprazola NN NN B-TREATMENT
m NN NN O

4 NN NN O
. NN NN O
Hydrochlorothiazid NN NN B-TREATMENT
e NN NN O
. NN NN O

5 NN NN O
. NN NN O
Dyazid NN NN B-TREATMENT
e NN NN O
. NN NN O

6 NN NN O
. NN NN O
Centru NN NN B-DRUG
m NN NN O
. NN NN O

Dr NN NN O
. NN NN O
X NN NN O
has NN NN O
given NN NN O
her NN NN O
some NN NN O
carboplati NN NN B-DRUG
n NN NN O
and NN NN O
Taxo NN NN B-TREATMENT
l NN NN O
more NN NN O
recently NN NN O
and NN NN O
feels NN NN O
that NN NN O
she NN NN O
would NN NN O
benefit NN NN O
from NN NN O
electron NN NN B-TREATMENT
beam NN NN I-TREATMENT
radiotherap NN NN I-TREATMENT
y NN NN O
to NN NN O
the NN NN O
left NN NN O
chest NN NN O
wall NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
neck NN NN O
. NN NN O

She NN NN O
previously NN NN O
received NN NN O
a NN NN O
total NN NN O
of NN NN O
46.8 NN NN O
Gy NN NN O
in NN NN O
26 NN NN O
fractions NN NN O
of NN NN O
external NN NN B-TREATMENT
beam NN NN I-TREATMENT
radiotherap NN NN I-TREATMENT
y NN NN O
to NN NN O
the NN NN O
left NN NN O
supraclavicular NN NN O
area NN NN O
. NN NN O

As NN NN O
such NN NN O
, NN NN O
I NN NN O
feel NN NN O
that NN NN O
we NN NN O
could NN NN O
safely NN NN O
re-treat NN NN O
the NN NN O
lower NN NN O
neck NN NN O
. NN NN O

Her NN NN B-TEST
weigh NN NN I-TEST
t NN NN O
has NN NN O
increased NN NN O
to NN NN O
189.5 NN NN O
from NN NN O
185.2 NN NN O
. NN NN O

She NN NN O
does NN NN O
complain NN NN O
of NN NN O
some NN NN B-PROBLEM
coughin NN NN I-PROBLEM
g NN NN O
and NN NN O
fatigu NN NN B-PROBLEM
e NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
NECK NN NN O
: NN NN O
On NN NN O
physical NN NN B-TEST
examinatio NN NN I-TEST
n NN NN O
palpable NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
left NN NN O
lower NN NN O
neck NN NN O
and NN NN O
supraclavicular NN NN O
area NN NN O
. NN NN O

No NN NN O
other NN NN B-PROBLEM
cervical NN NN I-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
or NN NN O
supraclavicular NN NN B-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
is NN NN O
present NN NN O
. NN NN O

RESPIRATORY NN NN O
: NN NN O
Good NN NN O
air NN NN O
entry NN NN O
bilaterally NN NN O
. NN NN O

Examination NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
chest NN NN I-TEST
wal NN NN I-TEST
l NN NN O
reveals NN NN O
a NN NN B-PROBLEM
small NN NN I-PROBLEM
lesio NN NN I-PROBLEM
n NN NN O
where NN NN O
the NN NN B-PROBLEM
chest NN NN I-PROBLEM
wall NN NN I-PROBLEM
recurrenc NN NN I-PROBLEM
e NN NN O
was NN NN O
resecte NN NN B-TREATMENT
d NN NN O
. NN NN O

No NN NN O
lump NN NN B-PROBLEM
s NN NN O
, NN NN O
bump NN NN B-PROBLEM
s NN NN O
or NN NN O
evidence NN NN O
of NN NN O
diseas NN NN B-PROBLEM
e NN NN O
involving NN NN O
the NN NN O
right NN NN O
breast NN NN O
is NN NN O
present NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Normal NN NN O
bowel NN NN O
sounds NN NN O
, NN NN O
no NN NN O
hepatomegal NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
tendernes NN NN B-PROBLEM
s NN NN O
on NN NN O
deep NN NN B-TEST
palpatio NN NN I-TEST
n NN NN O
. NN NN O

She NN NN O
has NN NN O
just NN NN O
started NN NN O
her NN NN O
last NN NN O
cycle NN NN O
of NN NN O
chemotherap NN NN B-DRUG
y NN NN O
today NN NN O
, NN NN O
and NN NN O
she NN NN O
wishes NN NN O
to NN NN O
visit NN NN O
her NN NN O
daughter NN NN O
in NN NN O
Brookly NN NN B-LOCATION
n NN NN O
, NN NN O
New NN NN B-LOCATION
Yor NN NN I-LOCATION
k NN NN O
. NN NN O

After NN NN O
this NN NN O
she NN NN O
will NN NN O
return NN NN O
in NN NN O
approximately NN NN O
3 NN NN O
to NN NN O
4 NN NN O
weeks NN NN O
and NN NN O
begin NN NN O
her NN NN B-TREATMENT
radiotherapy NN NN I-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
at NN NN O
that NN NN O
time NN NN O
. NN NN O

I NN NN O
look NN NN O
forward NN NN O
to NN NN O
keeping NN NN O
you NN NN O
informed NN NN O
of NN NN O
her NN NN O
progress NN NN O
. NN NN O

Thank NN NN O
you NN NN O
for NN NN O
having NN NN O
allowed NN NN O
me NN NN O
to NN NN O
participate NN NN O
in NN NN O
her NN NN O
care NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
carboplati NN NN B-TREATMENT
n NN NN O
, NN NN O
taxo NN NN B-TREATMENT
l NN NN O
, NN NN O
radiation NN NN B-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
, NN NN O
breast NN NN B-PROBLEM
adenocarcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
beam NN NN B-TREATMENT
radiotherap NN NN I-TREATMENT
y NN NN O
, NN NN O
chest NN NN B-TREATMENT
wal NN NN I-TREATMENT
l NN NN O
, NN NN O
radiotherap NN NN B-TREATMENT
y NN NN O
, NN NN O
supraclavicula NN NN B-TREATMENT
r NN NN O
, NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
, NN NN O
adenocarcinom NN NN B-PROBLEM
a NN NN O
, NN NN O
breas NN NN B-PROBLEM
t NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Lymph NN NN B-TEST
Node NN NN I-TEST
Excisional NN NN I-TEST
Biops NN NN I-TEST
y NN NN O
Description NN NN O
: NN NN O
Left NN NN B-TEST
axillary NN NN I-TEST
lymph NN NN I-TEST
node NN NN I-TEST
excisional NN NN I-TEST
biops NN NN I-TEST
y NN NN O
. NN NN O

Left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
Left NN NN B-TEST
axillary NN NN I-TEST
lymph NN NN I-TEST
node NN NN I-TEST
excisional NN NN I-TEST
biops NN NN I-TEST
y NN NN O
. NN NN O

ANESTHESIA NN NN O
: NN NN O
LM NN NN B-TREATMENT
A NN NN O
. NN NN O
INDICATIONS NN NN O
: NN NN O
Patient NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
woman NN NN O
who NN NN O
in NN NN O
200 NN NN B-DATE
6 NN NN O
had NN NN O
breast NN NN B-TREATMENT
conservation NN NN I-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
with NN NN O
radiatio NN NN B-TREATMENT
n NN NN O
only NN NN O
. NN NN O

Note NN NN O
, NN NN O
she NN NN O
refused NN NN O
her NN NN O
CM NN NN B-DRUG
F NN NN O
adjuvant NN NN O
therapy NN NN O
and NN NN O
this NN NN O
was NN NN O
for NN NN O
a NN NN B-PROBLEM
triple-negative NN NN I-PROBLEM
infiltrating NN NN I-PROBLEM
ductal NN NN I-PROBLEM
carcinoma NN NN I-PROBLEM
of NN NN I-PROBLEM
the NN NN I-PROBLEM
breas NN NN I-PROBLEM
t NN NN O
. NN NN O

Patient NN NN O
has NN NN O
been NN NN O
following NN NN O
with NN NN O
Dr NN NN O
. NN NN O
Diene NN NN B-NAME
r NN NN O
and NN NN O
Dr NN NN O
. NN NN O
Wilmo NN NN B-NAME
t NN NN O
. NN NN O

I NN NN O
believe NN NN O
that NN NN O
genetic NN NN O
counseling NN NN O
had NN NN O
been NN NN O
recommended NN NN O
to NN NN O
her NN NN O
and NN NN O
obviously NN NN O
the NN NN O
CM NN NN B-DRUG
F NN NN O
was NN NN O
recommended NN NN O
, NN NN O
but NN NN O
she NN NN O
declined NN NN O
both NN NN O
. NN NN O

She NN NN O
presented NN NN O
to NN NN O
the NN NN O
office NN NN O
with NN NN O
left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
in NN NN O
view NN NN O
of NN NN O
the NN NN O
high-risk NN NN O
nature NN NN O
of NN NN O
her NN NN B-PROBLEM
lesio NN NN I-PROBLEM
n NN NN O
. NN NN O

I NN NN O
recommended NN NN O
that NN NN O
she NN NN O
have NN NN O
this NN NN B-TREATMENT
lymph NN NN I-TREATMENT
nod NN NN I-TREATMENT
e NN NN O
removed NN NN O
. NN NN O

The NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
, NN NN O
purpose NN NN O
, NN NN O
risk NN NN O
, NN NN O
expected NN NN O
benefits NN NN O
, NN NN O
potential NN NN B-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
, NN NN O
alternative NN NN O
forms NN NN O
of NN NN O
therap NN NN B-TREATMENT
y NN NN O
were NN NN O
discussed NN NN O
with NN NN O
her NN NN O
and NN NN O
she NN NN O
was NN NN O
agreeable NN NN O
to NN NN O
surger NN NN B-TREATMENT
y NN NN O
. NN NN O

TECHNIQUE NN NN O
: NN NN O
Patient NN NN O
was NN NN O
identified NN NN O
, NN NN O
then NN NN O
taken NN NN O
into NN NN O
the NN NN O
operating NN NN O
room NN NN O
where NN NN O
after NN NN O
induction NN NN O
of NN NN O
appropriate NN NN O
anesthesi NN NN B-DRUG
a NN NN O
, NN NN O
her NN NN B-TREATMENT
left NN NN I-TREATMENT
chest NN NN I-TREATMENT
, NN NN I-TREATMENT
neck NN NN I-TREATMENT
, NN NN I-TREATMENT
axilla NN NN I-TREATMENT
, NN NN I-TREATMENT
and NN NN I-TREATMENT
ar NN NN I-TREATMENT
m NN NN O
were NN NN O
prepped NN NN O
with NN NN O
Betadin NN NN B-DRUG
e NN NN O
solutio NN NN B-FORM
n NN NN O
, NN NN O
draped NN NN O
in NN NN O
a NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

An NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
made NN NN O
at NN NN O
the NN NN O
hairline NN NN O
, NN NN O
carried NN NN O
down NN NN O
by NN NN O
sharp NN NN B-TREATMENT
dissection NN NN I-TREATMENT
through NN NN I-TREATMENT
the NN NN I-TREATMENT
clavipectoral NN NN I-TREATMENT
fasci NN NN I-TREATMENT
a NN NN O
. NN NN O

I NN NN O
was NN NN O
able NN NN O
to NN NN O
easily NN NN O
palpate NN NN O
the NN NN O
lymph NN NN O
node NN NN O
and NN NN O
grasp NN NN O
it NN NN O
with NN NN O
a NN NN B-TREATMENT
figure-of-eight NN NN I-TREATMENT
2-0 NN NN I-TREATMENT
silk NN NN I-TREATMENT
sutur NN NN I-TREATMENT
e NN NN O
and NN NN O
by NN NN O
sharp NN NN B-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
, NN NN O
was NN NN O
carried NN NN O
to NN NN O
hemocli NN NN B-TREATMENT
p NN NN O
all NN NN O
attached NN NN O
structures NN NN O
. NN NN O

The NN NN O
lymph NN NN O
node NN NN O
was NN NN O
excise NN NN B-TREATMENT
d NN NN O
in NN NN O
its NN NN O
entirety NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
irrigated NN NN O
. NN NN O

The NN NN O
lymph NN NN O
node NN NN O
sent NN NN O
to NN NN O
pathology NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
then NN NN O
closed NN NN O
. NN NN O

Hemostasis NN NN O
was NN NN O
assured NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

Keywords NN NN O
: NN NN O
hematology NN NN O
- NN NN O
oncology NN NN O
, NN NN O
axillary NN NN B-TEST
lymph NN NN I-TEST
node NN NN I-TEST
excisional NN NN I-TEST
biops NN NN I-TEST
y NN NN O
, NN NN O
sharp NN NN B-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
, NN NN O
excisional NN NN B-TEST
biops NN NN I-TEST
y NN NN O
, NN NN O
lymph NN NN B-TEST
node NN NN I-TEST
, NN NN I-TEST
axillary NN NN I-TEST
, NN NN I-TEST
excisiona NN NN I-TEST
l NN NN O
, NN NN O
biops NN NN B-TEST
y NN NN O
, NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Discharge NN NN O
Summary NN NN O
- NN NN O
Mesothelioma NN NN O
- NN NN O
1 NN NN O
Description NN NN O
: NN NN O
Mesotheliom NN NN B-PROBLEM
a NN NN O
, NN NN O
pleural NN NN B-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
, NN NN O
atrial NN NN B-PROBLEM
fibrillatio NN NN I-PROBLEM
n NN NN O
, NN NN O
anemi NN NN B-PROBLEM
a NN NN O
, NN NN O
ascite NN NN B-PROBLEM
s NN NN O
, NN NN O
esophageal NN NN B-PROBLEM
reflu NN NN I-PROBLEM
x NN NN O
, NN NN O
and NN NN O
history NN NN O
of NN NN O
deep NN NN B-PROBLEM
venous NN NN I-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PRINCIPAL NN NN O
DIAGNOSIS NN NN O
: NN NN O
Mesotheliom NN NN B-PROBLEM
a NN NN O
. NN NN O

SECONDARY NN NN O
DIAGNOSES NN NN O
: NN NN O
Pleural NN NN B-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
, NN NN O
atrial NN NN B-PROBLEM
fibrillatio NN NN I-PROBLEM
n NN NN O
, NN NN O
anemi NN NN B-PROBLEM
a NN NN O
, NN NN O
ascite NN NN B-PROBLEM
s NN NN O
, NN NN O
esophageal NN NN B-PROBLEM
reflu NN NN I-PROBLEM
x NN NN O
, NN NN O
and NN NN O
history NN NN O
of NN NN O
deep NN NN B-PROBLEM
venous NN NN I-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
. NN NN O

PROCEDURES NN NN O

1 NN NN O
. NN NN O
On NN NN O
August NN NN B-DATE
24 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
decortication NN NN B-TREATMENT
of NN NN I-TREATMENT
the NN NN I-TREATMENT
lun NN NN I-TREATMENT
g NN NN O
with NN NN O
pleural NN NN B-TEST
biops NN NN I-TEST
y NN NN O
and NN NN O
transpleural NN NN B-TEST
fluoroscop NN NN I-TEST
y NN NN O
. NN NN O

2 NN NN O
. NN NN O
On NN NN O
August NN NN B-DATE
20 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
thoracentesi NN NN B-TREATMENT
s NN NN O
. NN NN O

3 NN NN O
. NN NN O
On NN NN O
August NN NN B-DATE
31 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
Port-A-Cath NN NN B-TREATMENT
placemen NN NN I-TREATMENT
t NN NN O
. NN NN O

HISTORY NN NN O
AND NN NN O
PHYSICAL NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
41-year-ol NN NN B-AGE
d NN NN O
Vietnames NN NN B-LOCATION
e NN NN O
female NN NN O
with NN NN O
a NN NN B-PROBLEM
nonproductive NN NN I-PROBLEM
coug NN NN I-PROBLEM
h NN NN O
that NN NN O
started NN NN O
last NN NN O
week NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
right-sided NN NN B-PROBLEM
chest NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
radiating NN NN O
to NN NN O
her NN NN O
back NN NN O
with NN NN O
feve NN NN B-PROBLEM
r NN NN O
starting NN NN O
yesterday NN NN O
. NN NN O

She NN NN O
has NN NN O
a NN NN O
history NN NN O
of NN NN O
pericarditi NN NN B-PROBLEM
s NN NN O
and NN NN O
pericardectom NN NN B-TREATMENT
y NN NN O
in NN NN O
May NN NN B-DATE
200 NN NN I-DATE
6 NN NN O
and NN NN O
developed NN NN O
coug NN NN B-PROBLEM
h NN NN O
with NN NN O
right-sided NN NN B-PROBLEM
chest NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
and NN NN O
went NN NN O
to NN NN O
an NN NN O
urgent NN NN O
care NN NN O
center NN NN O
. NN NN O

Chest NN NN B-TEST
x-ra NN NN I-TEST
y NN NN O
revealed NN NN O
right-sided NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Pericardectom NN NN B-TREATMENT
y NN NN O
. NN NN O

2 NN NN O
. NN NN O
Pericarditi NN NN B-PROBLEM
s NN NN O
. NN NN O

2 NN NN O
. NN NN O
Atrial NN NN B-PROBLEM
fibrillatio NN NN I-PROBLEM
n NN NN O
. NN NN O

4 NN NN O
. NN NN O
RNCA NN NN O
with NN NN O
intracranial NN NN B-TREATMENT
thrombolytic NN NN I-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
. NN NN O

5 NN NN O
PTA NN NN O
of NN NN O
MCA NN NN O
. NN NN O

6 NN NN O
. NN NN O
Mesenteric NN NN B-PROBLEM
venous NN NN I-PROBLEM
thrombosi NN NN I-PROBLEM
s NN NN O
. NN NN O

7 NN NN O
. NN NN O
Pericardial NN NN B-TREATMENT
windo NN NN I-TREATMENT
w NN NN O
. NN NN O

8 NN NN O
. NN NN O
Cholecystectom NN NN B-TREATMENT
y NN NN O
. NN NN O

9 NN NN O
. NN NN O
Left NN NN B-TEST
thoracentesi NN NN I-TEST
s NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
No NN NN O
family NN NN O
history NN NN O
of NN NN O
coronary NN NN B-PROBLEM
artery NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
CV NN NN B-PROBLEM
A NN NN O
, NN NN O
diabete NN NN B-PROBLEM
s NN NN O
, NN NN O
CH NN NN B-PROBLEM
F NN NN O
or NN NN O
M NN NN B-PROBLEM
I NN NN O
. NN NN O
The NN NN O
patient NN NN O
has NN NN O
one NN NN O
family NN NN O
member NN NN O
, NN NN O
a NN NN O
sister NN NN O
, NN NN O
with NN NN O
history NN NN O
of NN NN O
cance NN NN B-PROBLEM
r NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
is NN NN O
married NN NN O
. NN NN O

Employed NN NN O
with NN NN O
the NN NN O
US NN NN B-LOCATION
Post NN NN I-LOCATION
Offic NN NN I-LOCATION
e NN NN O
. NN NN O

She NN NN O
is NN NN O
a NN NN O
mother NN NN O
of NN NN O
three NN NN O
. NN NN O

Denies NN NN O
tobacco NN NN O
, NN NN O
alcohol NN NN O
or NN NN O
illicit NN NN O
drug NN NN O
use NN NN O
. NN NN O

MEDICATIONS NN NN O

1 NN NN O
. NN NN O
Coumadi NN NN B-TREATMENT
n NN NN O
1 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

Last NN NN O
IN NN NN B-TEST
R NN NN O
was NN NN O
on NN NN O
Tuesda NN NN B-DATE
y NN NN O
, NN NN O
August NN NN B-DATE
14 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
and NN NN O
her NN NN B-TEST
IN NN NN I-TEST
R NN NN O
was NN NN O
2.3 NN NN O
. NN NN O

2 NN NN O
. NN NN O
Amiodaron NN NN B-TREATMENT
e NN NN O
100 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
p NN NN B-ROUTE
. NN NN I-ROUTE

o NN NN O
. NN NN O

dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
Complete NN NN O
review NN NN O
of NN NN O
system NN NN B-TEST
s NN NN O
negative NN NN O
except NN NN O
as NN NN O
in NN NN O
pulmonary NN NN O
as NN NN O
noted NN NN O
above NN NN O
. NN NN O

The NN NN O
patient NN NN O
also NN NN O
reports NN NN O
occasional NN NN B-PROBLEM
numbnes NN NN I-PROBLEM
s NN NN O
and NN NN O
tingling NN NN B-PROBLEM
of NN NN I-PROBLEM
her NN NN I-PROBLEM
left NN NN I-PROBLEM
ar NN NN I-PROBLEM
m NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Blood NN NN B-TEST
pressur NN NN I-TEST
e NN NN O
123/95 NN NN O
, NN NN O
heart NN NN B-TEST
rat NN NN I-TEST
e NN NN O
83 NN NN O
, NN NN O
respiration NN NN B-TEST
s NN NN O
20 NN NN O
, NN NN O
temperatur NN NN B-TEST
e NN NN O
97 NN NN O
, NN NN O
and NN NN O
oxygen NN NN B-TEST
saturatio NN NN I-TEST
n NN NN O
97% NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
Positive NN NN O
nonproductive NN NN B-PROBLEM
coug NN NN I-PROBLEM
h NN NN O
and NN NN O
pai NN NN B-PROBLEM
n NN NN O
with NN NN O
coughin NN NN B-PROBLEM
g NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
Pupils NN NN O
are NN NN O
equal NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
and NN NN O
accommodation NN NN O
. NN NN O

Tympanic NN NN O
membranes NN NN O
are NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

No NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
masse NN NN B-PROBLEM
s NN NN O
. NN NN O

RESPIRATORY NN NN O
: NN NN O
Pleural NN NN B-PROBLEM
friction NN NN I-PROBLEM
ru NN NN I-PROBLEM
b NN NN O
is NN NN O
noted NN NN O
. NN NN O

GI NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nondistende NN NN B-PROBLEM
d NN NN O
, NN NN O
and NN NN O
nontende NN NN B-PROBLEM
r NN NN O
. NN NN O

Positive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
organomegal NN NN B-PROBLEM
y NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
edem NN NN B-PROBLEM
a NN NN O
, NN NN O
no NN NN O
clubbin NN NN B-PROBLEM
g NN NN O
, NN NN O
no NN NN O
cyanosi NN NN B-PROBLEM
s NN NN O
, NN NN O
no NN NN O
tendernes NN NN B-PROBLEM
s NN NN O
. NN NN O

Full NN NN O
range NN NN O
of NN NN O
motion NN NN O
. NN NN O

Normal NN NN O
pulses NN NN O
in NN NN O
all NN NN O
extremities NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
breakdow NN NN B-PROBLEM
n NN NN O
or NN NN O
lesion NN NN B-PROBLEM
s NN NN O
. NN NN O

No NN NN O
ulcer NN NN B-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Grossly NN NN O
intact NN NN O
. NN NN O

No NN NN O
focal NN NN B-PROBLEM
deficit NN NN I-PROBLEM
s NN NN O
. NN NN O

Awake NN NN O
, NN NN O
alert NN NN O
, NN NN O
and NN NN O
oriented NN NN O
to NN NN O
person NN NN O
, NN NN O
place NN NN O
, NN NN O
and NN NN O
time NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
Lab NN NN B-TEST
s NN NN O
are NN NN O
pending NN NN O
. NN NN O

HOSPITAL NN NN O
COURSE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
admitted NN NN O
for NN NN O
a NN NN B-PROBLEM
right-sided NN NN I-PROBLEM
pleural NN NN I-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
for NN NN O
thoracentesi NN NN B-TREATMENT
s NN NN O
on NN NN O
Monda NN NN B-DATE
y NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
. NN NN O
Her NN NN O
Coumadi NN NN B-DRUG
n NN NN O
was NN NN O
placed NN NN O
on NN NN O
hold NN NN O
. NN NN O

A NN NN B-TEST
repeat NN NN I-TEST
echocardiogra NN NN I-TEST
m NN NN O
was NN NN O
checked NN NN O
. NN NN O

She NN NN O
was NN NN O
started NN NN O
on NN NN O
prophylaxi NN NN B-TREATMENT
s NN NN O
for NN NN O
DV NN NN B-PROBLEM
T NN NN O
with NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
40 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
subcutaneousl NN NN B-ROUTE
y NN NN O
. NN NN O

Her NN NN O
history NN NN O
dated NN NN O
back NN NN O
to NN NN O
March NN NN B-DATE
200 NN NN I-DATE
5 NN NN O
when NN NN O
she NN NN O
first NN NN O
sought NN NN O
medical NN NN O
attention NN NN O
for NN NN O
evidence NN NN O
of NN NN O
pericarditi NN NN B-PROBLEM
s NN NN O
, NN NN O
which NN NN O
was NN NN O
treated NN NN O
with NN NN O
pericardial NN NN B-TREATMENT
windo NN NN I-TREATMENT
w NN NN O
in NN NN O
an NN NN O
outside NN NN O
hospital NN NN O
, NN NN O
at NN NN O
that NN NN O
time NN NN O
she NN NN O
was NN NN O
also NN NN O
found NN NN O
to NN NN O
have NN NN O
mesenteric NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
and NN NN O
thrombosi NN NN B-PROBLEM
s NN NN O
, NN NN O
is NN NN O
now NN NN O
anticoagulate NN NN B-TREATMENT
d NN NN O
. NN NN O

Her NN NN O
pericardial NN NN O
fluid NN NN O
was NN NN O
accumulated NN NN O
and NN NN O
she NN NN O
was NN NN O
seen NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Y NN NN O
. NN NN O
At NN NN O
that NN NN O
time NN NN O
, NN NN O
she NN NN O
was NN NN O
recommended NN NN O
for NN NN O
pericardectom NN NN B-TREATMENT
y NN NN O
, NN NN O
which NN NN O
was NN NN O
performed NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Z NN NN O
. NN NN O
Review NN NN O
of NN NN O
her NN NN B-TEST
CT NN NN I-TEST
sca NN NN I-TEST
n NN NN O
from NN NN O
March NN NN B-DATE
200 NN NN I-DATE
6 NN NN O
prior NN NN O
to NN NN O
her NN NN B-TREATMENT
pericardectom NN NN I-TREATMENT
y NN NN O
, NN NN O
already NN NN O
shows NN NN O
bilateral NN NN B-PROBLEM
plural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
. NN NN O

The NN NN O
patient NN NN O
improved NN NN O
clinically NN NN O
after NN NN O
the NN NN B-TREATMENT
pericardectom NN NN I-TREATMENT
y NN NN O
with NN NN O
resolution NN NN O
of NN NN O
her NN NN B-PROBLEM
symptom NN NN I-PROBLEM
s NN NN O
. NN NN O

Recently NN NN O
, NN NN O
she NN NN O
was NN NN O
readmitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
with NN NN O
chest NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
and NN NN O
found NN NN O
to NN NN O
have NN NN O
bilateral NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusio NN NN I-PROBLEM
n NN NN O
, NN NN O
the NN NN O
right NN NN O
greater NN NN O
than NN NN O
the NN NN O
left NN NN O
. NN NN O

CT NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
ches NN NN I-TEST
t NN NN O
also NN NN O
revealed NN NN O
a NN NN B-PROBLEM
large NN NN I-PROBLEM
mediastinal NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
. NN NN O

We NN NN O
reviewed NN NN O
the NN NN B-TEST
patholog NN NN I-TEST
y NN NN O
obtained NN NN O
from NN NN O
the NN NN B-TREATMENT
pericardectom NN NN I-TREATMENT
y NN NN O
in NN NN O
March NN NN B-DATE
200 NN NN I-DATE
6 NN NN O
, NN NN O
which NN NN O
was NN NN O
diagnostic NN NN O
of NN NN O
mesotheliom NN NN B-PROBLEM
a NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
chest NN NN B-TREATMENT
tube NN NN I-TREATMENT
placemen NN NN I-TREATMENT
t NN NN O
for NN NN O
drainage NN NN B-PROBLEM
of NN NN I-PROBLEM
the NN NN I-PROBLEM
flui NN NN I-PROBLEM
d NN NN O
occurred NN NN O
and NN NN O
thoracoscop NN NN B-TREATMENT
y NN NN O
with NN NN O
fluid NN NN B-TEST
biopsie NN NN I-TEST
s NN NN O
, NN NN O
which NN NN O
were NN NN O
performed NN NN O
, NN NN O
which NN NN O
revealed NN NN O
epithelioid NN NN B-PROBLEM
malignant NN NN I-PROBLEM
mesotheliom NN NN I-PROBLEM
a NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
then NN NN O
stained NN NN O
with NN NN O
a NN NN B-TEST
PET NN NN I-TEST
C NN NN I-TEST
T NN NN O
, NN NN O
which NN NN O
showed NN NN O
extensive NN NN B-PROBLEM
uptake NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
ches NN NN I-PROBLEM
t NN NN O
, NN NN O
bilateral NN NN B-PROBLEM
pleural NN NN I-PROBLEM
pericardial NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
, NN NN O
and NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
. NN NN O

She NN NN O
also NN NN O
had NN NN O
acidic NN NN B-PROBLEM
flui NN NN I-PROBLEM
d NN NN O
, NN NN O
pectoral NN NN B-PROBLEM
and NN NN I-PROBLEM
intramammary NN NN I-PROBLEM
lymph NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
and NN NN O
uptake NN NN B-PROBLEM
in NN NN I-PROBLEM
L NN NN I-PROBLEM
4 NN NN O
with NN NN O
SU NN NN B-TEST
V NN NN O
of NN NN O

4 NN NN O
. NN NN O
This NN NN O
was NN NN O
consistent NN NN O
with NN NN O
stage NN NN B-PROBLEM
III NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
. NN NN O

Her NN NN B-TEST
repeat NN NN I-TEST
echocardiogra NN NN I-TEST
m NN NN O
showed NN NN O
an NN NN B-TEST
ejection NN NN I-TEST
fractio NN NN I-TEST
n NN NN O
of NN NN O
45% NN NN O
to NN NN O
49% NN NN O
. NN NN O

She NN NN O
was NN NN O
transferred NN NN O
to NN NN O
Oncology NN NN O
service NN NN O
and NN NN O
started NN NN O
on NN NN O
chemotherap NN NN B-TREATMENT
y NN NN O
on NN NN O
September NN NN B-DATE
1 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
with NN NN O
cisplati NN NN B-TREATMENT
n NN NN O
75 NN NN B-STRENGTH
mg/centimete NN NN I-STRENGTH
r NN NN O
squared NN NN O
equaling NN NN O
109 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
I NN NN B-ROUTE
V NN NN O
piggybac NN NN B-DRUG
k NN NN O
over NN NN B-DURATION
2 NN NN I-DURATION
hour NN NN I-DURATION
s NN NN O
on NN NN O
September NN NN B-DATE
1 NN NN I-DATE
, NN NN I-DATE
200 NN NN I-DATE
7 NN NN O
, NN NN O
Alimt NN NN B-TREATMENT
a NN NN O
500 NN NN B-STRENGTH
mg NN NN I-STRENGTH
/ NN NN O
centimeter NN NN B-FORM
square NN NN I-FORM
d NN NN O
equaling NN NN O
730 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
I NN NN B-ROUTE
V NN NN O
piggybac NN NN B-DRUG
k NN NN O
over NN NN B-DURATION
10 NN NN I-DURATION
minute NN NN I-DURATION
s NN NN O
. NN NN O

This NN NN O
was NN NN O
all NN NN O
initiated NN NN O
after NN NN O
a NN NN B-TREATMENT
Port-A-Cat NN NN I-TREATMENT
h NN NN O
was NN NN O
placed NN NN O
. NN NN O

The NN NN O
chemotherap NN NN B-DRUG
y NN NN O
was NN NN O
well NN NN O
tolerated NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
discharged NN NN O
the NN NN O
following NN NN O
day NN NN O
after NN NN O
discontinuing NN NN O
I NN NN B-ROUTE
V NN NN O
flui NN NN B-DRUG
d NN NN O
and NN NN O
I NN NN B-ROUTE
V NN NN O
. NN NN O
Her NN NN B-TREATMENT
Port-A-Cat NN NN I-TREATMENT
h NN NN O
was NN NN O
packed NN NN O
with NN NN O
hepari NN NN B-TREATMENT
n NN NN O
according NN NN O
to NN NN O
protocol NN NN O
. NN NN O

DISCHARGE NN NN B-TREATMENT
MEDICATION NN NN I-TREATMENT
S NN NN O
: NN NN O
Zofra NN NN B-TREATMENT
n NN NN O
, NN NN O
Phenerga NN NN B-TREATMENT
n NN NN O
, NN NN O
Coumadi NN NN B-TREATMENT
n NN NN O
, NN NN O
and NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
, NN NN O
and NN NN O
Vicodi NN NN B-TREATMENT
n NN NN O
DISCHARGE NN NN O
INSTRUCTIONS NN NN O
: NN NN O
She NN NN O
was NN NN O
instructed NN NN O
to NN NN O
followup NN NN O
with NN NN O
Dr NN NN O
. NN NN O
XY NN NN B-NAME
Z NN NN O
in NN NN O
the NN NN O
office NN NN O
to NN NN O
check NN NN O
her NN NN B-TEST
IN NN NN I-TEST
R NN NN O
on NN NN O
Tuesda NN NN B-DATE
y NN NN O
. NN NN O

She NN NN O
was NN NN O
instructed NN NN O
to NN NN O
call NN NN O
if NN NN O
she NN NN O
had NN NN O
any NN NN O
other NN NN O
questions NN NN O
or NN NN O
concerns NN NN O
in NN NN O
the NN NN O
interim NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
BCCa NN NN B-TREATMENT
Excision NN NN I-TREATMENT
- NN NN I-TREATMENT
Lower NN NN I-TREATMENT
Li NN NN I-TREATMENT
d NN NN O
Description NN NN O
: NN NN O
Excisio NN NN B-TREATMENT
n NN NN O
of NN NN O
large NN NN B-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN O
lower NN NN O
lid NN NN O
, NN NN O
and NN NN O
repaired NN NN O
with NN NN O
used NN NN O
dorsal NN NN B-TREATMENT
conjunctival NN NN I-TREATMENT
flap NN NN I-TREATMENT
in NN NN I-TREATMENT
the NN NN I-TREATMENT
upper NN NN I-TREATMENT
li NN NN I-TREATMENT
d NN NN O
and NN NN O
a NN NN B-TREATMENT
large NN NN I-TREATMENT
preauricular NN NN I-TREATMENT
skin NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Extremely NN NN B-PROBLEM
large NN NN I-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN B-PROBLEM
lower NN NN I-PROBLEM
li NN NN I-PROBLEM
d NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Extremely NN NN B-PROBLEM
large NN NN I-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN B-PROBLEM
lower NN NN I-PROBLEM
li NN NN I-PROBLEM
d NN NN O
. NN NN O

TITLE NN NN O
OF NN NN O
OPERATION NN NN O
: NN NN O
Excisio NN NN B-TREATMENT
n NN NN O
of NN NN O
large NN NN B-PROBLEM
basal NN NN I-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
, NN NN O
right NN NN O
lower NN NN O
lid NN NN O
, NN NN O
and NN NN O
repaired NN NN O
with NN NN O
used NN NN O
dorsal NN NN B-TREATMENT
conjunctival NN NN I-TREATMENT
flap NN NN I-TREATMENT
in NN NN I-TREATMENT
the NN NN I-TREATMENT
upper NN NN I-TREATMENT
li NN NN I-TREATMENT
d NN NN O
and NN NN O
a NN NN B-TREATMENT
large NN NN I-TREATMENT
preauricular NN NN I-TREATMENT
skin NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
brought NN NN O
into NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
prepped NN NN O
and NN NN O
draped NN NN O
in NN NN O
usual NN NN O
fashion NN NN O
. NN NN O

Xylocain NN NN B-TREATMENT
e NN NN O
2 NN NN B-STRENGTH
% NN NN O
with NN NN O
epinephrin NN NN B-TREATMENT
e NN NN O
was NN NN O
injected NN NN O
beneath NN NN O
the NN NN O
conjunctiva NN NN O
and NN NN O
skin NN NN O
of NN NN O
the NN NN O
lower NN NN O
lid NN NN O
and NN NN O
also NN NN O
beneath NN NN O
the NN NN O
conjunctiva NN NN O
and NN NN O
skin NN NN O
of NN NN O
the NN NN O
upper NN NN O
lid NN NN O
. NN NN O

A NN NN B-PROBLEM
frontal NN NN I-PROBLEM
nerve NN NN I-PROBLEM
bloc NN NN I-PROBLEM
k NN NN O
was NN NN O
also NN NN O
given NN NN O
on NN NN O
the NN NN O
right NN NN O
upper NN NN O
lid NN NN O
. NN NN O

The NN NN B-TREATMENT
anesthetic NN NN I-TREATMENT
agen NN NN I-TREATMENT
t NN NN O
was NN NN O
also NN NN O
injected NN NN O
in NN NN O
the NN NN O
right NN NN O
preauricular NN NN O
region NN NN O
which NN NN O
would NN NN O
provide NN NN O
a NN NN B-TREATMENT
donor NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
for NN NN O
the NN NN B-PROBLEM
right NN NN I-PROBLEM
lower NN NN I-PROBLEM
lid NN NN I-PROBLEM
defec NN NN I-PROBLEM
t NN NN O
. NN NN O

The NN NN O
area NN NN O
was NN NN O
marked NN NN O
with NN NN O
a NN NN O
marking NN NN O
pen NN NN O
with NN NN O
margins NN NN O
of NN NN O
3 NN NN O
to NN NN O
4 NN NN O
mm NN NN O
, NN NN O
and NN NN O
a NN NN B-TREATMENT
#15 NN NN I-TREATMENT
Bard-Parker NN NN I-TREATMENT
blad NN NN I-TREATMENT
e NN NN O
was NN NN O
used NN NN O
to NN NN O
make NN NN O
an NN NN B-PROBLEM
incision NN NN I-PROBLEM
at NN NN I-PROBLEM
the NN NN I-PROBLEM
nasal NN NN I-PROBLEM
and NN NN I-PROBLEM
temporal NN NN I-PROBLEM
margin NN NN I-PROBLEM
s NN NN O
of NN NN O
the NN NN B-PROBLEM
lesio NN NN I-PROBLEM
n NN NN O
. NN NN O

The NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
carried NN NN O
inferiorly NN NN O
, NN NN O
and NN NN O
using NN NN O
a NN NN B-TREATMENT
Steven NN NN I-TREATMENT
scissor NN NN I-TREATMENT
s NN NN O
the NN NN O
normal NN NN O
skin NN NN O
, NN NN O
muscle NN NN O
, NN NN O
and NN NN O
conjunctiva NN NN O
was NN NN O
excised NN NN B-TREATMENT
inferiorl NN NN I-TREATMENT
y NN NN O
. NN NN O

The NN NN B-TEST
specime NN NN I-TEST
n NN NN O
was NN NN O
then NN NN O
marked NN NN O
and NN NN O
sent NN NN O
to NN NN O
pathology NN NN O
for NN NN O
frozen NN NN B-TEST
sectio NN NN I-TEST
n NN NN O
. NN NN O

Bleedin NN NN B-PROBLEM
g NN NN O
was NN NN O
controlled NN NN O
with NN NN O
a NN NN B-TREATMENT
wet-field NN NN I-TREATMENT
cauter NN NN I-TREATMENT
y NN NN O
, NN NN O
and NN NN O
the NN NN O
right NN NN O
upper NN NN O
lid NN NN O
was NN NN O
everted NN NN O
, NN NN O
and NN NN O
an NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
made NN NN O
3 NN NN O
mm NN NN O
above NN NN O
the NN NN O
lid NN NN O
margin NN NN O
with NN NN O
the NN NN B-TREATMENT
Bard-Parker NN NN I-TREATMENT
blad NN NN I-TREATMENT
e NN NN O
in NN NN O
the NN NN O
entire NN NN O
length NN NN O
of NN NN O
the NN NN O
upper NN NN O
lid NN NN O
. NN NN O

The NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
reached NN NN O
the NN NN O
orbicularis NN NN O
, NN NN O
and NN NN O
Steven NN NN B-TREATMENT
scissor NN NN I-TREATMENT
s NN NN O
were NN NN O
used NN NN O
to NN NN O
separate NN NN O
the NN NN O
tarsus NN NN O
from NN NN O
the NN NN O
underlying NN NN O
orbicularis NN NN O
. NN NN O

Vertical NN NN O
cuts NN NN O
were NN NN O
made NN NN O
nasally NN NN O
and NN NN O
temporally NN NN O
, NN NN O
and NN NN O
a NN NN B-TREATMENT
large NN NN I-TREATMENT
dorsal NN NN I-TREATMENT
conjunctival NN NN I-TREATMENT
fla NN NN I-TREATMENT
p NN NN O
was NN NN O
fashioned NN NN O
with NN NN O
the NN NN O
conjunctiva NN NN O
attached NN NN O
superiorly NN NN O
. NN NN O

It NN NN O
was NN NN O
placed NN NN O
into NN NN O
the NN NN B-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
lower NN NN I-PROBLEM
lid NN NN I-PROBLEM
and NN NN I-PROBLEM
suture NN NN I-PROBLEM
d NN NN O
with NN NN O
multiple NN NN B-TREATMENT
interrupted NN NN I-TREATMENT
6-0 NN NN I-TREATMENT
Vicryl NN NN I-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
nasally NN NN O
, NN NN O
temporally NN NN O
, NN NN O
and NN NN O
inferiorly NN NN O
. NN NN O

The NN NN B-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
ski NN NN I-PROBLEM
n NN NN O
was NN NN O
measured NN NN O
and NN NN O
an NN NN B-TREATMENT
appropriate NN NN I-TREATMENT
large NN NN I-TREATMENT
preauricular NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
excised NN NN O
from NN NN O
the NN NN O
right NN NN O
preauricular NN NN O
region NN NN O
. NN NN O

The NN NN B-PROBLEM
defec NN NN I-PROBLEM
t NN NN O
was NN NN O
closed NN NN O
with NN NN O
interrupted NN NN B-TREATMENT
5-0 NN NN I-TREATMENT
Prolene NN NN I-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
, NN NN O
and NN NN O
the NN NN B-TREATMENT
preauricular NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
sutured NN NN O
in NN NN O
place NN NN O
with NN NN O
multiple NN NN B-TREATMENT
interrupted NN NN I-TREATMENT
6-0 NN NN I-TREATMENT
silk NN NN I-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
. NN NN O

The NN NN O
upper NN NN O
border NN NN O
of NN NN O
the NN NN B-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
attached NN NN O
to NN NN O
the NN NN O
upper NN NN O
lid NN NN O
after NN NN O
incisio NN NN B-PROBLEM
n NN NN O
was NN NN O
made NN NN O
in NN NN O
the NN NN B-TREATMENT
gray NN NN I-TREATMENT
lin NN NN I-TREATMENT
e NN NN O
with NN NN O
a NN NN B-TREATMENT
Superblad NN NN I-TREATMENT
e NN NN O
, NN NN O
and NN NN O
the NN NN O
superior NN NN O
portion NN NN O
of NN NN O
the NN NN B-TREATMENT
skin NN NN I-TREATMENT
graf NN NN I-TREATMENT
t NN NN O
was NN NN O
sutured NN NN O
to NN NN O
the NN NN O
upper NN NN O
lid NN NN O
through NN NN O
the NN NN O
anterior NN NN O
lamella NN NN O
created NN NN O
by NN NN O
the NN NN B-PROBLEM
razor NN NN I-PROBLEM
blade NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
. NN NN O

Cryotherap NN NN B-TREATMENT
y NN NN O
was NN NN O
then NN NN O
used NN NN O
to NN NN O
treat NN NN O
the NN NN O
nasal NN NN O
and NN NN O
temporal NN NN O
margins NN NN O
of NN NN O
the NN NN O
area NN NN O
of NN NN O
excisio NN NN B-TREATMENT
n NN NN O
because NN NN O
of NN NN O
positive NN NN B-PROBLEM
margin NN NN I-PROBLEM
s NN NN O
, NN NN O
and NN NN O
following NN NN O
this NN NN O
an NN NN O
antibiotic NN NN B-DRUG
steroi NN NN I-DRUG
d NN NN O
ointmen NN NN B-FORM
t NN NN O
was NN NN O
instilled NN NN O
and NN NN O
a NN NN B-TREATMENT
light NN NN I-TREATMENT
pressure NN NN I-TREATMENT
dressin NN NN I-TREATMENT
g NN NN O
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
well NN NN O
and NN NN O
was NN NN O
sent NN NN O
to NN NN O
recovery NN NN O
room NN NN O
in NN NN O
good NN NN O
condition NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Anemi NN NN B-PROBLEM
a NN NN O
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
Refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
that NN NN O
is NN NN O
transfusion NN NN B-PROBLEM
dependen NN NN I-PROBLEM
t NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
anemi NN NN B-PROBLEM
a NN NN O
with NN NN O
hemoglobi NN NN B-TEST
n NN NN O
of NN NN O
7.1 NN NN O
and NN NN O
requiring NN NN O
transfusio NN NN B-TREATMENT
n NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
DIAGNOSIS NN NN O
: NN NN O
Refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
that NN NN O
is NN NN O
transfusion NN NN B-PROBLEM
dependen NN NN I-PROBLEM
t NN NN O
. NN NN O

CHIEF NN NN O
COMPLAINT NN NN O
: NN NN O
I NN NN O
needed NN NN O
a NN NN O
blood NN NN O
transfusio NN NN B-ROUTE
n NN NN O
. NN NN O

HISTORY NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
78-year-ol NN NN B-AGE
d NN NN O
gentleman NN NN O
with NN NN O
no NN NN O
substantial NN NN O
past NN NN O
medical NN NN O
history NN NN O
except NN NN O
for NN NN O
diabete NN NN B-PROBLEM
s NN NN O
. NN NN O

He NN NN O
denies NN NN O
any NN NN B-PROBLEM
comorbid NN NN I-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
of NN NN O
the NN NN B-PROBLEM
diabete NN NN I-PROBLEM
s NN NN O
including NN NN O
kidney NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
heart NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
strok NN NN B-PROBLEM
e NN NN O
, NN NN O
vision NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
, NN NN O
or NN NN O
neuropath NN NN B-PROBLEM
y NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
he NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
anemi NN NN B-PROBLEM
a NN NN O
with NN NN O
hemoglobi NN NN B-TEST
n NN NN O
of NN NN O
7.1 NN NN O
and NN NN O
requiring NN NN O
transfusio NN NN B-TREATMENT
n NN NN O
. NN NN O

He NN NN O
reports NN NN O
that NN NN O
he NN NN O
has NN NN O
no NN NN O
signs NN NN O
or NN NN O
symptom NN NN O
of NN NN O
bleedin NN NN B-PROBLEM
g NN NN O
and NN NN O
had NN NN O
a NN NN B-TREATMENT
blood NN NN I-TREATMENT
transfusio NN NN I-TREATMENT
n NN NN O
approximately NN NN O
two NN NN O
months NN NN O
ago NN NN O
and NN NN O
actually NN NN O
several NN NN O
weeks NN NN O
before NN NN O
that NN NN B-TREATMENT
blood NN NN I-TREATMENT
transfusio NN NN I-TREATMENT
n NN NN O
, NN NN O
he NN NN O
had NN NN O
a NN NN B-TREATMENT
transfusio NN NN I-TREATMENT
n NN NN O
for NN NN O
anemi NN NN B-PROBLEM
a NN NN O
. NN NN O

He NN NN O
has NN NN O
been NN NN O
placed NN NN O
on NN NN O
B1 NN NN B-TREATMENT
2 NN NN O
, NN NN O
oral NN NN B-TREATMENT
iro NN NN I-TREATMENT
n NN NN O
, NN NN O
and NN NN O
Procri NN NN B-TREATMENT
t NN NN O
. NN NN O

At NN NN O
this NN NN O
time NN NN O
, NN NN O
we NN NN O
are NN NN O
asked NN NN O
to NN NN O
evaluate NN NN O
him NN NN O
for NN NN O
further NN NN O
causes NN NN O
and NN NN O
treatmen NN NN B-TREATMENT
t NN NN O
for NN NN O
his NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
. NN NN O

He NN NN O
denies NN NN O
any NN NN B-PROBLEM
constitutional NN NN I-PROBLEM
complaint NN NN I-PROBLEM
s NN NN O
except NN NN O
for NN NN O
fatigu NN NN B-PROBLEM
e NN NN O
, NN NN O
malais NN NN B-PROBLEM
e NN NN O
, NN NN O
and NN NN O
some NN NN B-PROBLEM
dyspne NN NN I-PROBLEM
a NN NN O
. NN NN O

He NN NN O
has NN NN O
no NN NN O
adenopath NN NN B-PROBLEM
y NN NN O
that NN NN O
he NN NN O
reports NN NN O
. NN NN O

No NN NN O
fever NN NN B-PROBLEM
s NN NN O
, NN NN O
night NN NN B-PROBLEM
sweat NN NN I-PROBLEM
s NN NN O
, NN NN O
bone NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
ras NN NN B-PROBLEM
h NN NN O
, NN NN O
arthralgia NN NN B-PROBLEM
s NN NN O
, NN NN O
or NN NN O
myalgia NN NN B-PROBLEM
s NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O
: NN NN O
Diabete NN NN B-PROBLEM
s NN NN O
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O
: NN NN O
Hernia NN NN B-TREATMENT
repai NN NN I-TREATMENT
r NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
He NN NN O
has NN NN O
no NN NN O
allergie NN NN B-PROBLEM
s NN NN O
. NN NN O

MEDICATIONS NN NN O
: NN NN O
Listed NN NN O
in NN NN O
the NN NN O
chart NN NN O
and NN NN O
include NN NN O
Coumadi NN NN B-TREATMENT
n NN NN O
, NN NN O
Lasi NN NN B-TREATMENT
x NN NN O
, NN NN O
metformi NN NN B-TREATMENT
n NN NN O
, NN NN O
folic NN NN B-TREATMENT
aci NN NN I-TREATMENT
d NN NN O
, NN NN O
diltiaze NN NN B-TREATMENT
m NN NN O
, NN NN O
B1 NN NN B-TREATMENT
2 NN NN O
, NN NN O
Prevaci NN NN B-TREATMENT
d NN NN O
, NN NN O
and NN NN O
Feoso NN NN B-TREATMENT
l NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
He NN NN O
is NN NN O
a NN NN O
tobacco NN NN O
user NN NN O
. NN NN O

He NN NN O
does NN NN O
not NN NN O
drink NN NN O
. NN NN O

He NN NN O
lives NN NN O
alone NN NN O
, NN NN O
but NN NN O
has NN NN O
family NN NN O
and NN NN O
social NN NN O
support NN NN O
to NN NN O
look NN NN O
on NN NN O
him NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Negative NN NN O
for NN NN O
blood NN NN B-PROBLEM
or NN NN I-PROBLEM
cancer NN NN I-PROBLEM
disorder NN NN I-PROBLEM
s NN NN O
according NN NN O
to NN NN O
the NN NN O
patient NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
: NN NN O
GENERAL NN NN O
: NN NN O
He NN NN O
is NN NN O
an NN NN O
elderly NN NN O
gentleman NN NN O
in NN NN O
no NN NN O
acute NN NN B-PROBLEM
distres NN NN I-PROBLEM
s NN NN O
. NN NN O

He NN NN O
is NN NN O
sitting NN NN O
up NN NN O
in NN NN O
bed NN NN O
eating NN NN O
his NN NN O
breakfast NN NN O
. NN NN O

He NN NN O
is NN NN O
alert NN NN O
and NN NN O
oriented NN NN O
and NN NN O
answering NN NN O
questions NN NN O
appropriately NN NN O
. NN NN O

VITAL NN NN O
SIGNS NN NN O
: NN NN O
Blood NN NN B-TEST
pressur NN NN I-TEST
e NN NN O
of NN NN O
110/60 NN NN O
, NN NN O
puls NN NN B-TEST
e NN NN O
of NN NN O
99 NN NN O
, NN NN O
respiratory NN NN B-TEST
rat NN NN I-TEST
e NN NN O
of NN NN O
14 NN NN O
, NN NN O
and NN NN O
temperatur NN NN B-TEST
e NN NN O
of NN NN O
97.4 NN NN O
. NN NN O

He NN NN O
is NN NN O
69 NN NN O
inches NN NN O
tall NN NN O
and NN NN O
weighs NN NN O
174 NN NN O
pounds NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
Sclerae NN NN O
show NN NN O
mild NN NN B-PROBLEM
arcus NN NN I-PROBLEM
senilis NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
righ NN NN I-PROBLEM
t NN NN O
. NN NN O

Left NN NN O
is NN NN O
clear NN NN O
. NN NN O

Pupils NN NN O
are NN NN O
equally NN NN O
round NN NN O
and NN NN O
reactive NN NN O
to NN NN O
light NN NN O
. NN NN O

Extraocular NN NN O
movements NN NN O
are NN NN O
intact NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

Trachea NN NN O
is NN NN O
midline NN NN O
. NN NN O

No NN NN O
jugular NN NN B-PROBLEM
venous NN NN I-PROBLEM
pressure NN NN I-PROBLEM
distentio NN NN I-PROBLEM
n NN NN O
is NN NN O
noted NN NN O
. NN NN O

No NN NN O
adenopathy NN NN B-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
cervical NN NN I-PROBLEM
, NN NN I-PROBLEM
supraclavicular NN NN I-PROBLEM
, NN NN I-PROBLEM
or NN NN I-PROBLEM
axillary NN NN I-PROBLEM
area NN NN I-PROBLEM
s NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
. NN NN O

HEART NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Soft NN NN O
and NN NN O
nontende NN NN B-PROBLEM
r NN NN O
. NN NN O

There NN NN O
may NN NN O
be NN NN O
some NN NN B-PROBLEM
fullness NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
left NN NN I-PROBLEM
upper NN NN I-PROBLEM
quadran NN NN I-PROBLEM
t NN NN O
, NN NN O
although NN NN O
I NN NN O
do NN NN O
not NN NN O
appreciate NN NN O
a NN NN O
true NN NN O
spleen NN NN O
with NN NN O
inspiration NN NN O
. NN NN O

EXTREMITIES NN NN O
: NN NN O
No NN NN O
clubbin NN NN B-PROBLEM
g NN NN O
, NN NN O
but NN NN O
there NN NN O
is NN NN O
some NN NN B-PROBLEM
edem NN NN I-PROBLEM
a NN NN O
, NN NN O
but NN NN O
no NN NN O
cyanosi NN NN B-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

DERMATOLOGIC NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

CARDIOVASCULAR NN NN O
: NN NN O
Noncontributory NN NN O
. NN NN O

IMPRESSION NN NN O
: NN NN O
At NN NN O
this NN NN O
time NN NN O
is NN NN O
refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
, NN NN O
which NN NN O
is NN NN O
transfusion NN NN B-PROBLEM
dependen NN NN I-PROBLEM
t NN NN O
. NN NN O

He NN NN O
is NN NN O
on NN NN O
B1 NN NN B-TREATMENT
2 NN NN O
, NN NN O
iro NN NN B-TREATMENT
n NN NN O
, NN NN O
folic NN NN B-TREATMENT
aci NN NN I-TREATMENT
d NN NN O
, NN NN O
and NN NN O
Procri NN NN B-TREATMENT
t NN NN O
. NN NN O

There NN NN O
are NN NN O
no NN NN O
sign NN NN O
or NN NN O
symptom NN NN O
of NN NN O
blood NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
and NN NN O
a NN NN B-TEST
recent NN NN I-TEST
esophagogastroduodenoscop NN NN I-TEST
y NN NN O
, NN NN O
which NN NN O
was NN NN O
negative NN NN O
. NN NN O

His NN NN B-TEST
creatinin NN NN I-TEST
e NN NN O
was NN NN O

1 NN NN O
. NN NN O
My NN NN O
impression NN NN O
at NN NN O
this NN NN O
time NN NN O
is NN NN O
that NN NN O
he NN NN O
probably NN NN O
has NN NN O
an NN NN B-PROBLEM
underlying NN NN I-PROBLEM
myelodysplastic NN NN I-PROBLEM
syndrom NN NN I-PROBLEM
e NN NN O
or NN NN O
bone NN NN B-PROBLEM
marrow NN NN I-PROBLEM
failur NN NN I-PROBLEM
e NN NN O
. NN NN O

His NN NN B-TEST
creatinin NN NN I-TEST
e NN NN O
on NN NN O
this NN NN O
hospitalization NN NN O
was NN NN O
up NN NN O
slightly NN NN O
to NN NN O
1.6 NN NN O
and NN NN O
this NN NN O
may NN NN O
contribute NN NN O
to NN NN O
his NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
. NN NN O

RECOMMENDATIONS NN NN O
: NN NN O
At NN NN O
this NN NN O
time NN NN O
, NN NN O
my NN NN O
recommendation NN NN O
for NN NN O
the NN NN O
patient NN NN O
is NN NN O
that NN NN O
he NN NN O
undergoes NN NN O
further NN NN B-TEST
serologic NN NN I-TEST
evaluatio NN NN I-TEST
n NN NN O
with NN NN O
reticulocyte NN NN B-TEST
coun NN NN I-TEST
t NN NN O
, NN NN O
serum NN NN B-TEST
protei NN NN I-TEST
n NN NN O
, NN NN O
and NN NN O
electrophoresi NN NN B-TEST
s NN NN O
, NN NN O
LD NN NN B-TEST
H NN NN O
, NN NN O
B1 NN NN B-TEST
2 NN NN O
, NN NN O
folat NN NN B-TEST
e NN NN O
, NN NN O
erythropoietin NN NN B-TEST
leve NN NN I-TEST
l NN NN O
, NN NN O
and NN NN O
he NN NN O
should NN NN O
undergo NN NN O
a NN NN B-TREATMENT
bone NN NN I-TREATMENT
marrow NN NN I-TREATMENT
aspiratio NN NN I-TREATMENT
n NN NN O
and NN NN O
biops NN NN B-TEST
y NN NN O
. NN NN O

I NN NN O
have NN NN O
discussed NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
in NN NN O
detail NN NN O
which NN NN O
the NN NN O
patient NN NN O
. NN NN O

I NN NN O
have NN NN O
discussed NN NN O
the NN NN O
risks NN NN O
, NN NN O
benefits NN NN O
, NN NN O
and NN NN O
successes NN NN O
of NN NN O
that NN NN O
treatment NN NN O
and NN NN O
usefulness NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
bone NN NN I-TEST
marro NN NN I-TEST
w NN NN O
and NN NN O
predicting NN NN O
his NN NN O
cause NN NN O
of NN NN O
refractory NN NN B-PROBLEM
anemi NN NN I-PROBLEM
a NN NN O
and NN NN O
further NN NN O
therapeutic NN NN B-TREATMENT
intervention NN NN I-TREATMENT
s NN NN O
, NN NN O
which NN NN O
might NN NN O
be NN NN O
beneficial NN NN O
to NN NN O
him NN NN O
. NN NN O

He NN NN O
is NN NN O
willing NN NN O
to NN NN O
proceed NN NN O
with NN NN O
the NN NN B-TEST
studie NN NN I-TEST
s NN NN O
I NN NN O
have NN NN O
described NN NN O
to NN NN O
him NN NN O
. NN NN O

We NN NN O
will NN NN O
order NN NN O
an NN NN B-TEST
ultrasound NN NN I-TEST
of NN NN I-TEST
his NN NN I-TEST
abdome NN NN I-TEST
n NN NN O
because NN NN O
of NN NN O
the NN NN O
possible NN NN O
fullness NN NN B-PROBLEM
of NN NN I-PROBLEM
the NN NN I-PROBLEM
splee NN NN I-PROBLEM
n NN NN O
, NN NN O
and NN NN O
I NN NN O
will NN NN O
probably NN NN O
see NN NN O
him NN NN O
in NN NN O
follow NN NN O
up NN NN O
after NN NN O
this NN NN B-TREATMENT
hospitalizatio NN NN I-TREATMENT
n NN NN O
. NN NN O

As NN NN O
always NN NN O
, NN NN O
we NN NN O
greatly NN NN O
appreciate NN NN O
being NN NN O
able NN NN O
to NN NN O
participate NN NN O
in NN NN O
the NN NN O
care NN NN O
of NN NN O
your NN NN O
patient NN NN O
. NN NN O

We NN NN O
appreciate NN NN O
the NN NN O
consultation NN NN O
of NN NN O
the NN NN O
patient NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Intensity-Modulated NN NN O
Radiation NN NN O
Therapy NN NN O
Description NN NN O
: NN NN O
Intensity-modulated NN NN B-TREATMENT
radiation NN NN I-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
is NN NN O
a NN NN O
complex NN NN O
set NN NN O
of NN NN O
procedure NN NN B-TREATMENT
s NN NN O
which NN NN O
requires NN NN O
appropriate NN NN O
positioning NN NN O
and NN NN O
immobilizatio NN NN B-TREATMENT
n NN NN O
typically NN NN O
with NN NN O
customized NN NN B-TREATMENT
immobilization NN NN I-TREATMENT
device NN NN I-TREATMENT
s NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
INTENSITY-MODULATED NN NN O
RADIATION NN NN O
THERAPY NN NN O
Intensity-modulated NN NN B-TREATMENT
radiation NN NN I-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
is NN NN O
a NN NN O
complex NN NN O
set NN NN O
of NN NN O
procedure NN NN B-TREATMENT
s NN NN O
which NN NN O
requires NN NN O
appropriate NN NN O
positioning NN NN O
and NN NN O
immobilizatio NN NN B-TREATMENT
n NN NN O
typically NN NN O
with NN NN O
customized NN NN B-TREATMENT
immobilization NN NN I-TREATMENT
device NN NN I-TREATMENT
s NN NN O
. NN NN O

The NN NN B-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
planning NN NN O
process NN NN O
requires NN NN O
at NN NN O
least NN NN O
4 NN NN O
hours NN NN O
of NN NN O
physician NN NN O
time NN NN O
. NN NN O

The NN NN O
technology NN NN O
is NN NN O
appropriate NN NN O
in NN NN O
this NN NN O
patient's NN NN O
case NN NN O
due NN NN O
to NN NN O
the NN NN O
fact NN NN O
that NN NN O
the NN NN O
target NN NN O
volume NN NN O
is NN NN O
adjacent NN NN O
to NN NN O
significant NN NN O
radiosensitive NN NN O
structures NN NN O
. NN NN O

Sequential NN NN B-TEST
CT NN NN I-TEST
scan NN NN I-TEST
s NN NN O
are NN NN O
obtained NN NN O
and NN NN O
transferred NN NN O
to NN NN O
the NN NN O
treatment NN NN O
planning NN NN O
software NN NN O
. NN NN O

Extensive NN NN B-TEST
analysi NN NN I-TEST
s NN NN O
occurs NN NN O
. NN NN O

The NN NN O
target NN NN O
volumes NN NN O
, NN NN O
including NN NN O
margins NN NN O
for NN NN O
uncertainty NN NN O
, NN NN O
patient NN NN O
movement NN NN O
and NN NN O
occult NN NN B-PROBLEM
tumor NN NN I-PROBLEM
extensio NN NN I-PROBLEM
n NN NN O
are NN NN O
selected NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
organs NN NN O
at NN NN O
risk NN NN O
are NN NN O
outlined NN NN O
. NN NN O

Doses NN NN O
are NN NN O
selected NN NN O
both NN NN O
for NN NN O
targets NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
for NN NN O
organs NN NN O
at NN NN O
risk NN NN O
. NN NN O

Associated NN NN B-TREATMENT
dose NN NN I-TREATMENT
constraint NN NN I-TREATMENT
s NN NN O
are NN NN O
placed NN NN O
. NN NN O

Inverse NN NN B-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
planning NN NN O
is NN NN O
then NN NN O
performed NN NN O
in NN NN O
conjunction NN NN O
with NN NN O
the NN NN O
physics NN NN O
staff NN NN O
. NN NN O

These NN NN O
are NN NN O
reviewed NN NN O
by NN NN O
the NN NN O
physician NN NN O
and NN NN O
ultimately NN NN O
performed NN NN O
only NN NN O
following NN NN O
approval NN NN O
by NN NN O
the NN NN O
physician NN NN O
. NN NN O

Multiple NN NN B-TREATMENT
beam NN NN I-TREATMENT
arrangement NN NN I-TREATMENT
s NN NN O
may NN NN O
be NN NN O
tested NN NN O
for NN NN O
appropriateness NN NN O
and NN NN O
optimal NN NN B-TREATMENT
dose NN NN I-TREATMENT
deliver NN NN I-TREATMENT
y NN NN O
in NN NN O
order NN NN O
to NN NN O
maximize NN NN O
the NN NN O
chance NN NN O
of NN NN O
controlling NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
, NN NN O
while NN NN O
minimizing NN NN O
exposure NN NN O
to NN NN O
organs NN NN O
at NN NN O
risk NN NN O
. NN NN O

This NN NN O
is NN NN O
performed NN NN O
in NN NN O
hopes NN NN O
of NN NN O
minimizing NN NN O
associated NN NN B-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
. NN NN O

The NN NN O
physician NN NN O
delineates NN NN O
the NN NN O
treatment NN NN O
type NN NN O
, NN NN O
number NN NN O
of NN NN O
fractions NN NN O
and NN NN O
total NN NN O
volume NN NN O
. NN NN O

During NN NN O
the NN NN O
time NN NN O
of NN NN O
treatmen NN NN B-TREATMENT
t NN NN O
, NN NN O
there NN NN O
is NN NN O
extensive NN NN B-TREATMENT
physician NN NN I-TREATMENT
interventio NN NN I-TREATMENT
n NN NN O
, NN NN O
monitorin NN NN B-TEST
g NN NN O
the NN NN O
patient NN NN O
set NN NN O
up NN NN O
and NN NN O
tolerance NN NN O
. NN NN O

In NN NN O
addition NN NN O
, NN NN O
specific NN NN O
QA NN NN O
is NN NN O
performed NN NN O
by NN NN O
the NN NN O
physics NN NN O
staff NN NN O
under NN NN O
the NN NN O
physician's NN NN O
direction NN NN O
. NN NN O

In NN NN O
view NN NN O
of NN NN O
the NN NN O
above NN NN O
, NN NN O
the NN NN B-TREATMENT
special NN NN I-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
code NN NN O
7747 NN NN B-ID
0 NN NN O
is NN NN O
deemed NN NN O
appropriate NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Neck NN NN O
Dissection NN NN O
Description NN NN O
: NN NN O
Left NN NN B-PROBLEM
neck NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
. NN NN O

Metastatic NN NN B-PROBLEM
papillary NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
left NN NN B-PROBLEM
nec NN NN I-PROBLEM
k NN NN O
. NN NN O

The NN NN O
patient NN NN O
had NN NN O
thyroid NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
papillary NN NN B-PROBLEM
cell NN NN I-PROBLEM
typ NN NN I-PROBLEM
e NN NN O
, NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
total NN NN I-TREATMENT
thyroidectom NN NN I-TREATMENT
y NN NN O
and NN NN O
then NN NN O
subsequently NN NN B-PROBLEM
recurrent NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
was NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
paratracheal NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
papillary NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
left NN NN O
neck NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
papillary NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
left NN NN O
neck NN NN O
. NN NN O

OPERATION NN NN O
PERFORMED NN NN O
: NN NN O
Left NN NN B-TREATMENT
neck NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN O
endotracheal NN NN O
. NN NN O

INDICATIONS NN NN O
: NN NN O
The NN NN O
patient NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
gentleman NN NN O
, NN NN O
who NN NN O
has NN NN O
had NN NN O
thyroid NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
papillary NN NN B-PROBLEM
cell NN NN I-PROBLEM
typ NN NN I-PROBLEM
e NN NN O
, NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
total NN NN I-TREATMENT
thyroidectom NN NN I-TREATMENT
y NN NN O
and NN NN O
then NN NN O
subsequently NN NN B-PROBLEM
recurrent NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
was NN NN O
removed NN NN O
with NN NN O
a NN NN B-TREATMENT
paratracheal NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
. NN NN O

He NN NN O
now NN NN O
has NN NN O
evidence NN NN O
of NN NN O
lesion NN NN B-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
left NN NN I-PROBLEM
mid NN NN I-PROBLEM
nec NN NN I-PROBLEM
k NN NN O
and NN NN O
the NN NN O
left NN NN O
superior NN NN O
neck NN NN O
on NN NN O
ultrasoun NN NN B-TEST
d NN NN O
, NN NN O
which NN NN O
are NN NN O
suspicious NN NN O
for NN NN O
recurrent NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
. NN NN O

Left NN NN B-TREATMENT
neck NN NN I-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
is NN NN O
indicated NN NN O
. NN NN O

DESCRIPTION NN NN O
OF NN NN O
OPERATION NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
placed NN NN O
on NN NN O
the NN NN O
operating NN NN O
room NN NN O
table NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
. NN NN O

After NN NN O
adequate NN NN O
general NN NN O
endotracheal NN NN O
anesthesi NN NN B-DRUG
a NN NN O
was NN NN O
administered NN NN O
, NN NN O
the NN NN O
table NN NN O
was NN NN O
then NN NN O
turned NN NN O
. NN NN O

A NN NN B-TREATMENT
shoulder NN NN I-TREATMENT
rol NN NN I-TREATMENT
l NN NN O
placed NN NN O
under NN NN O
the NN NN O
shoulders NN NN O
and NN NN O
the NN NN O
face NN NN O
was NN NN O
placed NN NN O
in NN NN O
an NN NN O
extended NN NN O
fashion NN NN O
. NN NN O

The NN NN O
left NN NN O
neck NN NN O
, NN NN O
chest NN NN O
, NN NN O
and NN NN O
face NN NN O
were NN NN O
prepped NN NN O
with NN NN O
Betadin NN NN B-TREATMENT
e NN NN O
and NN NN O
drape NN NN B-TREATMENT
d NN NN O
in NN NN O
a NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

A NN NN B-PROBLEM
hockey NN NN I-PROBLEM
stick NN NN I-PROBLEM
skin NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
performed NN NN O
, NN NN O
extending NN NN O
a NN NN B-TREATMENT
previous NN NN I-TREATMENT
incision NN NN I-TREATMENT
lin NN NN I-TREATMENT
e NN NN O
superiorly NN NN O
towards NN NN O
the NN NN O
mastoid NN NN O
cortex NN NN O
through NN NN O
skin NN NN O
, NN NN O
subcutaneous NN NN O
tissue NN NN O
and NN NN O
platysma NN NN O
with NN NN O
Bovie NN NN B-TREATMENT
electrocauter NN NN I-TREATMENT
y NN NN O
on NN NN O
cut NN NN O
mode NN NN O
. NN NN O

Subplatysmal NN NN B-TREATMENT
superior NN NN I-TREATMENT
and NN NN I-TREATMENT
inferior NN NN I-TREATMENT
flap NN NN I-TREATMENT
s NN NN O
were NN NN O
raised NN NN O
. NN NN O

The NN NN B-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
was NN NN O
left NN NN B-PROBLEM
lateral NN NN I-PROBLEM
neck NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
encompassing NN NN O
zones NN NN O
1 NN NN O
, NN NN O
2A NN NN O
, NN NN O
2 NN NN B-TEST
B NN NN O
, NN NN O
3 NN NN O
, NN NN O
and NN NN O
the NN NN O
superior NN NN O
portion NN NN O
of NN NN O

4 NN NN O
. NN NN O
The NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
was NN NN O
unwrapped NN NN O
at NN NN O
its NN NN O
fascial NN NN O
attachment NN NN O
and NN NN O
this NN NN O
was NN NN O
taken NN NN O
back NN NN O
posterior NN NN O
to NN NN O
the NN NN O
XI NN NN O
cranial NN NN O
nerve NN NN O
into NN NN O
the NN NN O
superior NN NN O
posterior NN NN O
most NN NN O
triangle NN NN O
of NN NN O
the NN NN O
neck NN NN O
. NN NN O

This NN NN O
was NN NN O
carried NN NN O
forward NN NN O
off NN NN O
of NN NN O
the NN NN O
deep NN NN O
rooted NN NN O
muscles NN NN O
including NN NN O
the NN NN B-PROBLEM
splenius NN NN I-PROBLEM
capiti NN NN I-PROBLEM
s NN NN O
and NN NN O
anterior NN NN B-PROBLEM
and NN NN I-PROBLEM
middle NN NN I-PROBLEM
scalene NN NN I-PROBLEM
s NN NN O
taken NN NN O
medially NN NN O
off NN NN O
of NN NN O
these NN NN O
muscles NN NN O
including NN NN O
the NN NN O
fascia NN NN O
of NN NN O
the NN NN O
muscles NN NN O
, NN NN O
stripped NN NN O
from NN NN O
the NN NN O
carotid NN NN O
artery NN NN O
, NN NN O
the NN NN O
X NN NN O
cranial NN NN O
nerve NN NN O
, NN NN O
the NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
and NN NN O
then NN NN O
carried NN NN O
anteriorly NN NN O
to NN NN O
the NN NN O
lateral NN NN O
most NN NN O
extent NN NN O
of NN NN O
the NN NN B-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
previously NN NN O
done NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
in NN NN O
the NN NN O
paratracheal NN NN O
region NN NN O
. NN NN O

The NN NN O
submandibular NN NN O
gland NN NN O
was NN NN O
removed NN NN O
as NN NN O
well NN NN O
. NN NN O

The NN NN O
X NN NN O
, NN NN O
XI NN NN O
, NN NN O
and NN NN O
XII NN NN O
cranial NN NN O
nerves NN NN O
were NN NN O
preserved NN NN O
. NN NN O

The NN NN O
internal NN NN O
jugular NN NN O
vein NN NN O
and NN NN O
carotid NN NN O
artery NN NN O
were NN NN O
preserved NN NN O
as NN NN O
well NN NN O
. NN NN O

Copious NN NN B-TREATMENT
irrigatio NN NN I-TREATMENT
n NN NN O
of NN NN O
the NN NN B-PROBLEM
wound NN NN I-PROBLEM
be NN NN I-PROBLEM
d NN NN O
showed NN NN O
no NN NN O
identifiable NN NN B-PROBLEM
bleedin NN NN I-PROBLEM
g NN NN O
at NN NN O
the NN NN O
termination NN NN O
of NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
. NN NN O

There NN NN O
were NN NN O
two NN NN B-PROBLEM
obviously NN NN I-PROBLEM
positive NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
in NN NN O
this NN NN B-PROBLEM
neck NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
. NN NN O

One NN NN O
was NN NN O
left NN NN O
medial NN NN O
neck NN NN O
just NN NN O
lateral NN NN O
to NN NN O
the NN NN B-PROBLEM
previous NN NN I-PROBLEM
tracheal NN NN I-PROBLEM
dissectio NN NN I-PROBLEM
n NN NN O
and NN NN O
one NN NN O
was NN NN O
in NN NN O
the NN NN O
mid NN NN O
region NN NN O
of NN NN O
zone NN NN O

2 NN NN O
. NN NN O
A NN NN B-TREATMENT
#10 NN NN I-TREATMENT
flat NN NN I-TREATMENT
fluted NN NN I-TREATMENT
Blake NN NN I-TREATMENT
drai NN NN I-TREATMENT
n NN NN O
was NN NN O
placed NN NN O
through NN NN O
a NN NN B-PROBLEM
separate NN NN I-PROBLEM
stab NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
and NN NN O
it NN NN O
was NN NN O
secured NN NN O
to NN NN O
the NN NN O
skin NN NN O
with NN NN O
a NN NN B-TREATMENT
2-0 NN NN I-TREATMENT
silk NN NN I-TREATMENT
ligatur NN NN I-TREATMENT
e NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
closed NN NN O
in NN NN O
layers NN NN O
using NN NN O
a NN NN B-TREATMENT
3-0 NN NN I-TREATMENT
Vicry NN NN I-TREATMENT
l NN NN O
in NN NN O
a NN NN B-TREATMENT
buried NN NN I-TREATMENT
kno NN NN I-TREATMENT
t NN NN O
interrupted NN NN O
fashion NN NN O
for NN NN O
the NN NN O
subcutaneous NN NN O
tissue NN NN O
and NN NN O
the NN NN O
skin NN NN O
was NN NN O
closed NN NN O
with NN NN O
staple NN NN B-TREATMENT
s NN NN O
. NN NN O

A NN NN B-TREATMENT
fluff NN NN I-TREATMENT
and NN NN I-TREATMENT
Kling NN NN I-TREATMENT
pressure NN NN I-TREATMENT
dressin NN NN I-TREATMENT
g NN NN O
was NN NN O
then NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
extubated NN NN O
in NN NN O
the NN NN O
operating NN NN O
room NN NN O
, NN NN O
brought NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
satisfactory NN NN O
condition NN NN O
. NN NN O

There NN NN O
were NN NN O
no NN NN O
intraoperative NN NN B-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
HDR NN NN B-TREATMENT
Brachytherap NN NN I-TREATMENT
y NN NN O
Description NN NN O
: NN NN O
HDR NN NN B-TREATMENT
Brachytherap NN NN I-TREATMENT
y NN NN O
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
HDR NN NN B-TREATMENT
BRACHYTHERAP NN NN I-TREATMENT
Y NN NN O
The NN NN B-TREATMENT
intracavitary NN NN I-TREATMENT
brachytherapy NN NN I-TREATMENT
applicato NN NN I-TREATMENT
r NN NN O
was NN NN O
placed NN NN O
appropriately NN NN O
and NN NN O
secured NN NN O
after NN NN O
the NN NN O
patient NN NN O
was NN NN O
identified NN NN O
. NN NN O

Simulation NN NN B-TEST
film NN NN I-TEST
s NN NN O
were NN NN O
obtained NN NN O
, NN NN O
documenting NN NN O
its NN NN O
positioning NN NN O
. NN NN O

The NN NN O
3-dimensional NN NN O
treatment NN NN O
planning NN NN O
process NN NN O
was NN NN O
accomplished NN NN O
utilizing NN NN O
the NN NN B-TEST
C NN NN I-TEST
T NN NN O
derived NN NN O
data NN NN O
. NN NN O

A NN NN O
treatment NN NN O
plan NN NN O
was NN NN O
selected NN NN O
utilizing NN NN O
sequential NN NN O
dwell NN NN O
positions NN NN O
within NN NN O
a NN NN B-TREATMENT
single NN NN I-TREATMENT
cathete NN NN I-TREATMENT
r NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
treatment NN NN O
area NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
appropriately NN NN O
positioned NN NN O
and NN NN O
the NN NN O
position NN NN O
of NN NN O
the NN NN B-TREATMENT
intracavitary NN NN I-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
was NN NN O
checked NN NN O
. NN NN O

Catheter NN NN B-TEST
length NN NN I-TEST
measurement NN NN I-TEST
s NN NN O
were NN NN O
taken NN NN O
. NN NN O

Appropriate NN NN O
measurements NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
probe NN NN I-TEST
dimension NN NN I-TEST
s NN NN O
and NN NN O
assembly NN NN O
were NN NN O
also NN NN O
performed NN NN O
. NN NN O

The NN NN B-TREATMENT
applicato NN NN I-TREATMENT
r NN NN O
was NN NN O
attached NN NN O
to NN NN O
the NN NN B-TREATMENT
HDR NN NN I-TREATMENT
after-loader NN NN I-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
. NN NN O

The NN NN B-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
ran NN NN O
through NN NN O
its NN NN O
checking NN NN O
sequences NN NN O
appropriately NN NN O
and NN NN O
the NN NN B-TREATMENT
brachytherap NN NN I-TREATMENT
y NN NN O
was NN NN O
then NN NN O
delivered NN NN O
without NN NN O
difficult NN NN B-PROBLEM
y NN NN O
or NN NN O
complicatio NN NN B-PROBLEM
n NN NN O
. NN NN O

The NN NN B-TREATMENT
brachytherap NN NN I-TREATMENT
y NN NN O
source NN NN O
was NN NN O
appropriately NN NN O
removed NN NN O
back NN NN O
to NN NN O
the NN NN B-TREATMENT
brachytherap NN NN I-TREATMENT
y NN NN O
safe NN NN O
within NN NN O
the NN NN B-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
. NN NN O

Radiation NN NN B-TEST
screenin NN NN I-TEST
g NN NN O
was NN NN O
performed NN NN O
with NN NN O
the NN NN B-TREATMENT
Geiger-Muller NN NN I-TREATMENT
counte NN NN I-TREATMENT
r NN NN O
both NN NN O
prior NN NN O
to NN NN O
and NN NN O
after NN NN O
the NN NN B-TREATMENT
brachytherapy NN NN I-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
was NN NN O
completed NN NN O
and NN NN O
the NN NN O
results NN NN O
were NN NN O
deemed NN NN O
appropriate NN NN O
. NN NN O

Following NN NN O
completion NN NN O
of NN NN O
the NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
, NN NN O
the NN NN B-TREATMENT
intracavitary NN NN I-TREATMENT
devic NN NN I-TREATMENT
e NN NN O
was NN NN O
removed NN NN O
without NN NN O
difficult NN NN B-PROBLEM
y NN NN O
. NN NN O

The NN NN O
patient NN NN O
was NN NN O
in NN NN O
no NN NN O
apparent NN NN B-PROBLEM
distres NN NN I-PROBLEM
s NN NN O
and NN NN O
was NN NN O
discharged NN NN O
home NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Biops NN NN B-TEST
y NN NN O
- NN NN O
Cervical NN NN O
Lymph NN NN O
Node NN NN O
Description NN NN O
: NN NN O
Excisional NN NN B-TEST
biopsy NN NN I-TEST
of NN NN I-TEST
right NN NN I-TEST
cervical NN NN I-TEST
lymph NN NN I-TEST
nod NN NN I-TEST
e NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Cervical NN NN B-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Cervical NN NN B-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
Excisional NN NN B-TEST
biopsy NN NN I-TEST
of NN NN I-TEST
right NN NN I-TEST
cervical NN NN I-TEST
lymph NN NN I-TEST
nod NN NN I-TEST
e NN NN O
. NN NN O

ANESTHESIA NN NN O
: NN NN O
General NN NN B-TREATMENT
endotracheal NN NN I-TREATMENT
anesthesi NN NN I-TREATMENT
a NN NN O
. NN NN O

SPECIMEN NN NN O
: NN NN O
Right NN NN B-PROBLEM
cervical NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
. NN NN O

EB NN NN B-TEST
L NN NN O
: NN NN O
10 NN NN O
cc NN NN O
. NN NN O

COMPLICATIONS NN NN O
: NN NN O
None NN NN O
. NN NN O

FINDINGS NN NN O
: NN NN O
Enlarged NN NN B-PROBLEM
level NN NN I-PROBLEM
2 NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
was NN NN O
identified NN NN O
and NN NN O
removed NN NN O
and NN NN O
sent NN NN O
for NN NN O
pathologic NN NN B-TEST
examinatio NN NN I-TEST
n NN NN O
. NN NN O

FLUIDS NN NN O
: NN NN O
Please NN NN O
see NN NN O
anesthesia NN NN O
report NN NN O
. NN NN O

URINE NN NN O
OUTPUT NN NN O
: NN NN O
None NN NN O
recorded NN NN O
during NN NN O
the NN NN O
case NN NN O
. NN NN O

INDICATIONS NN NN O
FOR NN NN O
PROCEDURE NN NN O
: NN NN O
This NN NN O
is NN NN O
a NN NN O
43-year-ol NN NN B-AGE
d NN NN O
female NN NN O
with NN NN O
a NN NN O
several-year NN NN O
history NN NN O
of NN NN O
persistent NN NN B-PROBLEM
cervical NN NN I-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

She NN NN O
reports NN NN O
that NN NN O
it NN NN O
is NN NN O
painfu NN NN B-PROBLEM
l NN NN O
to NN NN O
palpation NN NN B-TEST
on NN NN I-TEST
the NN NN I-TEST
righ NN NN I-TEST
t NN NN O
and NN NN O
has NN NN O
had NN NN O
multiple NN NN B-TEST
CT NN NN I-TEST
scan NN NN I-TEST
s NN NN O
as NN NN O
well NN NN O
as NN NN O
an NN NN B-TEST
FN NN NN I-TEST
A NN NN O
which NN NN O
were NN NN O
all NN NN O
nondiagnostic NN NN O
. NN NN O

After NN NN O
risks NN NN O
and NN NN O
benefits NN NN O
of NN NN O
surger NN NN B-TREATMENT
y NN NN O
were NN NN O
discussed NN NN O
with NN NN O
the NN NN O
patient NN NN O
, NN NN O
an NN NN O
informed NN NN O
consent NN NN O
was NN NN O
obtained NN NN O
. NN NN O

She NN NN O
was NN NN O
scheduled NN NN O
for NN NN O
an NN NN B-TEST
excisional NN NN I-TEST
biopsy NN NN I-TEST
of NN NN I-TEST
the NN NN I-TEST
right NN NN I-TEST
cervical NN NN I-TEST
lymph NN NN I-TEST
nod NN NN I-TEST
e NN NN O
. NN NN O

PROCEDURE NN NN O
IN NN NN O
DETAIL NN NN O
: NN NN O
The NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
the NN NN O
operating NN NN O
room NN NN O
and NN NN O
placed NN NN O
in NN NN O
the NN NN O
supine NN NN O
position NN NN O
. NN NN O

She NN NN O
was NN NN O
anesthetized NN NN O
with NN NN O
general NN NN B-TREATMENT
endotracheal NN NN I-TREATMENT
anesthesi NN NN I-TREATMENT
a NN NN O
. NN NN O

The NN NN O
neck NN NN O
was NN NN O
then NN NN O
prepped NN NN B-TREATMENT
and NN NN I-TREATMENT
drape NN NN I-TREATMENT
d NN NN O
in NN NN O
the NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

Again NN NN O
, NN NN O
noted NN NN O
on NN NN O
palpatio NN NN B-TEST
n NN NN O
there NN NN O
was NN NN O
an NN NN B-PROBLEM
enlarged NN NN I-PROBLEM
level NN NN I-PROBLEM
2 NN NN I-PROBLEM
cervical NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
. NN NN O

A NN NN B-PROBLEM
3-cm NN NN I-PROBLEM
horizontal NN NN I-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
made NN NN O
over NN NN O
this NN NN O
lymph NN NN O
node NN NN O
. NN NN O

Dissectio NN NN B-TREATMENT
n NN NN O
was NN NN O
carried NN NN O
down NN NN O
until NN NN O
the NN NN O
sternocleidomastoid NN NN O
muscle NN NN O
was NN NN O
identified NN NN O
. NN NN O

The NN NN B-PROBLEM
enlarged NN NN I-PROBLEM
lymph NN NN I-PROBLEM
nod NN NN I-PROBLEM
e NN NN O
that NN NN O
measured NN NN O
approximately NN NN O
2 NN NN O
cm NN NN O
in NN NN O
diameter NN NN O
was NN NN O
identified NN NN O
and NN NN O
was NN NN O
removed NN NN O
and NN NN O
sent NN NN O
to NN NN O
Pathology NN NN O
for NN NN O
touch NN NN B-TEST
prep NN NN I-TEST
evaluatio NN NN I-TEST
n NN NN O
. NN NN O

The NN NN O
area NN NN O
was NN NN O
then NN NN O
explored NN NN O
for NN NN O
any NN NN B-PROBLEM
other NN NN I-PROBLEM
enlarged NN NN I-PROBLEM
lymph NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
. NN NN O

None NN NN O
were NN NN O
identified NN NN O
, NN NN O
and NN NN O
hemostasi NN NN B-TREATMENT
s NN NN O
was NN NN O
achieved NN NN O
with NN NN O
electrocauter NN NN B-TREATMENT
y NN NN O
. NN NN O

A NN NN B-TREATMENT
quarter-inch NN NN I-TREATMENT
Penrose NN NN I-TREATMENT
drai NN NN I-TREATMENT
n NN NN O
was NN NN O
placed NN NN O
in NN NN O
the NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
then NN NN O
irrigated NN NN O
and NN NN O
closed NN NN O
with NN NN O
3-0 NN NN O
interrupted NN NN O
Vicryl NN NN B-TREATMENT
suture NN NN I-TREATMENT
s NN NN O
for NN NN O
a NN NN B-TREATMENT
deep NN NN I-TREATMENT
closur NN NN I-TREATMENT
e NN NN O
followed NN NN O
by NN NN O
a NN NN B-TREATMENT
running NN NN I-TREATMENT
4-0 NN NN I-TREATMENT
Prolene NN NN I-TREATMENT
subcuticular NN NN I-TREATMENT
sutur NN NN I-TREATMENT
e NN NN O
. NN NN O

Mastiso NN NN B-TREATMENT
l NN NN O
and NN NN O
Steri-Stri NN NN B-TREATMENT
p NN NN O
were NN NN O
placed NN NN O
over NN NN O
the NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
, NN NN O
and NN NN O
sterile NN NN B-TREATMENT
bandag NN NN I-TREATMENT
e NN NN O
was NN NN O
applied NN NN O
. NN NN O

The NN NN O
patient NN NN O
tolerated NN NN O
this NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
well NN NN O
and NN NN O
was NN NN O
extubated NN NN O
without NN NN O
complication NN NN B-PROBLEM
s NN NN O
and NN NN O
transported NN NN O
to NN NN O
the NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

She NN NN O
will NN NN O
return NN NN O
to NN NN O
the NN NN O
office NN NN O
tomorrow NN NN O
in NN NN O
followup NN NN O
to NN NN O
have NN NN O
the NN NN B-TREATMENT
Penrose NN NN I-TREATMENT
drai NN NN I-TREATMENT
n NN NN O
removed NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
Ovarian NN NN I-PROBLEM
Cance NN NN I-PROBLEM
r NN NN O
- NN NN O
Consult NN NN O
Description NN NN O
: NN NN O
A NN NN O
very NN NN O
pleasant NN NN O
66-year-ol NN NN B-AGE
d NN NN O
woman NN NN O
with NN NN O
recurrent NN NN B-PROBLEM
metastatic NN NN I-PROBLEM
ovarian NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
REASON NN NN O
FOR NN NN O
CONSULTATION NN NN O
: NN NN O
Metastatic NN NN B-PROBLEM
ovarian NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
. NN NN O

HISTORY NN NN O
OF NN NN O
PRESENT NN NN O
ILLNESS NN NN O
: NN NN O
Mrs NN NN O
. NN NN O

ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
nice NN NN O
66-year-ol NN NN B-AGE
d NN NN O
woman NN NN O
who NN NN O
is NN NN O
followed NN NN O
in NN NN O
clinic NN NN O
by NN NN O
Dr NN NN O
. NN NN O
X NN NN O
for NN NN O
history NN NN O
of NN NN O
renal NN NN B-PROBLEM
cell NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
breast NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
as NN NN O
well NN NN O
as NN NN O
ovarian NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
, NN NN O
which NN NN O
was NN NN O
initially NN NN O
diagnosed NN NN O
10 NN NN O
years NN NN O
ago NN NN O
, NN NN O
but NN NN O
over NN NN O
the NN NN O
last NN NN O
several NN NN O
months NN NN O
has NN NN O
recurred NN NN O
and NN NN O
is NN NN O
now NN NN O
metastati NN NN B-PROBLEM
c NN NN O
. NN NN O

She NN NN O
last NN NN O
saw NN NN O
Dr NN NN O
. NN NN O
X NN NN O
in NN NN O
clinic NN NN O
towards NN NN O
the NN NN O
beginning NN NN O
of NN NN O
this NN NN O
month NN NN O
. NN NN O

She NN NN O
has NN NN O
been NN NN O
receiving NN NN O
gemcitabin NN NN B-DRUG
e NN NN O
and NN NN O
carboplati NN NN B-DRUG
n NN NN O
, NN NN O
and NN NN O
she NN NN O
receives NN NN O
three NN NN O
cycles NN NN O
of NN NN O
this NN NN O
with NN NN O
the NN NN O
last NN NN O
one NN NN O
being NN NN O
given NN NN O
on NN NN O
12/15/0 NN NN B-DATE

8 NN NN O
. NN NN O
She NN NN O
was NN NN O
last NN NN O
seen NN NN O
in NN NN O
clinic NN NN O
on NN NN O
12/22/0 NN NN B-DATE
8 NN NN O
by NN NN O
Dr NN NN O
. NN NN O
Y NN NN O
. NN NN O
At NN NN O
that NN NN O
point NN NN O
, NN NN O
her NN NN B-TEST
white NN NN I-TEST
coun NN NN I-TEST
t NN NN O
was NN NN O
0.9 NN NN O
with NN NN O
the NN NN B-TEST
hemoglobi NN NN I-TEST
n NN NN O
of NN NN O
10.3 NN NN O
, NN NN O
hematocri NN NN B-TEST
t NN NN O
of NN NN O
30% NN NN O
, NN NN O
and NN NN O
platelet NN NN B-TEST
s NN NN O
of NN NN O
81,000 NN NN O
. NN NN O

Her NN NN B-TEST
AN NN NN I-TEST
C NN NN O
was NN NN O
0.5 NN NN O
. NN NN O

She NN NN O
was NN NN O
started NN NN O
on NN NN O
prophylactic NN NN O
Augmenti NN NN B-DRUG
n NN NN O
as NN NN O
well NN NN O
as NN NN O
Neupogen NN NN B-TREATMENT
shot NN NN I-TREATMENT
s NN NN O
. NN NN O

She NN NN O
has NN NN O
also NN NN O
had NN NN O
history NN NN O
of NN NN O
recurrent NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusions NN NN I-PROBLEM
with NN NN I-PROBLEM
the NN NN I-PROBLEM
kne NN NN I-PROBLEM
e NN NN O
for NN NN O
thoracentesi NN NN B-TREATMENT
s NN NN O
. NN NN O

She NN NN O
had NN NN O
two NN NN O
of NN NN O
these NN NN O
performed NN NN O
in NN NN O
Novembe NN NN B-DATE
r NN NN O
and NN NN O
the NN NN O
last NN NN O
one NN NN O
was NN NN O
done NN NN O
about NN NN O
a NN NN O
week NN NN O
ago NN NN O
. NN NN O

Over NN NN O
the NN NN O
last NN NN O
2 NN NN O
or NN NN O
3 NN NN O
days NN NN O
, NN NN O
she NN NN O
states NN NN O
she NN NN O
has NN NN O
been NN NN O
getting NN NN O
more NN NN B-PROBLEM
short NN NN I-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
. NN NN O

Her NN NN O
history NN NN O
is NN NN O
somewhat NN NN O
limited NN NN O
today NN NN O
as NN NN O
she NN NN O
is NN NN O
very NN NN B-PROBLEM
tire NN NN I-PROBLEM
d NN NN O
and NN NN O
falls NN NN O
asleep NN NN O
readily NN NN O
. NN NN O

Her NN NN O
history NN NN O
comes NN NN O
from NN NN O
herself NN NN O
but NN NN O
also NN NN O
from NN NN O
the NN NN O
review NN NN O
of NN NN O
the NN NN O
records NN NN O
. NN NN O

Overall NN NN O
, NN NN O
her NN NN B-PROBLEM
shortness NN NN I-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
has NN NN O
been NN NN O
going NN NN O
on NN NN O
for NN NN O
the NN NN O
past NN NN O
few NN NN O
weeks NN NN O
related NN NN O
to NN NN O
her NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
. NN NN O

She NN NN O
was NN NN O
seen NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
this NN NN O
time NN NN O
and NN NN O
on NN NN O
chest NN NN B-TEST
x-ra NN NN I-TEST
y NN NN O
was NN NN O
found NN NN O
to NN NN O
have NN NN O
a NN NN B-PROBLEM
new NN NN I-PROBLEM
right-sided NN NN I-PROBLEM
pulmonic NN NN I-PROBLEM
consolidative NN NN I-PROBLEM
infiltrat NN NN I-PROBLEM
e NN NN O
, NN NN O
which NN NN O
was NN NN O
felt NN NN O
to NN NN O
be NN NN O
possibly NN NN O
related NN NN O
to NN NN O
pneumoni NN NN B-PROBLEM
a NN NN O
. NN NN O

She NN NN O
specifically NN NN O
denied NN NN O
any NN NN O
fever NN NN B-PROBLEM
s NN NN O
or NN NN O
chill NN NN B-PROBLEM
s NN NN O
. NN NN O

However NN NN O
, NN NN O
she NN NN O
was NN NN O
complaining NN NN O
of NN NN O
chest NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
. NN NN O

She NN NN O
states NN NN O
that NN NN O
the NN NN B-PROBLEM
chest NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
was NN NN O
located NN NN O
in NN NN O
the NN NN O
substernal NN NN O
area NN NN O
, NN NN O
described NN NN O
as NN NN O
achin NN NN B-PROBLEM
g NN NN O
, NN NN O
coming NN NN O
and NN NN O
going NN NN O
and NN NN O
associated NN NN O
with NN NN O
shortness NN NN B-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
and NN NN O
coug NN NN B-PROBLEM
h NN NN O
. NN NN O

When NN NN O
she NN NN O
did NN NN O
coug NN NN B-PROBLEM
h NN NN O
, NN NN O
it NN NN O
was NN NN O
nonproductive NN NN O
. NN NN O

While NN NN O
in NN NN O
the NN NN O
emergency NN NN O
room NN NN O
on NN NN O
examinatio NN NN B-TEST
n NN NN O
, NN NN O
her NN NN B-TEST
vital NN NN I-TEST
sign NN NN I-TEST
s NN NN O
were NN NN O
stable NN NN O
except NN NN O
that NN NN O
she NN NN O
required NN NN O
5 NN NN B-DOSAGE
liter NN NN I-DOSAGE
s NN NN O
nasal NN NN B-ROUTE
cannul NN NN I-ROUTE
a NN NN O
to NN NN O
maintain NN NN O
oxygen NN NN B-TEST
saturation NN NN I-TEST
s NN NN O
. NN NN O

An NN NN B-TEST
EK NN NN I-TEST
G NN NN O
was NN NN O
performed NN NN O
, NN NN O
which NN NN O
showed NN NN O
sinus NN NN B-PROBLEM
rhyth NN NN I-PROBLEM
m NN NN O
without NN NN O
any NN NN O
evidence NN NN O
of NN NN O
Q NN NN B-PROBLEM
wave NN NN I-PROBLEM
s NN NN O
or NN NN O
other NN NN B-PROBLEM
ischemic NN NN I-PROBLEM
change NN NN I-PROBLEM
s NN NN O
. NN NN O

The NN NN B-TEST
chest NN NN I-TEST
x-ra NN NN I-TEST
y NN NN O
described NN NN O
above NN NN O
showed NN NN O
a NN NN B-PROBLEM
right NN NN I-PROBLEM
lower NN NN I-PROBLEM
lobe NN NN I-PROBLEM
infiltrat NN NN I-PROBLEM
e NN NN O
. NN NN O

A NN NN B-TEST
V/Q NN NN I-TEST
sca NN NN I-TEST
n NN NN O
was NN NN O
done NN NN O
, NN NN O
which NN NN O
showed NN NN O
a NN NN B-PROBLEM
small NN NN I-PROBLEM
mismatched NN NN I-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
left NN NN I-PROBLEM
upper NN NN I-PROBLEM
lob NN NN I-PROBLEM
e NN NN O
and NN NN O
a NN NN B-PROBLEM
mass NN NN I-PROBLEM
defect NN NN I-PROBLEM
in NN NN I-PROBLEM
the NN NN I-PROBLEM
right NN NN I-PROBLEM
upper NN NN I-PROBLEM
lob NN NN I-PROBLEM
e NN NN O
. NN NN O

The NN NN O
findings NN NN O
were NN NN O
compatible NN NN O
with NN NN O
an NN NN O
indeterminate NN NN O
study NN NN O
for NN NN O
a NN NN B-PROBLEM
pulmonary NN NN I-PROBLEM
embolis NN NN I-PROBLEM
m NN NN O
. NN NN O

Apparently NN NN O
, NN NN O
an NN NN B-TEST
ultrasound NN NN I-TEST
of NN NN I-TEST
the NN NN I-TEST
lower NN NN I-TEST
extremitie NN NN I-TEST
s NN NN O
was NN NN O
done NN NN O
and NN NN O
was NN NN O
negative NN NN O
for NN NN O
DV NN NN B-PROBLEM
T NN NN O
. NN NN O
There NN NN O
was NN NN O
apparently NN NN O
still NN NN O
some NN NN O
concern NN NN O
that NN NN O
this NN NN O
might NN NN O
be NN NN O
pulmonary NN NN B-PROBLEM
embolis NN NN I-PROBLEM
m NN NN O
and NN NN O
she NN NN O
was NN NN O
started NN NN O
on NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
. NN NN O

There NN NN O
was NN NN O
also NN NN O
concern NN NN O
for NN NN O
pneumoni NN NN B-PROBLEM
a NN NN O
and NN NN O
she NN NN O
was NN NN O
started NN NN O
on NN NN O
Zosy NN NN B-TREATMENT
n NN NN O
as NN NN O
well NN NN O
as NN NN O
vancomyci NN NN B-TREATMENT
n NN NN O
and NN NN O
admitted NN NN O
to NN NN O
the NN NN O
hospital NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
we NN NN O
have NN NN O
been NN NN O
consulted NN NN O
to NN NN O
help NN NN O
follow NN NN O
along NN NN O
with NN NN O
this NN NN O
patient NN NN O
who NN NN O
is NN NN O
well NN NN O
known NN NN O
to NN NN O
our NN NN O
clinic NN NN O
. NN NN O

PAST NN NN O
MEDICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Ovarian NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
- NN NN O
This NN NN O
was NN NN O
initially NN NN O
diagnosed NN NN O
about NN NN O
10 NN NN O
years NN NN O
ago NN NN O
and NN NN O
treated NN NN O
with NN NN O
surgical NN NN B-TREATMENT
resectio NN NN I-TREATMENT
n NN NN O
including NN NN O
TA NN NN B-TREATMENT
H NN NN O
and NN NN O
BS NN NN B-TREATMENT
O NN NN O
. NN NN O
This NN NN O
has NN NN O
recurred NN NN O
over NN NN O
the NN NN O
last NN NN O
couple NN NN O
of NN NN O
months NN NN O
with NN NN O
metastatic NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
. NN NN O

2 NN NN O
. NN NN O
History NN NN O
of NN NN O
breast NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
- NN NN O
She NN NN O
has NN NN O
been NN NN O
treated NN NN O
with NN NN O
bilateral NN NN B-TREATMENT
mastectom NN NN I-TREATMENT
y NN NN O
with NN NN O
the NN NN O
first NN NN O
one NN NN O
about NN NN O
14 NN NN O
years NN NN O
and NN NN O
the NN NN O
second NN NN O
one NN NN O
about NN NN O
5 NN NN O
years NN NN O
ago NN NN O
. NN NN O

She NN NN O
has NN NN O
had NN NN O
no NN NN O
recurrent NN NN B-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
. NN NN O

3 NN NN O
. NN NN O
Renal NN NN B-PROBLEM
cell NN NN I-PROBLEM
carcinom NN NN I-PROBLEM
a NN NN O
- NN NN O
She NN NN O
is NN NN O
status NN NN O
post NN NN O
nephrectom NN NN B-TREATMENT
y NN NN O
. NN NN O

4 NN NN O
. NN NN O
Hypertensio NN NN B-PROBLEM
n NN NN O
. NN NN O

5 NN NN O
. NN NN O
Anxiety NN NN B-PROBLEM
disorde NN NN I-PROBLEM
r NN NN O
. NN NN O

6 NN NN O
. NN NN O
Chronic NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
from NN NN O
neuropath NN NN B-PROBLEM
y NN NN O
secondary NN NN O
to NN NN O
chemotherap NN NN B-DRUG
y NN NN O
from NN NN O
breast NN NN B-TREATMENT
cancer NN NN I-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
. NN NN O

7 NN NN O
. NN NN O
Ongoing NN NN O
tobacco NN NN O
use NN NN O
. NN NN O

PAST NN NN O
SURGICAL NN NN O
HISTORY NN NN O

1 NN NN O
. NN NN O
Recent NN NN O
and NN NN O
multiple NN NN B-TREATMENT
thoracentesi NN NN I-TREATMENT
s NN NN O
as NN NN O
described NN NN O
above NN NN O
. NN NN O

2 NN NN O
. NN NN O
Bilateral NN NN B-TREATMENT
mastectomie NN NN I-TREATMENT
s NN NN O
. NN NN O

3 NN NN O
. NN NN O
Multiple NN NN B-TREATMENT
abdominal NN NN I-TREATMENT
surgerie NN NN I-TREATMENT
s NN NN O
. NN NN O

4 NN NN O
. NN NN O
Cholecystectom NN NN B-TREATMENT
y NN NN O
. NN NN O

5 NN NN O
. NN NN O
Remote NN NN B-PROBLEM
right NN NN I-PROBLEM
ankle NN NN I-PROBLEM
fractur NN NN I-PROBLEM
e NN NN O
. NN NN O

ALLERGIES NN NN O
: NN NN O
No NN NN O
known NN NN B-PROBLEM
drug NN NN I-PROBLEM
allergie NN NN I-PROBLEM
s NN NN O
. NN NN O

MEDICATIONS NN NN O
: NN NN O
At NN NN O
home NN NN O
, NN NN O

1 NN NN O
. NN NN O
Atenolo NN NN B-TREATMENT
l NN NN O
50 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
dail NN NN B-FREQUENCY
y NN NN O

2 NN NN O
. NN NN O
Ativa NN NN B-TREATMENT
n NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

3 NN NN O
. NN NN O
Clonidin NN NN B-TREATMENT
e NN NN O
0.1 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
nightl NN NN B-FREQUENCY
y NN NN O
. NN NN O

4 NN NN O
. NN NN O
Compazin NN NN B-DRUG
e NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

5 NN NN O
. NN NN O
Dilaudi NN NN B-TREATMENT
d NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

6 NN NN O
. NN NN O
Gabapenti NN NN B-TREATMENT
n NN NN O
300 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
p NN NN B-ROUTE
. NN NN I-ROUTE

o NN NN O
. NN NN O

t.i NN NN B-FREQUENCY
. NN NN I-FREQUENCY
d NN NN O
. NN NN O

7 NN NN O
. NN NN O
K-Du NN NN B-TREATMENT
r NN NN O
20 NN NN B-STRENGTH
mE NN NN I-STRENGTH
q NN NN O
p NN NN B-ROUTE
. NN NN I-ROUTE

o NN NN O
. NN NN O

dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

8 NN NN O
. NN NN O
Lasi NN NN B-TREATMENT
x NN NN O
unknown NN NN O
dose NN NN O
dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

9 NN NN O
. NN NN O
Norvas NN NN B-TREATMENT
c NN NN O
5 NN NN B-STRENGTH
m NN NN I-STRENGTH
g NN NN O
dail NN NN B-FREQUENCY
y NN NN O
. NN NN O

10 NN NN O
. NN NN O
Zofra NN NN B-TREATMENT
n NN NN O
p.r NN NN B-FREQUENCY
. NN NN I-FREQUENCY
n NN NN O
. NN NN O

SOCIAL NN NN O
HISTORY NN NN O
: NN NN O
She NN NN O
smokes NN NN O
about NN NN O
6-7 NN NN O
cigarettes NN NN O
per NN NN O
day NN NN O
and NN NN O
has NN NN O
done NN NN O
so NN NN O
for NN NN O
more NN NN O
than NN NN O
50 NN NN O
years NN NN O
. NN NN O

She NN NN O
quit NN NN O
smoking NN NN O
about NN NN O
6 NN NN O
weeks NN NN O
ago NN NN O
. NN NN O

She NN NN O
occasionally NN NN O
has NN NN O
alcohol NN NN O
. NN NN O

She NN NN O
is NN NN O
married NN NN O
and NN NN O
has NN NN O
3 NN NN O
children NN NN O
. NN NN O

She NN NN O
lives NN NN O
at NN NN O
home NN NN O
with NN NN O
her NN NN O
husband NN NN O
. NN NN O

She NN NN O
used NN NN O
to NN NN O
work NN NN O
as NN NN O
a NN NN O
unit NN NN B-PROFESSION
cler NN NN I-PROFESSION
k NN NN O
at NN NN O
XYZ NN NN B-LOCATION
Medical NN NN I-LOCATION
Cente NN NN I-LOCATION
r NN NN O
. NN NN O

FAMILY NN NN O
HISTORY NN NN O
: NN NN O
Both NN NN O
her NN NN O
mother NN NN O
and NN NN O
father NN NN O
had NN NN O
a NN NN O
history NN NN O
of NN NN O
lung NN NN B-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
and NN NN O
both NN NN O
were NN NN O
smokers NN NN O
. NN NN O

REVIEW NN NN O
OF NN NN O
SYSTEMS NN NN O
: NN NN O
GENERAL/CONSTITUTIONAL NN NN O
: NN NN O
She NN NN O
has NN NN O
not NN NN O
had NN NN O
any NN NN B-PROBLEM
feve NN NN I-PROBLEM
r NN NN O
, NN NN O
chill NN NN B-PROBLEM
s NN NN O
, NN NN O
night NN NN B-PROBLEM
sweat NN NN I-PROBLEM
s NN NN O
, NN NN O
but NN NN O
has NN NN O
had NN NN O
fatigu NN NN B-PROBLEM
e NN NN O
and NN NN O
weight NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
of NN NN O
unspecified NN NN O
amount NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
She NN NN O
has NN NN O
not NN NN O
had NN NN O
trouble NN NN O
with NN NN O
headache NN NN B-PROBLEM
s NN NN O
; NN NN O

mouth NN NN O
, NN NN O
jaw NN NN B-PROBLEM
, NN NN I-PROBLEM
or NN NN I-PROBLEM
teeth NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
; NN NN O

change NN NN B-PROBLEM
in NN NN I-PROBLEM
visio NN NN I-PROBLEM
n NN NN O
; NN NN O

double NN NN B-PROBLEM
visio NN NN I-PROBLEM
n NN NN O
; NN NN O

or NN NN O
loss NN NN B-PROBLEM
of NN NN I-PROBLEM
hearin NN NN I-PROBLEM
g NN NN O
or NN NN O
ringing NN NN B-PROBLEM
in NN NN I-PROBLEM
her NN NN I-PROBLEM
ear NN NN I-PROBLEM
s NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Per NN NN O
the NN NN O
HPI NN NN O
, NN NN O
she NN NN O
has NN NN O
had NN NN O
some NN NN B-PROBLEM
increasing NN NN I-PROBLEM
dyspne NN NN I-PROBLEM
a NN NN O
, NN NN O
shortness NN NN B-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
with NN NN O
exertion NN NN O
, NN NN O
coug NN NN B-PROBLEM
h NN NN O
, NN NN O
but NN NN O
no NN NN O
sputum NN NN B-PROBLEM
productio NN NN I-PROBLEM
n NN NN O
or NN NN O
hemoptysi NN NN B-PROBLEM
s NN NN O
. NN NN O

CV NN NN B-TEST
S NN NN O
: NN NN O
She NN NN O
has NN NN O
had NN NN O
the NN NN O
episodes NN NN O
of NN NN O
chest NN NN B-PROBLEM
pain NN NN I-PROBLEM
s NN NN O
as NN NN O
described NN NN O
above NN NN O
but NN NN O
has NN NN O
not NN NN O
had NN NN O
, NN NN O
PND NN NN B-PROBLEM
, NN NN I-PROBLEM
orthopnea NN NN I-PROBLEM
lower NN NN I-PROBLEM
extremity NN NN I-PROBLEM
swellin NN NN I-PROBLEM
g NN NN O
or NN NN O
palpitation NN NN B-PROBLEM
s NN NN O
. NN NN O

GI NN NN O
: NN NN O
No NN NN O
heartbur NN NN B-PROBLEM
n NN NN O
, NN NN O
odynophagi NN NN B-PROBLEM
a NN NN O
, NN NN O
dysphagi NN NN B-PROBLEM
a NN NN O
, NN NN O
nause NN NN B-PROBLEM
a NN NN O
, NN NN O
vomitin NN NN B-PROBLEM
g NN NN O
, NN NN O
diarrhe NN NN B-PROBLEM
a NN NN O
, NN NN O
constipatio NN NN B-PROBLEM
n NN NN O
, NN NN O
blood NN NN B-PROBLEM
in NN NN I-PROBLEM
her NN NN I-PROBLEM
stoo NN NN I-PROBLEM
l NN NN O
, NN NN O
and NN NN O
black NN NN B-PROBLEM
tarry NN NN I-PROBLEM
stool NN NN I-PROBLEM
s NN NN O
. NN NN O

GU NN NN O
: NN NN O
No NN NN O
dysuri NN NN B-PROBLEM
a NN NN O
, NN NN O
burning NN NN B-PROBLEM
with NN NN I-PROBLEM
urinatio NN NN I-PROBLEM
n NN NN O
, NN NN O
kidney NN NN B-PROBLEM
stone NN NN I-PROBLEM
s NN NN O
, NN NN O
and NN NN O
difficulty NN NN B-PROBLEM
voidin NN NN I-PROBLEM
g NN NN O
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
No NN NN O
new NN NN B-PROBLEM
back NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
hip NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
rib NN NN B-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
, NN NN O
swollen NN NN B-PROBLEM
joint NN NN I-PROBLEM
s NN NN O
, NN NN O
history NN NN O
of NN NN O
gou NN NN B-PROBLEM
t NN NN O
, NN NN O
or NN NN O
muscle NN NN B-PROBLEM
weaknes NN NN I-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
She NN NN O
has NN NN O
been NN NN O
diffusely NN NN B-PROBLEM
wea NN NN I-PROBLEM
k NN NN O
but NN NN O
no NN NN O
lateralizing NN NN B-PROBLEM
loss NN NN I-PROBLEM
of NN NN I-PROBLEM
strength NN NN I-PROBLEM
or NN NN I-PROBLEM
feelin NN NN I-PROBLEM
g NN NN O
. NN NN O

She NN NN O
has NN NN O
some NN NN B-PROBLEM
chronic NN NN I-PROBLEM
neuropathic NN NN I-PROBLEM
pai NN NN I-PROBLEM
n NN NN O
and NN NN O
numbnes NN NN B-PROBLEM
s NN NN O
as NN NN O
described NN NN O
above NN NN O
in NN NN O
the NN NN O
past NN NN O
medical NN NN O
history NN NN O
. NN NN O

She NN NN O
is NN NN O
fatigue NN NN B-PROBLEM
d NN NN O
and NN NN O
tire NN NN B-PROBLEM
d NN NN O
today NN NN O
and NN NN O
falls NN NN O
asleep NN NN O
while NN NN O
talking NN NN O
but NN NN O
is NN NN O
easily NN NN O
arousable NN NN O
. NN NN O

Some NN NN O
of NN NN O
this NN NN O
is NN NN O
related NN NN O
to NN NN O
her NN NN O
lack NN NN O
of NN NN O
sleep NN NN O
over NN NN O
the NN NN O
admission NN NN O
thus NN NN O
far NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
VITAL NN NN O
SIGNS NN NN O
: NN NN O
Her NN NN B-TEST
T-ma NN NN I-TEST
x NN NN O
is NN NN O
99.3 NN NN O
. NN NN O

Her NN NN B-TEST
puls NN NN I-TEST
e NN NN O
is NN NN O
54 NN NN O
, NN NN O
her NN NN B-TEST
respiration NN NN I-TEST
s NN NN O
is NN NN O
12 NN NN O
, NN NN O
and NN NN O
blood NN NN B-TEST
pressur NN NN I-TEST
e NN NN O
118/61 NN NN O
. NN NN O

GENERAL NN NN O
: NN NN O
Somewhat NN NN B-PROBLEM
fatigue NN NN I-PROBLEM
d NN NN O
appearing NN NN O
but NN NN O
in NN NN O
no NN NN O
acute NN NN B-PROBLEM
distres NN NN I-PROBLEM
s NN NN O
. NN NN O

HEENT NN NN O
: NN NN O
NC/A NN NN B-PROBLEM
T NN NN O
. NN NN O
Sclerae NN NN B-PROBLEM
anicteri NN NN I-PROBLEM
c NN NN O
. NN NN O

Conjunctiva NN NN O
clear NN NN O
. NN NN O

Oropharynx NN NN O
is NN NN O
clear NN NN O
without NN NN O
any NN NN B-PROBLEM
erythem NN NN I-PROBLEM
a NN NN O
, NN NN O
exudat NN NN B-PROBLEM
e NN NN O
, NN NN O
or NN NN O
discharg NN NN B-PROBLEM
e NN NN O
. NN NN O

NECK NN NN O
: NN NN O
Supple NN NN O
. NN NN O

Nontende NN NN B-PROBLEM
r NN NN O
. NN NN O

No NN NN O
elevated NN NN B-PROBLEM
JV NN NN I-PROBLEM
P NN NN O
. NN NN O
No NN NN O
thyromegal NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
thyroid NN NN B-PROBLEM
nodule NN NN I-PROBLEM
s NN NN O
. NN NN O

CHEST NN NN O
: NN NN O
Clear NN NN O
to NN NN O
auscultatio NN NN B-TEST
n NN NN O
and NN NN O
percussio NN NN B-TEST
n NN NN O
bilaterally NN NN O
with NN NN O
decreased NN NN B-PROBLEM
breath NN NN I-PROBLEM
sounds NN NN I-PROBLEM
on NN NN I-PROBLEM
the NN NN I-PROBLEM
righ NN NN I-PROBLEM
t NN NN O
. NN NN O

CVS NN NN O
: NN NN O
Regular NN NN O
rate NN NN O
and NN NN O
rhythm NN NN O
. NN NN O

No NN NN O
murmur NN NN B-PROBLEM
s NN NN O
, NN NN O
gallop NN NN B-PROBLEM
s NN NN O
or NN NN O
rub NN NN B-PROBLEM
s NN NN O
. NN NN O

Normal NN NN O
S1 NN NN O
and NN NN O
S2 NN NN O
. NN NN O

No NN NN O
S NN NN B-PROBLEM
3 NN NN O
or NN NN O
S NN NN B-PROBLEM

4 NN NN O
. NN NN O
ABDOMEN NN NN O
: NN NN O
Soft NN NN O
, NN NN O
nontende NN NN B-PROBLEM
r NN NN O
, NN NN O
nondistende NN NN B-PROBLEM
d NN NN O
. NN NN O

Normoactive NN NN O
bowel NN NN O
sounds NN NN O
. NN NN O

No NN NN O
guardin NN NN B-PROBLEM
g NN NN O
or NN NN O
reboun NN NN B-PROBLEM
d NN NN O
. NN NN O

No NN NN O
hepatosplenomegal NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
masse NN NN B-PROBLEM
s NN NN O
. NN NN O

MUSCULOSKELETAL NN NN O
: NN NN O
Generalized NN NN B-PROBLEM
muscle NN NN I-PROBLEM
weaknes NN NN I-PROBLEM
s NN NN O
but NN NN O
no NN NN O
joint NN NN B-PROBLEM
swellin NN NN I-PROBLEM
g NN NN O
or NN NN O
other NN NN B-PROBLEM
abnormalitie NN NN I-PROBLEM
s NN NN O
. NN NN O

SKIN NN NN O
: NN NN O
No NN NN O
rashe NN NN B-PROBLEM
s NN NN O
, NN NN O
bruisin NN NN B-PROBLEM
g NN NN O
, NN NN O
or NN NN O
petechi NN NN B-PROBLEM
a NN NN O
. NN NN O

No NN NN O
non-healing NN NN B-PROBLEM
wound NN NN I-PROBLEM
s NN NN O
or NN NN O
ulceration NN NN B-PROBLEM
s NN NN O
. NN NN O

NEUROLOGIC NN NN O
: NN NN O
She NN NN O
is NN NN O
oriented NN NN O
x3 NN NN O
but NN NN O
she NN NN O
falls NN NN O
asleep NN NN O
readily NN NN O
. NN NN O

On NN NN O
exa NN NN B-TEST
m NN NN O
and NN NN O
conversation NN NN O
, NN NN O
her NN NN O
cranial NN NN O
nerves NN NN O
are NN NN O
intact NN NN O
. NN NN O

She NN NN O
has NN NN O
no NN NN O
sensory NN NN B-PROBLEM
los NN NN I-PROBLEM
s NN NN O
. NN NN O

Her NN NN O
strength NN NN O
is NN NN O
symmetric NN NN O
. NN NN O

LABORATORY NN NN O
DATA NN NN O
: NN NN O
Her NN NN B-TEST
white NN NN I-TEST
blood NN NN I-TEST
cell NN NN I-TEST
coun NN NN I-TEST
t NN NN O
is NN NN O
8.0 NN NN O
, NN NN O
hemoglobi NN NN B-TEST
n NN NN O
11.1 NN NN O
, NN NN O
hematocri NN NN B-TEST
t NN NN O
33.2% NN NN O
, NN NN O
and NN NN O
platelet NN NN B-TEST
s NN NN O
29,000 NN NN O
. NN NN O

Her NN NN B-TEST
differentia NN NN I-TEST
l NN NN O
shows NN NN O
2% NN NN B-PROBLEM
metamyelocyte NN NN I-PROBLEM
s NN NN O
, NN NN O
57% NN NN O
neutrophil NN NN B-TEST
s NN NN O
, NN NN O
29% NN NN O
band NN NN B-TEST
s NN NN O
, NN NN O
6% NN NN O
lymphocyte NN NN B-TEST
s NN NN O
, NN NN O
5% NN NN B-TEST
monocyte NN NN I-TEST
s NN NN O
, NN NN O
and NN NN O
1% NN NN B-TEST
eosinophil NN NN I-TEST
s NN NN O
. NN NN O

Her NN NN B-TEST
sodiu NN NN I-TEST
m NN NN O
is NN NN O
138 NN NN O
, NN NN O
potassiu NN NN B-TEST
m NN NN O
4.0 NN NN O
, NN NN O
chlorid NN NN B-TEST
e NN NN O
101 NN NN O
, NN NN O
CO NN NN B-TEST
2 NN NN O
of NN NN O
23 NN NN O
, NN NN O
BU NN NN B-TEST
N NN NN O
21 NN NN O
, NN NN O
creatinin NN NN B-TEST
e NN NN O
1.4 NN NN O
, NN NN O
glucos NN NN B-TEST
e NN NN O
107 NN NN O
, NN NN O
and NN NN O
calciu NN NN B-TEST
m NN NN O
8.7 NN NN O
. NN NN O

Her NN NN B-TEST
IN NN NN I-TEST
R NN NN O
is NN NN O
1.0 NN NN O
, NN NN O
P NN NN B-TEST
T NN NN O
of NN NN O
12 NN NN O
, NN NN O
and NN NN O
PT NN NN B-TEST
T NN NN O

24 NN NN O
. NN NN O
Urinalysi NN NN B-TEST
s NN NN O
negative NN NN O
for NN NN O
nitrit NN NN B-PROBLEM
e NN NN O
and NN NN O
leukocyte NN NN B-TEST
esteras NN NN I-TEST
e NN NN O
with NN NN O
moderate NN NN B-PROBLEM
epithelial NN NN I-PROBLEM
cell NN NN I-PROBLEM
s NN NN O
, NN NN O
bacteri NN NN B-PROBLEM
a NN NN O
, NN NN O
white NN NN B-TEST
blood NN NN I-TEST
cell NN NN I-TEST
s NN NN O
, NN NN O
and NN NN O
yeas NN NN B-PROBLEM
t NN NN O
suggesting NN NN O
of NN NN O
contaminatio NN NN B-PROBLEM
n NN NN O
. NN NN O

Her NN NN B-TEST
troponin NN NN I-TEST
s NN NN O
have NN NN O
been NN NN O
negative NN NN O
x3 NN NN O
. NN NN O

IMAGINING NN NN O
DATA NN NN O
: NN NN O
CT NN NN B-TEST
scan NN NN I-TEST
of NN NN I-TEST
her NN NN I-TEST
ches NN NN I-TEST
t NN NN O
on NN NN O
12/25/0 NN NN B-DATE
8 NN NN O
shows NN NN O
bilateral NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
, NN NN O
larger NN NN O
on NN NN O
the NN NN O
right NN NN O
than NN NN O
the NN NN O
left NN NN O
but NN NN O
these NN NN O
are NN NN O
somewhat NN NN O
decreased NN NN O
in NN NN O
size NN NN O
compared NN NN O
to NN NN O
the NN NN B-TEST
prior NN NN I-TEST
CT NN NN I-TEST
sca NN NN I-TEST
n NN NN O
at NN NN O
the NN NN O
end NN NN O
of NN NN O
Novembe NN NN B-DATE
r NN NN O
. NN NN O

There NN NN O
is NN NN O
some NN NN B-PROBLEM
consolidative NN NN I-PROBLEM
atelectasi NN NN I-PROBLEM
s NN NN O
at NN NN O
the NN NN O
bilateral NN NN O
basis NN NN O
. NN NN O

There NN NN O
is NN NN O
some NN NN B-PROBLEM
peripheral NN NN I-PROBLEM
interstitial NN NN I-PROBLEM
opacification NN NN I-PROBLEM
s NN NN O
noted NN NN O
in NN NN O
the NN NN O
right NN NN O
lung NN NN O
and NN NN O
to NN NN O
a NN NN O
lesser NN NN O
extent NN NN O
in NN NN O
the NN NN O
left NN NN O
lung NN NN O
possibly NN NN O
consistent NN NN O
with NN NN O
pneumoniti NN NN B-PROBLEM
s NN NN O
. NN NN O

There NN NN O
are NN NN O
small NN NN B-PROBLEM
peripheral NN NN I-PROBLEM
nodular NN NN I-PROBLEM
densities NN NN I-PROBLEM
in NN NN I-PROBLEM
both NN NN I-PROBLEM
lung NN NN I-PROBLEM
s NN NN O
unchanged NN NN O
compared NN NN O
to NN NN O
prior NN NN B-TEST
sca NN NN I-TEST
n NN NN O
. NN NN O

There NN NN O
is NN NN O
an NN NN B-PROBLEM
enlarged NN NN I-PROBLEM
right NN NN I-PROBLEM
adrenal NN NN I-PROBLEM
glan NN NN I-PROBLEM
d NN NN O
again NN NN O
noted NN NN O
without NN NN O
change NN NN O
. NN NN O

ASSESSMENT NN NN O
: NN NN O
ABCD NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
66-year-ol NN NN B-AGE
d NN NN O
woman NN NN O
with NN NN O
recurrent NN NN B-PROBLEM
metastatic NN NN I-PROBLEM
ovarian NN NN I-PROBLEM
cance NN NN I-PROBLEM
r NN NN O
known NN NN O
to NN NN O
our NN NN O
clinic NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
she NN NN O
has NN NN O
been NN NN O
admitted NN NN O
for NN NN O
shortness NN NN B-PROBLEM
of NN NN I-PROBLEM
breat NN NN I-PROBLEM
h NN NN O
with NN NN O
possible NN NN O
presumed NN NN O
pneumoni NN NN B-PROBLEM
a NN NN O
. NN NN O

The NN NN O
possibility NN NN O
of NN NN O
a NN NN B-PROBLEM
P NN NN I-PROBLEM
E NN NN O
also NN NN O
remains NN NN O
and NN NN O
the NN NN O
plan NN NN O
has NN NN O
been NN NN O
to NN NN O
do NN NN O
a NN NN B-TEST
CT NN NN I-TEST
A NN NN O
once NN NN O
her NN NN B-TEST
kidney NN NN I-TEST
functio NN NN I-TEST
n NN NN O
improves NN NN O
. NN NN O

Currently NN NN O
, NN NN O
she NN NN O
is NN NN O
being NN NN O
treated NN NN O
with NN NN O
broad-spectrum NN NN B-TREATMENT
antibiotic NN NN I-TREATMENT
s NN NN O
and NN NN O
Loveno NN NN B-TREATMENT
x NN NN O
prophylactically NN NN O
. NN NN O

At NN NN O
this NN NN O
point NN NN O
, NN NN O
it NN NN O
does NN NN O
not NN NN O
appear NN NN O
that NN NN O
her NN NN B-PROBLEM
pleural NN NN I-PROBLEM
effusion NN NN I-PROBLEM
s NN NN O
have NN NN O
increased NN NN O
and NN NN O
this NN NN O
would NN NN O
not NN NN O
be NN NN O
the NN NN O
etiology NN NN O
behind NN NN O
her NN NN B-PROBLEM
worsening NN NN I-PROBLEM
symptom NN NN I-PROBLEM
s NN NN O
. NN NN O

Her NN NN B-TEST
blood NN NN I-TEST
count NN NN I-TEST
s NN NN O
appear NN NN O
to NN NN O
be NN NN O
recovering NN NN O
from NN NN O
chemotherap NN NN B-TREATMENT
y NN NN O
except NN NN O
for NN NN O
the NN NN O
fact NN NN O
that NN NN O
her NN NN B-TEST
platelet NN NN I-TEST
s NN NN O
have NN NN O
gone NN NN O
lower NN NN O
. NN NN O

It NN NN O
is NN NN O
unclear NN NN O
as NN NN O
to NN NN O
the NN NN O
etiology NN NN O
behind NN NN O
this NN NN O
but NN NN O
may NN NN O
still NN NN O
be NN NN O
related NN NN O
to NN NN O
chemotherap NN NN B-DRUG
y NN NN O
effect NN NN O
. NN NN O

This NN NN O
also NN NN O
could NN NN O
be NN NN O
related NN NN O
to NN NN O
consumptive NN NN B-PROBLEM
proces NN NN I-PROBLEM
s NN NN O
such NN NN O
as NN NN O
DI NN NN B-PROBLEM
C NN NN O
in NN NN O
the NN NN O
face NN NN O
of NN NN O
infection NN NN B-PROBLEM
s NN NN O
or NN NN O
medication NN NN B-PROBLEM
effec NN NN I-PROBLEM
t NN NN O
. NN NN O

We NN NN O
will NN NN O
keep NN NN O
track NN NN O
of NN NN O
her NN NN B-TEST
blood NN NN I-TEST
count NN NN I-TEST
s NN NN O
over NN NN O
this NN NN O
admission NN NN O
. NN NN O

We NN NN O
will NN NN O
continue NN NN O
to NN NN O
follow NN NN O
along NN NN O
through NN NN O
the NN NN O
course NN NN O
of NN NN O
her NN NN O
admission NN NN O
. NN NN O

She NN NN O
has NN NN O
requested NN NN O
being NN NN O
full NN NN B-TREATMENT
cod NN NN I-TREATMENT
e NN NN O
. NN NN O

I NN NN O
went NN NN O
back NN NN O
and NN NN O
looked NN NN O
at NN NN O
Dr NN NN O
. NN NN O
X's NN NN O
chart NN NN O
after NN NN O
our NN NN O
clinic NN NN O
chart NN NN O
and NN NN O
at NN NN O
the NN NN O
last NN NN O
visit NN NN O
with NN NN O
Dr NN NN O
. NN NN O
X NN NN O
and NN NN O
Dr NN NN O
. NN NN O
Y NN NN O
, NN NN O
she NN NN O
confirmed NN NN O
that NN NN O
she NN NN O
wanted NN NN O
to NN NN O
be NN NN O
DNR/DNI NN NN O
. NN NN O

I NN NN O
am NN NN O
not NN NN O
sure NN NN O
why NN NN O
this NN NN O
is NN NN O
changed NN NN O
and NN NN O
I NN NN O
will NN NN O
address NN NN O
this NN NN O
issue NN NN O
with NN NN O
her NN NN O
once NN NN O
she NN NN O
is NN NN O
more NN NN O
alert NN NN O
. NN NN O

Thank NN NN O
you NN NN O
very NN NN O
much NN NN O
for NN NN O
this NN NN O
consult NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Breast NN NN O
Radiation NN NN O
Therapy NN NN O
Followup NN NN O
Description NN NN O
: NN NN O
Breast NN NN O
radiation NN NN O
therapy NN NN O
followup NN NN O
note NN NN O
. NN NN O

Left NN NN B-PROBLEM
breast NN NN I-PROBLEM
adenocarcinoma NN NN I-PROBLEM
stage NN NN I-PROBLEM
T NN NN I-PROBLEM
3 NN NN O
N1b NN NN O
M0 NN NN O
, NN NN O
stage NN NN B-PROBLEM
III NN NN I-PROBLEM
A NN NN O
. NN NN O
( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NN NN B-PROBLEM
breast NN NN I-PROBLEM
adenocarcinoma NN NN I-PROBLEM
stage NN NN I-PROBLEM
T NN NN I-PROBLEM
3 NN NN O
N1b NN NN O
M0 NN NN O
, NN NN O
stage NN NN B-PROBLEM
III NN NN I-PROBLEM
A NN NN O
. NN NN O
She NN NN O
has NN NN O
been NN NN O
found NN NN O
more NN NN O
recently NN NN O
to NN NN O
have NN NN O
stage NN NN B-PROBLEM
IV NN NN I-PROBLEM
diseas NN NN I-PROBLEM
e NN NN O
with NN NN O
metastatic NN NN B-PROBLEM
deposit NN NN I-PROBLEM
s NN NN O
and NN NN O
recurrence NN NN B-PROBLEM
involving NN NN I-PROBLEM
the NN NN I-PROBLEM
chest NN NN I-PROBLEM
wal NN NN I-PROBLEM
l NN NN O
and NN NN O
lower NN NN B-PROBLEM
left NN NN I-PROBLEM
neck NN NN I-PROBLEM
lymph NN NN I-PROBLEM
node NN NN I-PROBLEM
s NN NN O
. NN NN O

CURRENT NN NN O
MEDICATIONS NN NN O

1 NN NN O
. NN NN O
Glucosamin NN NN B-DRUG
e NN NN O
complex NN NN O
. NN NN O

2 NN NN O
. NN NN O
Toprol NN NN B-TREATMENT
X NN NN I-TREATMENT
L NN NN O
. NN NN O

3 NN NN O
. NN NN O
Alprazola NN NN B-TREATMENT
m NN NN O

4 NN NN O
. NN NN O
Hydrochlorothiazid NN NN B-TREATMENT
e NN NN O
. NN NN O

5 NN NN O
. NN NN O
Dyazid NN NN B-TREATMENT
e NN NN O
. NN NN O

6 NN NN O
. NN NN O
Centru NN NN B-DRUG
m NN NN O
. NN NN O

Dr NN NN O
. NN NN O
X NN NN O
has NN NN O
given NN NN O
her NN NN O
some NN NN O
carboplati NN NN B-DRUG
n NN NN O
and NN NN O
Taxo NN NN B-TREATMENT
l NN NN O
more NN NN O
recently NN NN O
and NN NN O
feels NN NN O
that NN NN O
she NN NN O
would NN NN O
benefit NN NN O
from NN NN O
electron NN NN B-TREATMENT
beam NN NN I-TREATMENT
radiotherap NN NN I-TREATMENT
y NN NN O
to NN NN O
the NN NN O
left NN NN O
chest NN NN O
wall NN NN O
as NN NN O
well NN NN O
as NN NN O
the NN NN O
neck NN NN O
. NN NN O

She NN NN O
previously NN NN O
received NN NN O
a NN NN O
total NN NN O
of NN NN O
46.8 NN NN O
Gy NN NN O
in NN NN O
26 NN NN O
fractions NN NN O
of NN NN O
external NN NN B-TREATMENT
beam NN NN I-TREATMENT
radiotherap NN NN I-TREATMENT
y NN NN O
to NN NN O
the NN NN O
left NN NN O
supraclavicular NN NN O
area NN NN O
. NN NN O

As NN NN O
such NN NN O
, NN NN O
I NN NN O
feel NN NN O
that NN NN O
we NN NN O
could NN NN O
safely NN NN O
re-treat NN NN O
the NN NN O
lower NN NN O
neck NN NN O
. NN NN O

Her NN NN B-TEST
weigh NN NN I-TEST
t NN NN O
has NN NN O
increased NN NN O
to NN NN O
189.5 NN NN O
from NN NN O
185.2 NN NN O
. NN NN O

She NN NN O
does NN NN O
complain NN NN O
of NN NN O
some NN NN B-PROBLEM
coughin NN NN I-PROBLEM
g NN NN O
and NN NN O
fatigu NN NN B-PROBLEM
e NN NN O
. NN NN O

PHYSICAL NN NN O
EXAMINATION NN NN O
NECK NN NN O
: NN NN O
On NN NN O
physical NN NN B-TEST
examinatio NN NN I-TEST
n NN NN O
palpable NN NN O
lymphadenopath NN NN B-PROBLEM
y NN NN O
is NN NN O
present NN NN O
in NN NN O
the NN NN O
left NN NN O
lower NN NN O
neck NN NN O
and NN NN O
supraclavicular NN NN O
area NN NN O
. NN NN O

No NN NN O
other NN NN B-PROBLEM
cervical NN NN I-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
or NN NN O
supraclavicular NN NN B-PROBLEM
lymphadenopath NN NN I-PROBLEM
y NN NN O
is NN NN O
present NN NN O
. NN NN O

RESPIRATORY NN NN O
: NN NN O
Good NN NN O
air NN NN O
entry NN NN O
bilaterally NN NN O
. NN NN O

Examination NN NN B-TEST
of NN NN I-TEST
the NN NN I-TEST
chest NN NN I-TEST
wal NN NN I-TEST
l NN NN O
reveals NN NN O
a NN NN B-PROBLEM
small NN NN I-PROBLEM
lesio NN NN I-PROBLEM
n NN NN O
where NN NN O
the NN NN B-PROBLEM
chest NN NN I-PROBLEM
wall NN NN I-PROBLEM
recurrenc NN NN I-PROBLEM
e NN NN O
was NN NN O
resecte NN NN B-TREATMENT
d NN NN O
. NN NN O

No NN NN O
lump NN NN B-PROBLEM
s NN NN O
, NN NN O
bump NN NN B-PROBLEM
s NN NN O
or NN NN O
evidence NN NN O
of NN NN O
diseas NN NN B-PROBLEM
e NN NN O
involving NN NN O
the NN NN O
right NN NN O
breast NN NN O
is NN NN O
present NN NN O
. NN NN O

ABDOMEN NN NN O
: NN NN O
Normal NN NN O
bowel NN NN O
sounds NN NN O
, NN NN O
no NN NN O
hepatomegal NN NN B-PROBLEM
y NN NN O
. NN NN O

No NN NN O
tendernes NN NN B-PROBLEM
s NN NN O
on NN NN O
deep NN NN B-TEST
palpatio NN NN I-TEST
n NN NN O
. NN NN O

She NN NN O
has NN NN O
just NN NN O
started NN NN O
her NN NN O
last NN NN O
cycle NN NN O
of NN NN O
chemotherap NN NN B-DRUG
y NN NN O
today NN NN O
, NN NN O
and NN NN O
she NN NN O
wishes NN NN O
to NN NN O
visit NN NN O
her NN NN O
daughter NN NN O
in NN NN O
Brookly NN NN B-LOCATION
n NN NN O
, NN NN O
New NN NN B-LOCATION
Yor NN NN I-LOCATION
k NN NN O
. NN NN O

After NN NN O
this NN NN O
she NN NN O
will NN NN O
return NN NN O
in NN NN O
approximately NN NN O
3 NN NN O
to NN NN O
4 NN NN O
weeks NN NN O
and NN NN O
begin NN NN O
her NN NN B-TREATMENT
radiotherapy NN NN I-TREATMENT
treatmen NN NN I-TREATMENT
t NN NN O
at NN NN O
that NN NN O
time NN NN O
. NN NN O

I NN NN O
look NN NN O
forward NN NN O
to NN NN O
keeping NN NN O
you NN NN O
informed NN NN O
of NN NN O
her NN NN O
progress NN NN O
. NN NN O

Thank NN NN O
you NN NN O
for NN NN O
having NN NN O
allowed NN NN O
me NN NN O
to NN NN O
participate NN NN O
in NN NN O
her NN NN O
care NN NN O
. NN NN O

Sample NN NN O
Type NN NN O
/ NN NN O
Medical NN NN O
Specialty NN NN O
: NN NN O
Hematology NN NN O
- NN NN O
Oncology NN NN O
Sample NN NN O
Name NN NN O
: NN NN O
Lymph NN NN B-TEST
Node NN NN I-TEST
Excisional NN NN I-TEST
Biops NN NN I-TEST
y NN NN O
Description NN NN O
: NN NN O
Left NN NN B-TEST
axillary NN NN I-TEST
lymph NN NN I-TEST
node NN NN I-TEST
excisional NN NN I-TEST
biops NN NN I-TEST
y NN NN O
. NN NN O

Left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

( NN NN O
Medical NN NN O
Transcription NN NN O
Sample NN NN O
Report NN NN O
) NN NN O
PREOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

POSTOPERATIVE NN NN O
DIAGNOSIS NN NN O
: NN NN O
Left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
. NN NN O

PROCEDURE NN NN O
: NN NN O
Left NN NN B-TEST
axillary NN NN I-TEST
lymph NN NN I-TEST
node NN NN I-TEST
excisional NN NN I-TEST
biops NN NN I-TEST
y NN NN O
. NN NN O

ANESTHESIA NN NN O
: NN NN O
LM NN NN B-TREATMENT
A NN NN O
. NN NN O
INDICATIONS NN NN O
: NN NN O
Patient NN NN O
is NN NN O
a NN NN O
very NN NN O
pleasant NN NN O
woman NN NN O
who NN NN O
in NN NN O
200 NN NN B-DATE
6 NN NN O
had NN NN O
breast NN NN B-TREATMENT
conservation NN NN I-TREATMENT
therap NN NN I-TREATMENT
y NN NN O
with NN NN O
radiatio NN NN B-TREATMENT
n NN NN O
only NN NN O
. NN NN O

Note NN NN O
, NN NN O
she NN NN O
refused NN NN O
her NN NN O
CM NN NN B-DRUG
F NN NN O
adjuvant NN NN O
therapy NN NN O
and NN NN O
this NN NN O
was NN NN O
for NN NN O
a NN NN B-PROBLEM
triple-negative NN NN I-PROBLEM
infiltrating NN NN I-PROBLEM
ductal NN NN I-PROBLEM
carcinoma NN NN I-PROBLEM
of NN NN I-PROBLEM
the NN NN I-PROBLEM
breas NN NN I-PROBLEM
t NN NN O
. NN NN O

Patient NN NN O
has NN NN O
been NN NN O
following NN NN O
with NN NN O
Dr NN NN O
. NN NN O
Diene NN NN B-NAME
r NN NN O
and NN NN O
Dr NN NN O
. NN NN O
Wilmo NN NN B-NAME
t NN NN O
. NN NN O

I NN NN O
believe NN NN O
that NN NN O
genetic NN NN O
counseling NN NN O
had NN NN O
been NN NN O
recommended NN NN O
to NN NN O
her NN NN O
and NN NN O
obviously NN NN O
the NN NN O
CM NN NN B-DRUG
F NN NN O
was NN NN O
recommended NN NN O
, NN NN O
but NN NN O
she NN NN O
declined NN NN O
both NN NN O
. NN NN O

She NN NN O
presented NN NN O
to NN NN O
the NN NN O
office NN NN O
with NN NN O
left NN NN B-PROBLEM
axillary NN NN I-PROBLEM
adenopath NN NN I-PROBLEM
y NN NN O
in NN NN O
view NN NN O
of NN NN O
the NN NN O
high-risk NN NN O
nature NN NN O
of NN NN O
her NN NN B-PROBLEM
lesio NN NN I-PROBLEM
n NN NN O
. NN NN O

I NN NN O
recommended NN NN O
that NN NN O
she NN NN O
have NN NN O
this NN NN B-TREATMENT
lymph NN NN I-TREATMENT
nod NN NN I-TREATMENT
e NN NN O
removed NN NN O
. NN NN O

The NN NN B-TREATMENT
procedur NN NN I-TREATMENT
e NN NN O
, NN NN O
purpose NN NN O
, NN NN O
risk NN NN O
, NN NN O
expected NN NN O
benefits NN NN O
, NN NN O
potential NN NN B-PROBLEM
complication NN NN I-PROBLEM
s NN NN O
, NN NN O
alternative NN NN O
forms NN NN O
of NN NN O
therap NN NN B-TREATMENT
y NN NN O
were NN NN O
discussed NN NN O
with NN NN O
her NN NN O
and NN NN O
she NN NN O
was NN NN O
agreeable NN NN O
to NN NN O
surger NN NN B-TREATMENT
y NN NN O
. NN NN O

TECHNIQUE NN NN O
: NN NN O
Patient NN NN O
was NN NN O
identified NN NN O
, NN NN O
then NN NN O
taken NN NN O
into NN NN O
the NN NN O
operating NN NN O
room NN NN O
where NN NN O
after NN NN O
induction NN NN O
of NN NN O
appropriate NN NN O
anesthesi NN NN B-DRUG
a NN NN O
, NN NN O
her NN NN B-TREATMENT
left NN NN I-TREATMENT
chest NN NN I-TREATMENT
, NN NN I-TREATMENT
neck NN NN I-TREATMENT
, NN NN I-TREATMENT
axilla NN NN I-TREATMENT
, NN NN I-TREATMENT
and NN NN I-TREATMENT
ar NN NN I-TREATMENT
m NN NN O
were NN NN O
prepped NN NN O
with NN NN O
Betadin NN NN B-DRUG
e NN NN O
solutio NN NN B-FORM
n NN NN O
, NN NN O
draped NN NN O
in NN NN O
a NN NN O
sterile NN NN O
fashion NN NN O
. NN NN O

An NN NN B-PROBLEM
incisio NN NN I-PROBLEM
n NN NN O
was NN NN O
made NN NN O
at NN NN O
the NN NN O
hairline NN NN O
, NN NN O
carried NN NN O
down NN NN O
by NN NN O
sharp NN NN B-TREATMENT
dissection NN NN I-TREATMENT
through NN NN I-TREATMENT
the NN NN I-TREATMENT
clavipectoral NN NN I-TREATMENT
fasci NN NN I-TREATMENT
a NN NN O
. NN NN O

I NN NN O
was NN NN O
able NN NN O
to NN NN O
easily NN NN O
palpate NN NN O
the NN NN O
lymph NN NN O
node NN NN O
and NN NN O
grasp NN NN O
it NN NN O
with NN NN O
a NN NN B-TREATMENT
figure-of-eight NN NN I-TREATMENT
2-0 NN NN I-TREATMENT
silk NN NN I-TREATMENT
sutur NN NN I-TREATMENT
e NN NN O
and NN NN O
by NN NN O
sharp NN NN B-TREATMENT
dissectio NN NN I-TREATMENT
n NN NN O
, NN NN O
was NN NN O
carried NN NN O
to NN NN O
hemocli NN NN B-TREATMENT
p NN NN O
all NN NN O
attached NN NN O
structures NN NN O
. NN NN O

The NN NN O
lymph NN NN O
node NN NN O
was NN NN O
excise NN NN B-TREATMENT
d NN NN O
in NN NN O
its NN NN O
entirety NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
irrigated NN NN O
. NN NN O

The NN NN O
lymph NN NN O
node NN NN O
sent NN NN O
to NN NN O
pathology NN NN O
. NN NN O

The NN NN B-PROBLEM
woun NN NN I-PROBLEM
d NN NN O
was NN NN O
then NN NN O
closed NN NN O
. NN NN O

Hemostasis NN NN O
was NN NN O
assured NN NN O
and NN NN O
the NN NN O
patient NN NN O
was NN NN O
taken NN NN O
to NN NN O
recovery NN NN O
room NN NN O
in NN NN O
stable NN NN O
condition NN NN O
. NN NN O

isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-TREATMENT
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O
isim NN NN O
: NN NN O
Elif NN NN O
Yılmaz NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
15/03/199 NN NN B-DATE
1 NN NN O
ilaç NN NN O
: NN NN O
Omeprazol NN NN B-DRUG
e NN NN O
20m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
01/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
01/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Ahmet NN NN O
Demir NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
12/02/198 NN NN B-DATE
0 NN NN O
ilaç NN NN O
: NN NN O
Lansoprazol NN NN B-DRUG
e NN NN O
30m NN NN B-STRENGTH
g NN NN O
başlama NN NN O
tarihi NN NN O
: NN NN O
02/01/202 NN NN B-DATE
4 NN NN O
bitiş NN NN O
tarihi NN NN O
: NN NN O
02/07/202 NN NN B-DATE
4 NN NN O
isim NN NN O
: NN NN O
Zeynep NN NN B-NAME
Kay NN NN I-NAME
a NN NN O
doğum NN NN O
tarihi NN NN O
: NN NN O
23/04/199 NN NN B-DATE
2 NN NN O
ilaç NN NN O
: NN NN O
Esomeprazol NN NN B-DRUG
e NN NN O

